ELSEVIER

Psychiatry Research 66 (1997) 179–182

PSYCHIATRY RESEARCH

Author Index for 1996

Abbruzzese, M., **64**:27
Abel, K., **64**:11
Abramovitz-Schnaider, P., **63**:143
Adler, L.E., **64**:121
Akiskal, H.S., **65**:73
Albert, P.S., 63:161
Alda, M., **63**:17, **64**:91
Alpert, J.E., **62**:213
Aluoja, A., **66**:59
Araki, S., **62**:11, **62**:285
Arancio, C., **66**:69
Arndt, S., **62**:191
Arolt, V., **66**:145
Asnis, G.M., **64**:77
Avanzini, P., **66**:33
Azorin, J.-M., **63**:151, **66**:87

Bakish, D., **66**:73
Barbato, M., **65**:65
Barbini, B., **65**:121, **65**:179
Barr, W., **66**:153
Barry, R.J., **64**:179
Bartels, D.M., **66**:45
Baruah, S., **62**:191
Bathélémy, C., **65**:33
Batistini, A., **65**:73
Baumert, K., **62**:191
Beiser, M., **64**:19
Bellodi, L., **66**:69
Benedetti, F., **65**:179
Benson, K.L., **66**:111
Berger, M., **65**:45
Berger, R., **66**:167
Berghmans, R., **64**:161
Bertelli, S., **65**:121
Biederman, J., **62**:213
Biswas, A.K., **64**:115
Black, D.W., **64**:59
Bloomfield, S.M., **65**:15
Blum, N., **65**:61
Bohus, M., **65**:45
Bolis, C.L., **62**:1
Borbély, A.A., **66**:97
Bosmans, E., **64**:161
Bouhuys, A.L., **64**:193
Bradshaw, D., **66**:13
Bradwejn, J., **62**:131, **66**:59
Brady, K., **63**:205, **65**:189
Brambilla, F., **62**:97, **66**:33
Brewerton, T.D., **62**:31, **63**:231
Broocks, A., **64**:1
Brown, G.M., **63**:219
Brown, L.F., **62**:161
Brunetta, M., **62**:97
Buican, B., **63**:77
Buitelaar, J.K., **63**:33
Burkart, M., **62**:227
Burke, T., **64**:105
Buysse, D.J., **62**:161

Caccavari, R., **66**:33
Cahill, J., **65**:15
Caldirola, D., **66**:69
Campion, D., **62**:221
Campori, E., **65**:179
Canter, S.K., **64**:1
Canuso, C.M., **63**:227
Capozzoli, J., **63**:205, **65**:189
Carter, C.S., **62**:111
Casper, R.C., **62**:85
Cassano, G.B., **65**:73
Catts, S.V., **65**:171, **64**:121
Cavazzoni, P.A., **63**:17, **64**:91, **66**:73
Chaderjian, M., **62**:111
Chan, A., **63**:109
Charbonnier, F., **62**:221
Charney, D.S., **64**:169
Chen, W.J., **62**:239
Cherpi, C., **65**:33
Chi, D., **63**:191
Chittolini, B., **66**:33
Chiu, C., **63**:25
Christensen, L., **62**:191
Chudzik, J., **66**:73
Clark, W.C., **63**:57
Clayton, R., **64**:97
Clopton, P., **62**:147
Coccaro, E.F., **62**:139
Coffey, C.E., **62**:179
Colgan, K., **64**:105
Colombo, C., **65**:121, **65**:179
Comings, D.E., **63**:25
Constantino, J.N., **65**:129
Cook, B., **65**:61
Cooney, J., **62**:191
Cooper, T.B., **62**:139, **65**:65
Cooremans, W., **66**:1
Coplan, J.D., **64**:83
Copolov, D.L., **62**:259
Cordás, T.A., **62**:17
Cornblatt, B.A., **66**:121
Coron, B., **62**:221
Correnti, E.E., **63**:133
Corrigan, P.W., **62**:251, **63**:77
Cover, H., **62**:147
Cowley, D.S., **65**:53
Cross, L.W., **63**:57
Cutlip, W.D., **65**:15

Dassa, D., **63**:151, **64**:11, **66**:87
Davis, A.V., **63**:109
Davis, L.L., **63**:223
Davis, M., **64**:169
Dean, B., **62**:259
Delange, J., **66**:1
DeLecuona, J.M., **64**:77
DeLisi, L.E., **65**:1
Dell'Osso, L., **65**:73
Deisignore, R., **66**:33
Demedts, P., **65**:159
Denckla, M.B., **63**:205, **65**:189
DeRubeis, R.J., **65**:97
Desnyder, R., **66**:1
Dew, M.A., **62**:161, **63**:183
Diamond, B.I., **64**:209
Diamond, P.M., **63**:67
Dollfus, S., **62**:221
Draisci, A., **62**:97
Dubbert, B., **64**:1
Duffy, A., **63**:17, **64**:91
Dunayevich, E., **64**:69
Dyer, A., **63**:191

Eckert, S.L., **63**:67
Elangovan, N., **65**:65
Endo, T., **66**:97
Erlenmeyer-Kimling, L., **66**:121

Faraone, S.V., **66**:131
Fava, M., **62**:213
Ferrari, E., **62**:97
Ferri, S., **64**:27

Flint, A.J., **66**:23
Flisher, A.J., **66**:13
Förstner, U., **65**:45
Frank, E., **63**:183
Frebourg, T., **62**:221
Freeman, E.W., **65**:97
Freudstein-Dan, A., **63**:143
Freund, L., **63**:205, **65**:189
Frosch, E., **63**:205
Fukuda, M., **63**:7
Funderburg, L.G., **63**:67

Gabel, J., **64**:59
Gabriel, S.M., **62**:139
Gaebel, W., **65**:23
Garman, A., **62**:251
Garvey, M.J., **62**:171, **65**:61
Gebicke-Härter, P., **65**:45
Geerts, E., **64**:193
Germine, M., **63**:223
Gerra, G., **66**:33
Gerring, J.P., **63**:205, **65**:189
Gerson, A.C., **63**:205, **65**:189
Ghaemi, S.N., **65**:113
Gilbertson, M.W., **64**:47
Gillin, J.C., **62**:147
Giucastro, G., **66**:33
Goddard, A.W., **63**:223
Gold, P.W., **62**:75
Goldman, M.B., **63**:227
Goldstein, J.M., **66**:131
Gorman, J.M., **64**:83
Goto, K., **63**:93
Grady, T.A., **64**:1
Grant, I., **63**:169
Grignon, S., **63**:151
Grillon, C., **64**:169
Grof, E., **63**:17, **64**:91
Grof, P., **63**:17, **64**:91
Gurklis, J.A., **64**:47
Gurrera, R.J., **64**:137

Hallford, H.G., **64**:35
Halmi, K.A., **62**:23
Hamdy, R., **63**:191
Hamner, M.B., **64**:209
Haque-Nizamie, S., **64**:115
Hardt, J., **62**:227
Harris, M.J., **63**:169
Harrison, K., **63**:57
Hata, A., **63**:7
Hauger, R., **62**:147
Haut, M.W., **65**:15
Heaton, R.K., **63**:109
Hebben, N., **65**:113
Hecht, H., **65**:45
Hegde, A.L., **62**:265
Hegerl, U., **63**:47, **65**:23
Hellwig, B., **64**:205
Hérault, J., **65**:33
Herholz, K., **62**:105
Hesslinger, B., **64**:205
Heun, R., **62**:227
Hill, J.L., **64**:1
Hiramatsu, K.-I., **63**:7
Hoch, C.C., **62**:161
Hoff, A.L., **65**:1
Hoffer, L.D., **64**:121
Hoffmann, K., **66**:153
Honda, H., **63**:7
Horrobin, D.F., **63**:133
Houck, P.R., **62**:161, **63**:183
Hrdina, P.D., **66**:73
Huang, Y.-J., **62**:239
Hubain, P., **63**:83
Hughes, C.W., **65**:79
Huxley, P., **66**:153
Hwu, H.-G., **62**:239

Iacono, W.G., **64**:19
Ide, M., **62**:11, **62**:285
Ikemoto, S., **63**:93–107
Inosaka, T., **64**:47
Isermann, M., **66**:153
Ishiguro, T., **63**:93
Iwanami, A., **63**:7

Jagomägi, K., **66**:59
Jeanningros, R., **63**:151, **66**:87
Jenkins, K., **63**:133
Jenner, J.A., **64**:193
Jeste, D.V., **63**:109, **63**:169
Jimerson, D.C., **62**:31
Joffe, R.T., **65**:185
Johnson, C., **64**:97
Johnstone, S.J., **64**:179
Jones, P., **64**:11
Joshi, P.T., **63**:205, **65**:189
Juckel, G., **63**:47, **65**:23
Juritz, J.M., **66**:13

Kaiser, W., **66**:153
Kakuma, T., **63**:57
Kalus, O., **64**:77
Kaplan, R.M., **63**:169
Karmally, W., **64**:83
Katsanis, J., **64**:19
Kavoussi, R.J., **62**:139
Kaye, W.H., **62**:65
Keck, P.E., Jr., **64**:69
Kelley, M.E., **64**:47
Kemner, C., **63**:33
Kemperman, I., **63**:57
Kennedy, S.H., **63**:219
Kent, J.M., **64**:83
Keshavan, M.S., **66**:121
Kiefer, C., **65**:45
Kingisepp, P.-H., **66**:59
Kirchner, H., **66**:145
Koch, W.L., **63**:169
Koszycki, D., **62**:131
Kramer, G.L., **63**:223, **65**:53, **65**:79
Kremen, W.S., **66**:131
Krystal, A.D., **62**:179
Kuboki, T., **62**:11, **62**:285
Kupfer, D.J., **63**:183, **62**:161
Kusumakar, V., **63**:1
Kutcher, S.P., **63**:219

La Via, M.C., **63**:231
Lachman, H.M., **63**:197
Lane, A., **64**:105
Langlois, S., **62**:221
Laor, N., **63**:143
Lapierre, Y.D., **66**:73
Larkin, C., **64**:105
Laurent, C., **62**:221
Leibenluft, E., **63**:161
Lelord, G., **65**:33
LeVeau, B., **62**:147
Li, X., **63**:191
Licinio, J., **62**:1, **62**:75
Liebert, B.J., **64**:121, **65**:171
Lindner, K., **66**:45
Lingjaerde, O., **62**:273
Linkowski, P., **63**:83
Lloyd, A., **65**:171
Lutzenberger, W., **66**:45
Lyons, M.J., **66**:131

Maciel, P., **63**:17
Maddocks, A., **62**:213
Maes, M., **64**:147, **64**:161, **66**:1, **65**:159
Maestri, D., **66**:33
Magistretti, P., **62**:1
Mahadik, S.P., **63**:133
Maier, W., **62**:227
Makela, E.H., **65**:15
Mallet, J., **62**:221
Mandal, M.K., **64**:115
Marazziti, D., **65**:73
Marin, R.S., **63**:205
Martin, C., **62**:221
Martin, R., **63**:17, **64**:91
Martineau, J., **65**:33
Martinez, J., **64**:83
Mazumdar, S., **62**:161, **63**:183
McCall, W.V., **62**:179

McClure, E., **64**:97
McConaghy, N., **65**:171
McConville, B.J., **64**:69
McElroy, S.L., **64**:69
Meltzer, H.Y., **64**:147, **66**:1
Mendlewicz, J., **63**:83
Mersch, P.P.A., **64**:193
Miller, A.L., **63**:67
Mintz, M., **65**:107
Monahan, P., **64**:59
Monica, C., **66**:33
Monk, T.H., **62**:161
Moreau, V., **62**:221
Morgan, C.A., **64**:169
Moscona, S., **63**:169
Moss, H.B., **62**:203, **63**:123
Mostofi, N., **62**:147
Moynihan, F., **64**:105
Müh, J.P., **65**:33
Muhleman, D., **63**:25
Mukherjee, S., **63**:133
Müller, E.E., **62**:51
Müller-Schubert, A., **65**:23
Murphy, D.L., **64**:1, **65**:129
Murray, R.M., **64**:11

Nakagome, K., **63**:7
Narayan, M., **63**:223
Neels, H., **65**:159
Negrao A.B., **62**:17
Nelson, D., **62**:251
Nierenberg, A.A., **62**:213
Niwa, S.-I., **63**:7
Nixon, S.J., **64**:35
Nolte, A., **66**:145
Nomura, S., **62**:11, **62**:285
Nordahl, T.E., **62**:111, **62**:121
Noyes, R., Jr., **65**:61

O'Callaghan, E., **64**:105
O'Donnell, M.C., **64**:121, **65**:171
O'Sullivan, R., **62**:213
Oreland, L., **62**:273
Oshora-Celaya, L., **62**:111

Palego, L., **65**:73
Palladino, M., **66**:33
Pandey, R., **64**:115
Panerai, A., **62**:97
Papolos, D.F., **63**:197
Papp, L.A., **64**:83
Parry, B.L., **62**:147
Parry, C.D.H., **66**:13
Patterson, T.L., **63**:169
Paulsen, J.S., **63**:109
Pava, J.A., **62**:213
Peirone, A., **62**:97
Perna, G., **66**:69
Perrot, A., **65**:33
Peters, J.L., **64**:47
Petit, E., **65**:33
Petit, M., **62**:221
Petty, F., **63**:223, **65**:53, **65**:79
Pigott, T.A., **64**:1
Pinnow, M., **66**:145
Pirke, K.M., **62**:43
Ponnudurai, R., **62**:281
Pope, H.G., Jr., **65**:113
Preterre, P., **62**:221
Priebe, S., **66**:153
Prigerson, H.G., **62**:161

Ralevski, E., **63**:219
Ranjan, R., **66**:1
Ravindran, A., **66**:73
Rehavi, M., **63**:143
Reichborn-Kjennerud, T., **62**:273
Reynolds, C.F., III, **62**:161, **63**:183
Richter, M.A., **65**:185
Rickels, K., **65**:97
Rifat, S.L., **66**:23
Rin, H., **62**:239
Robertson, L.C., **62**:111, **62**:121
Röder-Wanner, U.-U., **66**:153
Rogeness, G.A., **64**:97
Rolla, M., **62**:51
Romero, R., **63**:109
Rommelspacher, H., **63**:47
Rosenbaum, E., **63**:197
Rosenbaum, J.F., **62**:213
Rosenberg, D.R., **66**:121
Rosenthal, N.E., **63**:161
Rothermundt, M., **66**:145
Rouleau, G.A., **63**:17, **64**:91
Roy-Byrne, P.P., **65**:53
Russ, M.J., **63**:57
Rybakowski, J., **64**:161

Sacamano, J., **63**:1
Sacerdote, P., **62**:97
Saito, H., **64**:47
Sakuma, M., **65**:1
Salo, R., **62**:121
Sandborn, W., **63**:191
Sato, M., **64**:47
Sax, K.W., **64**:69
Scarone, S., **64**:27
Scharpé, S., **66**:1
Scheffer, R.E., **63**:133
Schiffer, R.A., **65**:107
Schmidt, L.G., **63**:47
Schujovitsky, A., **63**:143
Schwierin, B., **66**:97
Seidman, L.J., **66**:131
Semple, S.J., **63**:169
Serres, F., **63**:151, **66**:87
Sham, P.C., **64**:11
Sheikha, S., **65**:79
Shlik, J., **66**:59
Siever, L.J., **62**:139
Sigal, M., **65**:107
Sluzewska, A., **64**:161
Smeraldi, E., **65**:121, **65**:179
Sobieska, M., **64**:161
Sokulski, D.E., **63**:123
Songer, D.A., **66**:167
Sorter, M.T., **64**:69
Southwick, S.M., **64**:169
Spraul, G., **65**:45
Squires-Wheeler, E., **66**:121
Staner, L., **63**:83
Stevens, A., **66**:45
Stevenson, J.M., **65**:15
Stoll, A.L., **65**:113
Strakowski, S.M., **64**:69
Strik, W., **66**:45
Suematsu, H., **62**:11, **62**:285
Summerfeldt, L.J., **65**:185
Sundram, A., **62**:259
Sverd, J., **63**:25
Sweeney, J.A., **66**:121
Swinson, R.P., **65**:185

Thibaut, F., **62**:221
Thompson, N.M., **64**:97
Timmer, J., **65**:45
Tivis, R.D., **64**:35
Tobler, I., **66**:97
Toomey, R., **63**:77, **66**:131
Trestman, R.L., **62**:139
True, J.E., **63**:67
Tsuang, M.T., **66**:131
Tuason, V.B., **62**:171
Turecki, G., **63**:17, **64**:91

van Beijsterveld, C.E.M., **63**:33
van Calker, D., **65**:45
van Engeland, H., **63**:33
van Hunsel, F., **65**:159
van Kammen, D.P., **63**:123, **64**:47
van Os, J., **64**:11
van Praag, H.M., **65**:143
van Ree, J.M., **63**:33
Van Veeren, C., **63**:83
Vandoolaeghe, E., **65**:159
Vasar, E., **66**:59
Vasar, V., **66**:59
Vasse, T., **62**:221
Velligan, D.I., **63**:67
Verbaten, M.N., **63**:33

Waddington, J.L., **64**:105
Wakefield, D., **65**:171
Wakeling, A., **62**:3
Walden, J., **64**:205
Ward, P.B., **64**:121, **65**:171
Wark, H.J., **65**:45
Wauters, A., **65**:159
Waziri, R., **62**:191
Wehr, T.A., **63**:161
Weiner, R.D., **62**:179
Weitzsch, C., **66**:145
Weizman, R., **63**:143
Wetzler, S., **64**:77
Wiktorowicz, K., **64**:161
Wilcke, I., **66**:145
Wingerson, D.K., **65**:53
Winsberg, B., **65**:65
Wolmer, L., **63**:143
Wong, M.-L., **62**:75
Woods, S.W., **63**:223
Woodson, H., **62**:265
Worthington, J.J., III, **62**:213
Wu, S., **63**:25
Yao, J.K., **62**:203, **63**:123, **64**:47
Yatham, L.N., **63**:1
Yeh, L.-L., **62**:239
Yeragani, S., **66**:167
Yeragani, V.K., **66**:167
Yu, Y.-M., **63**:197
Yui, K., **63**:93

Zacharko, R.M., **62**:131
Zaimovic, A., **66**:33
Zarcone, V.P., **66**:111

UMI

SHOULD READ SUBJECT INDEX 1996-1997

ELSEVIER

Psychiatry Research 66 (1997) 183–216

PSYCHIATRY RESEARCH

Subject index for 1996

Adrenocorticotropic hormone
anorexia nervosa, corticotropin-releasing hormone, **62**:75, **62**:97
anorexia nervosa, cortisol, **62**:75, **62**:97
anorexia nervosa, dexamethasone suppression test, **62**:75
beta-endorphin, anorexia and bulimia nervosa, **62**:97
bulimia nervosa, corticotropin-releasing hormone, **62**:97
bulimia nervosa, cortisol, **62**:97
cholecystokinin, anorexia nervosa, **62**:97
corticotropin-releasing hormone, anorexia nervosa, **62**:75, **62**:97
cortisol, anorexia nervosa, **62**:75, **62**:97
cortisol, bulimia nervosa, **62**:97
dexamethasone suppression test, anorexia nervosa, **62**:75
immunology, anorexia and bulimia nervosa, **62**:97
phytohemoagglutinin, anorexia and bulimia nervosa, **62**:97
T-lymphocytes, anorexia and bulimia nervosa, **62**:97

Affective disorder
acute phase proteins, antidepressants, **64**:159
acute phase proteins, bipolar subtype, **66**:1
acute phase proteins, immunology, **64**:161, **64**:159, **66**:1
age, bereavement, **62**:161
age, circadian rhythms, **62**:161
age, circannual rhythms, **62**:265
age, polysomnography, **62**:161
age, seasonal depression, **62**:265
age, sleep impairment, **62**:161
age, Social Rhythm Metric, **62**:161
aggression, cortisol, **65**:143
aggression, serotonin, **65**:143
aggression, stress, **65**:143
albumin, immunology, **65**:159
amineptine, bipolar subtype, **65**:179
amineptine, dopamine, **65**:179
amineptine, sleep deprivation, **65**:179
antidepressants, acute phase proteins, **65**:159
antidepressants, balance, **63**:191
antidepressants, erythrocytes, **66**:87
antidepressants, immunology, **65**:159
antidepressants, kinetics, **66**:87
antidepressants, paroxetine binding in platelets, **66**:73
antidepressants, postural reflexes, **63**:191
antidepressants, psychomotor activity, **63**:191
antidepressants, selective serotonin reuptake inhibitors, **63**:191
antidepressants, serotonin, **66**:73, **66**:87
antidepressants, serotonin receptors, **66**:73
antidepressants, suicidal thoughts, **66**:73
antidepressants, tricyclics, **63**:191
antidepressants, tryptophan, **66**:87
anxiety, cortisol, **65**:143
anxiety, dopamine, **64**:209
anxiety, late-life depression, **66**:23
anxiety, norepinephrine, **64**:209
anxiety, outcome, **66**:23
anxiety, psychomotor retardation, **64**:209
attention deficit hyperactivity disorder, childhood history, **62**:213
attention deficit hyperactivity disorder, comorbidity, **62**:213
attention, eye tracking, **66**:121
attention, smooth pursuit eye movements, **66**:121
balance, antidepressants, **63**:191
balance, postural reflexes, **63**:191
balance, psychomotor activity, **63**:191
balance, selective serotonin reuptake inhibitors, **63**:191
balance, tricyclics, **63**:191
bereavement, age, **62**:161
bereavement, circadian rhythms, **62**:161
bereavement, late-life depression, **62**:161
bereavement, polysomnography, **62**:161
bereavement, sleep impairment, **62**:161
bereavement, Social Rhythm Metric, **62**:161
beta-globulin, immunology, **65**:159
bipolar subtype, acute phase proteins, **66**:1
bipolar subtype, amineptine, **65**:179
bipolar subtype, candidate genes, **63**:17
bipolar subtype, chromosome-18 markers, **63**:17
bipolar subtype, circadian rhythms, **63**:161, **63**:219
bipolar subtype, comorbidity, **64**:69
bipolar subtype, dopamine, **65**:179
bipolar subtype, genetics, **63**:17, **64**:91
bipolar subtype, immunology, **66**:1
bipolar subtype, lack of insight, **65**:113
bipolar subtype, linkage analysis, **63**:17
bipolar subtype, lithium, **63**:17, lithium, **64**:91
bipolar subtype, manic symptomatology, **65**:121
bipolar subtype, melatonin, **63**:219
bipolar subtype, migraine, **65**:73
bipolar subtype, neuropsychology, **65**:113

bipolar subtype, personality disorder, **64**:69
bipolar subtype, phenolsulfotransferase, **65**:73
bipolar subtype, psychotropic drugs, **66**:1
bipolar subtype, race effects, **64**:69
bipolar subtype, rapid cycling, **63**:161
bipolar subtype, sleep, **63**:161, **65**:121
bipolar subtype, sleep deprivation, **65**:179
bipolar subtype, sleep duration, **65**:121
bipolar subtype, tyrosine hydroxylase gene, **64**:91
calcium, inositol-phospholipid system, **65**:45
calcium, second messengers, **65**:45
candidate genes, chromosome-18 markers, **63**:17
candidate genes, linkage analysis, **63**:17
childhood history, attention deficit hyperactivity disorder, **62**:213
chromosome-18 markers, bipolar subtype, **63**:17
chromosome-18 markers, linkage analysis, **63**:17
chromosome-18 markers, lithium, **63**:17
circadian rhythms, age, **62**:161
circadian rhythms, bereavement, **62**:161
circadian rhythms, bipolar subtype, **63**:161, **63**:219
circadian rhythms, late-life depression, **62**:161
circadian rhythms, melatonin, **63**:219
circadian rhythms, polysomnography, **62**:161
circadian rhythms, rapid cycling bipolar disorder, **63**:161
circadian rhythms, sleep, **62**:161, **63**:161
circadian rhythms, sleep impairment, **62**:161
circadian rhythms, Social Rhythm Metric, **62**:161
circannual rhythms, age, **62**:265
circannual rhythms, seasonal depression, **62**:265
comorbidity, attention deficit hyperactivity disorder, **62**:213
comorbidity, personality disorder, **64**:69
comorbidity, race effects, **64**:69
cortisol, stress, **65**:143
cross-cultural, mortality rates in Taiwan, **62**:239
depressive spectrum disease, family history, **62**:171
depressive spectrum disease, methoxy-hydroxyphenylglycol, **62**:171
depressive spectrum disease, symptom severity, **62**:171
depressive spectrum disease, unipolar subtype, **62**:171
dexamethasone suppression test, endogenous subtype, **63**:83
dexamethasone suppression test, polysomnography, **63**:83
dexamethasone suppression test, sleep, **63**:83
dexamethasone suppression test, symptom severity, **63**:83
dopamine, amineptine, **65**:179
dopamine, anxiety, **64**:209
dopamine, bipolar subtype, **65**:179
dopamine, psychomotor retardation, **64**:209
dopamine, sleep deprivation, **65**:179
electroconvulsive therapy, psychotic depression, **62**:191
electroconvulsive therapy, seizure duration, **62**:191
electroconvulsive therapy, seizure threshold, **62**:179
endogenous subtype, dexamethasone suppression test, **63**:83
endogenous subtype, polysomnography, **63**:83
endogenous subtype, sleep, **63**:83
endogenous subtype, symptom severity, **63**:83
endogenous subtype, thyrotropin-releasing hormone, **63**:83
erythrocytes, antidepressants, **66**:87
erythrocytes, kinetic analysis, **63**:151, **66**:87
erythrocytes, serotonin, **63**:151, **66**:87
erythrocytes, tryptophan, **63**:151, **66**:87
eye tracking, attention, **66**:121
eye tracking, high-risk study, **66**:121
eye tracking, smooth pursuit eye movements, **66**:121
facial emotional discrimination, persistence of depression, **64**:193
family history, dementia, **62**:227
family history, depressive spectrum disease, **62**:171
gamma-globulin, immunology, **65**:159
General Life Functioning Scale, interpersonal psychotherapy, **63**:183
General Life Functioning Scale, late-life depression, **63**:183
General Life Functioning Scale, nortriptyline, **63**:183
genetics, bipolar subtype, **63**:17, **64**:91
genetics, chromosome-18 markers, **63**:17
genetics, linkage analysis, **63**:17
genetics, lithium, **63**:17, **64**:91
genetics, tyrosine hydroxylase gene, **64**:91
geriatric psychiatry, diagnostic accuracy of family history method, **62**:227
high-risk study, attention, **66**:121
high-risk study, eye tracking, **66**:121
high-risk study, smooth pursuit eye movements, **66**:121
immunology, acute phase proteins, **64**:161, **65**:159, **66**:1
immunology, albumin, **65**:159
immunology, antidepressants, **65**:159
immunology, beta-globulin, **65**:159
immunology, bipolar subtype, **66**:1
immunology, gamma-globulin, **65**:159
immunology, interleukins, **64**:161
immunology, psychotropic drugs, **66**:1
immunology, total serum protein, **65**:159
immunology, transferrin receptor, **64**:161
inositol-phospholipid system, calcium, **65**:45
inositol-phospholipid system, second messengers, **65**:45
interleukins, immunology, **64**:161
interpersonal psychotherapy, General Life Functioning Scale, **63**:183
interpersonal psychotherapy, late-life depression, **63**:183
interpersonal psychotherapy, nortriptyline, **63**:183
interpersonal psychotherapy, quality of life, **63**:183
kinetic analysis, antidepressants, **66**:87
kinetic analysis, erythrocytes, **63**:151, **66**:87
kinetic analysis, serotonin, **63**:151, **66**:87
kinetic analysis, tryptophan, **63**:151, **66**:87
late-life depression, anxiety, **66**:23
late-life depression, bereavement, **62**:161
late-life depression, circadian rhythms, **62**:161
late-life depression, General Life Functioning Scale, **63**:183
late-life depression, interpersonal psychotherapy, **63**:183
late-life depression, nortriptyline, **63**:183
late-life depression, outcome, **66**:23
late-life depression, polysomnography, **62**:161
late-life depression, quality of life, **63**:183
late-life depression, sleep impairment, **62**:161
late-life depression, Social Rhythm Metric, **62**:161
linkage analysis, bipolar subtype, **63**:17
linkage analysis, candidate genes, **63**:17
linkage analysis, chromosome-18 markers, **63**:17
lithium, bipolar subtype, **63**:17, **64**:91

lithium, chromosome-18 markers, **63**:17
lithium, genetics, **63**:17, **64**:91
lithium, tyrosine hydroxylase gene, **64**:91
manic symptomatology, bipolar subtype, **65**:121
manic symptomatology, sleep, **65**:121
manic symptomatology, sleep duration, **65**:121
melatonin, bipolar subtype, **63**:219
melatonin, circadian rhythms, **63**:219
methoxy-hydroxyphenylglycol, depressive spectrum disease, **62**:171
methoxy-hydroxyphenylglycol, symptom severity, **62**:171
methoxy-hydroxyphenylglycol, unipolar subtype, **62**:171
methoxy-hydroxyphenylglycol, urinary levels, **62**:171
migraine, phenolsulfotransferase, **65**:73
monoamine oxidase, platelets, **62**:273
monoamine oxidase, seasonal depression, **62**:273
monoamine oxidase, suicide attempts, **62**:273
mortality rates, cross-cultural, Taiwan, **62**:239
neuropsychology, bipolar subtype, **65**:113
norepinephrine, anxiety, **64**:209
norepinephrine, psychomotor retardation, **64**:209
nortriptyline, General Life Functioning Scale, **63**:183
nortriptyline, interpersonal psychotherapy, **63**:183
nortriptyline, late-life depression, **63**:183
nortriptyline, quality of life, **63**:183
outcome, late-life depression, **66**:23
paroxetine binding in platelets, serotonin receptors, **66**:73
paroxetine binding in platelets, suicidal thoughts, **66**:73
persistence of depression, facial emotional discrimination, **64**:193
personality disorder, comorbidity, **64**:69
phenolsulfotransferase, bipolar subtype, **65**:73
phenolsulfotransferase, migraine, **65**:73
phenolsulfotransferase, platelets, **65**:73
phenolsulfotransferase, unipolar subtype, **65**:73
polysomnography, age, **62**:161
polysomnography, bereavement, **62**:161
polysomnography, circadian rhythms, **62**:161
polysomnography, dexamethasone suppression test, **63**:83
polysomnography, endogenous subtype, **63**:83
polysomnography, late-life depression, **62**:161
polysomnography, Social Rhythm Metric, **62**:161
polysomnography, symptom severity, **63**:83
polysomnography, thyrotropin-releasing hormone, **63**:83
postural reflexes, antidepressants, **63**:191
postural reflexes, balance, **63**:191
postural reflexes, psychomotor activity, **63**:191
postural reflexes, selective serotonin reuptake inhibitors, **63**:191
postural reflexes, tricyclics, **63**:191
psychomotor activity, antidepressants, **63**:191
psychomotor activity, balance, **63**:191
psychomotor activity, postural reflexes, **63**:191
psychomotor activity, selective serotonin reuptake inhibitors, **63**:191
psychomotor activity, tricyclics, **63**:191
psychomotor retardation, anxiety, **64**:209
psychomotor retardation, dopamine, **64**:209
psychomotor retardation, norepinephrine, **64**:209
psychotic depression, electroconvulsive therapy, **62**:191
psychotropic drugs, acute phase proteins, **66**:1
psychotropic drugs, immunology, **66**:1
quality of life, General Life Functioning Scale, **63**:183
quality of life, interpersonal psychotherapy, **63**:183
quality of life, late-life depression, **63**:183
quality of life, nortriptyline, **63**:183
race effects, comorbidity, **64**:69
race effects, personality disorder, **64**:69
rapid cycling, bipolar subtype, **63**:161
seasonal depression, circannual rhythms, **62**:265
seasonal depression, monoamine oxidase, platelets, **62**:273
seasonal depression, suicide attempts, **62**:273
second messengers, calcium, **65**:45
second messengers, inositol-phospholipid system, **65**:45
seizure duration, electroconvulsive therapy, **62**:191
seizure threshold, electroconvulsive therapy, **62**:179
selective serotonin reuptake inhibitors, balance, **63**:191
selective serotonin reuptake inhibitors, postural reflexes, **63**:191
selective serotonin reuptake inhibitors, psychomotor activity, **63**:191
serotonin, adolescents, **65**:79
serotonin, aggression, **65**:143
serotonin, antidepressants, **66**:73, **66**:87
serotonin, anxiety, **65**:143
serotonin, paroxetine binding in platelets, **66**:73
serotonin, serotonin receptors, **66**:73
serotonin, stress, **65**:143
serotonin, suicidal thoughts, **66**:73
serotonin, tryptophan, **63**:151, **66**:87
serotonin, whole blood, **65**:79
sleep, age, **62**:161
sleep, bereavement, **62**:161
sleep, bipolar subtype, **63**:161, **65**:121
sleep, circadian rhythms, **62**:161, **63**:161
sleep, dexamethasone suppression test, **63**:83
sleep, duration, **65**:121
sleep, endogenous subtype, **63**:83
sleep, impairment, **62**:161
sleep, late-life depression, **62**:161
sleep, manic symptomatology, **65**:121
sleep, polysomnography, **62**:161, **63**:83
sleep, rapid cycling bipolar disorder, **63**:161
sleep, Social Rhythm Metric, **62**:161
sleep, symptom severity, **63**:83
sleep, thyrotropin-releasing hormone, **63**:83
sleep deprivation, amineptine, **65**:179
sleep deprivation, bipolar subtype, **65**:179
sleep deprivation, dopamine, **65**:179
sleep duration, bipolar subtype, **65**:121
sleep duration, manic symptomatology, **65**:121
sleep impairment, age, **62**:161
sleep impairment, bereavement, **62**:161
sleep impairment, late-life depression, **62**:161
sleep impairment, Social Rhythm Metric, **62**:161
smooth pursuit eye movements, attention, **66**:121
smooth pursuit eye movements, eye tracking, **66**:121
smooth pursuit eye movements, high-risk study, **66**:121

Social Rhythm Metric, age, **62**:161
Social Rhythm Metric, bereavement, **62**:161
Social Rhythm Metric, circadian rhythms, **62**:161
Social Rhythm Metric, late-life depression, **62**:161
Social Rhythm Metric, polysomnography, **62**:161
Social Rhythm Metric, sleep impairment, **62**:161
stress, aggression, **65**:143
stress, anxiety, **65**:143
stress, cortisol, **65**:143
stress, diagnostic subtype, **65**:143
stress, serotonin, **65**:143
suicidal thoughts, paroxetine binding in platelets, **66**:73
suicidal thoughts, serotonin receptors, **66**:73
suicide attempts, monoamine oxidase, platelets, **62**:273
suicide attempts, seasonal depression, **62**:273
symptom severity, depressive spectrum disease, **62**:171
symptom severity, dexamethasone suppression test, **63**:83
symptom severity, endogenous subtype, **63**:83
symptom severity, family history, **62**:171
symptom severity, methoxy-hydroxyphenylglycol, **62**:171
symptom severity, polysomnography, **63**:83
symptom severity, sleep, **63**:83
symptom severity, thyrotropin-releasing hormone, **63**:83
symptom severity, unipolar subtype, **62**:171
thyrotropin-releasing hormone, endogenous subtype, **63**:83
thyrotropin-releasing hormone, polysomnography, **63**:83
thyrotropin-releasing hormone, sleep, **63**:83
thyrotropin-releasing hormone, symptom severity, **63**:83
total serum protein, acute phase proteins, **65**:159
total serum protein, immunology, **65**:159
transferrin receptor, acute phase proteins, **64**:161
transferrin receptor, immunology, **64**:161
tricyclics, balance, **63**:191
tricyclics, postural reflexes, **63**:191
tricyclics, psychomotor activity, **63**:191
tryptophan, antidepressants, **66**:87
tryptophan, erythrocytes, **63**:151, **66**:87
tryptophan, kinetic analysis, **63**:151, **66**:87
tryptophan, serotonin, **63**:151, **66**:87
tyrosine hydroxylase gene, bipolar subtype, **64**:91
tyrosine hydroxylase gene, lithium, **64**:91
unipolar subtype, depressive spectrum disease, **62**:171
unipolar subtype, family history, **62**:171
unipolar subtype, methoxy-hydroxyphenylglycol, **62**:171
unipolar subtype, migraine, **65**:73
unipolar subtype, phenolsulfotransferase, **65**:73
unipolar subtype, symptom severity, **62**:171
urinary levels, methoxy-hydroxyphenylglycol, **62**:171

Age
affective disorder, circadian rhythms, **62**:161
affective disorder, polysomnography, **62**:161
affective disorder, sleep impairment, **62**:161
affective disorder, Social Rhythm Metric, **62**:161
bereavement, circadian rhythms, **62**:161
bereavement, late-life depression, **62**:161
bereavement, polysomnography, **62**:161
bereavement, sleep impairment, **62**:161
bereavement, Social Rhythm Metric, **62**:161
circadian rhythms, bereavement, **62**:161
circadian rhythms, late-life depression, **62**:161
circadian rhythms, polysomnography, **62**:161
circadian rhythms, sleep impairment, **62**:161
late-life depression, circadian rhythms, **62**:161
late-life depression, polysomnography, **62**:161
late-life depression, sleep impairment, **62**:161
late-life depression, Social Rhythm Metric, **62**:161
late-life psychosis, positive symptoms of schizophrenia, **63**:169
late-life psychosis, Quality of Well-Being Scale, **63**:169
late-life psychosis, schizoaffective disorder and schizophrenia, **63**:169
polysomnography, bereavement, **62**:161
polysomnography, late-life depression, **62**:161
polysomnography, sleep impairment, **62**:161
schizoaffective disorder, late-life psychosis, **63**:169
schizoaffective disorder, Quality of Well-Being Scale, **63**:169
schizophrenia, late-life psychosis, **63**:169
schizophrenia, positive symptoms, **63**:169
schizophrenia, Quality of Well-Being Scale, **63**:169
sleep, bereavement, **62**:161
sleep, late-life depression, **62**:161
sleep, Social Rhythm Metric, **62**:161
sleep impairment, bereavement, **62**:161
sleep impairment, circadian rhythms, **62**:161
sleep impairment, late-life depression, **62**:161
sleep impairment, polysomnography, **62**:161
sleep impairment, Social Rhythm Metric, **62**:161
Social Rhythm Metric, bereavement, **62**:161
Social Rhythm Metric, circadian rhythms, **62**:161
Social Rhythm Metric, late-life depression, **62**:161
Social Rhythm Metric, polysomnography, **62**:161
Social Rhythm Metric, sleep impairment, **62**:161

Aggression
cortisol, personality, **66**:33
growth hormone, personality, **66**:33
norepinephrine, personality, **66**:33
prolactin, personality, **66**:33
testosterone, personality, **66**:33

Alcohol abuse/dependence. *See also* Substance abuse/dependence
comorbidity, schizophrenia, **64**:35
evoked potentials, dipole activity, **63**:47
evoked potentials, serotonin, **63**:47
evoked potentials, stimulus intensity, **63**:47
neuropsychology, comorbidity, **64**:35
schizophrenia, comorbidity, **64**:35
serotonin, evoked potentials, **63**:47
stimulus intensity, evoked potentials, **63**:47
stimulus intensity, serotonin, **63**:47

Amineptine
affective disorder, bipolar subtype, **65**:179
affective disorder, dopamine, **65**:179
affective disorder, sleep deprivation, **65**:179
bipolar affective disorder, dopamine, **65**:179
bipolar affective disorder, sleep deprivation, **65**:179
dopamine, affective disorder, bipolar subtype, **65**:179
dopamine, sleep deprivation, **65**:179
sleep deprivation, affective disorder, bipolar subtype, **65**:179
sleep deprivation, dopamine, **65**:179

Amphetamine
activation-euphoria, ondansetron, **64**:1
activation-euphoria, serotonin, **64**:1
blood pressure, ondansetron, **64**:1
cortisol, ondansetron, **64**:1
growth hormone, ondansetron, **64**:1
ondansetron, activation-euphoria, **64**:1
ondansetron, blood pressure, **64**:1
ondansetron, cortisol, **64**:1
ondansetron, growth hormone, **64**:1
ondansetron, prolactin, **64**:1
ondansetron, serotonin, **64**:1
prolactin, ondansetron, **64**:1
serotonin, activation-euphoria, **64**:1
serotonin, ondansetron, **64**:1

Animal models
anorexia nervosa, beagle dogs, **62**:51
antisense oligonucleotide, hippocampus, **63**:197
antisense oligonucleotide, learned helplessness, **63**:197
antisense oligonucleotide, serotonin, **63**:197
antisense oligonucleotide, Sprague-Dawley rats, **63**:197
beagle dogs, anorexia nervosa, **62**:51
beagle dogs, caloric restriction, **62**:51
beagle dogs, cholinergic agonists and antagonists, **62**:51
beagle dogs, growth hormone, **62**:51
beagle dogs, somatostatin, **62**:51
beagle dogs, thyrotropin-releasing hormone, **62**:51
cholinergic agonists and antagonists, beagle dogs, **62**:51
cholinergic agonists and antagonists, caloric restriction, **62**:51
clozapine, dopamine, **62**:259
clozapine, Sprague-Dawley rats, **62**:259
clozapine, uptake of dopamine in platelets, **62**:259
dopamine, clozapine, **62**:259
dopamine, haloperidol, **62**:259
dopamine, Sprague-Dawley rats, **62**:259
dopamine uptake in platelets, **62**:259
growth hormone, beagle dogs, **62**:51
haloperidol, dopamine, **62**:259
haloperidol, Sprague-Dawley rats, **62**:259
haloperidol, uptake of dopamine in platelets, **62**:259
hippocampus, antisense oligonucleotide, **63**:197
hippocampus, learned helplessness, **63**:197
hippocampus, serotonin, **63**:197
hippocampus, Sprague-Dawley rats, **63**:197
learned helplessness, antisense oligonucleotide, **63**:197
learned helplessness, hippocampus, **63**:197
learned helplessness, serotonin, **63**:197
learned helplessness, Sprague-Dawley rats, **63**:197
rapid eye movement sleep, sleep deprivation, **66**:97
rapid eye movement sleep, Sprague-Dawley rats, **66**:97
serotonin, antisense oligonucleotide, **63**:197
serotonin, hippocampus, **63**:197
serotonin, learned helplessness, **63**:197
serotonin, Sprague-Dawley rats, **63**:197
sleep deprivation, rapid eye movement sleep, **66**:97
sleep deprivation, slow wave sleep, **66**:97
sleep deprivation, Sprague-Dawley rats, **66**:97
slow wave sleep, Sprague-Dawley rats, **66**:97
somatostatin, beagle dogs, **62**:51
somatostatin, caloric restriction, **62**:51
Sprague-Dawley rats, antisense oligonucleotide, **63**:197
Sprague-Dawley rats, clozapine, **62**:259
Sprague-Dawley rats, haloperidol, **62**:259
Sprague-Dawley rats, hippocampus, **63**:197
Sprague-Dawley rats, learned helplessness, **63**:197
Sprague-Dawley rats, rapid eye movement sleep, **66**:97
Sprague-Dawley rats, serotonin, **63**:197
Sprague-Dawley rats, sleep deprivation, **66**:97
Sprague-Dawley rats, slow wave sleep, **66**:97
Sprague-Dawley rats, uptake of dopamine in platelets, **62**:259
thyrotropin-releasing hormone, beagle dogs, **62**:51
thyrotropin-releasing hormone, caloric restriction, **62**:51
uptake of dopamine in platelets, clozapine, **62**:259
uptake of dopamine in platelets, haloperidol, **62**:259
uptake of dopamine in platelets, Sprague-Dawley rats, **62**:259

Anorexia nervosa. *See* Eating disorders

Antidepressants
affective disorder, balance, **63**:191
affective disorder, postural reflexes, **63**:191
affective disorder, psychomotor activity, **63**:191
psychomotor activity, affective disorder, **63**:191
psychomotor activity, selective serotonin reuptake inhibitors, **63**:191
psychomotor activity, tricyclics, **63**:191
selective serotonin reuptake inhibitors, balance, **63**:191
selective serotonin reuptake inhibitors, postural reflexes, **63**:191
selective serotonin reuptake inhibitors, psychomotor activity, **63**:191
tricyclics, balance, **63**:191
tricyclics, postural reflexes, **63**:191
tricyclics, psychomotor activity, **63**:191

Antisocial personality
beta-endorphin, prepubertal boys, family history in fathers, **62**:203
homovanillic acid, prepubertal boys, family history in fathers, **62**:203
methoxy-hydroxyphenylglycol, prepubertal boys, family history in fathers, **62**:203
prepubertal boys, family history, **62**:203

Anxiety. *See also* Generalized anxiety disorder; Panic disorder
benzodiazepines, dopamine, **65**:53
benzodiazepines, homovanillic acid, **65**:53
cortisol, stress, **63**:7
diazepam, dopamine, **65**:53
diazepam, homovanillic acid, **65**:53
dopamine, benzodiazepines, **65**:53
dopamine, diazepam, **65**:53
dopamine, homovanillic acid, **65**:53
homovanillic acid, benzodiazepines, **65**:53
homovanillic acid, diazepam, **65**:53
homovanillic acid, dopamine, **65**:53
homovanillic acid, stress, **63**:7
hydroxyindoleacetic acid, stress, **63**:7
methoxy-hydroxyphenylglycol, stress, **63**:7

stress, cortisol, **63**:7
stress, homovanillic acid, **63**:7
stress, hydroxyindoleacetic acid, **63**:7
stress, methoxy-hydroxyphenylglycol, **63**:7
stress, vanillylmandelic acid, **63**:7
vanillylmandelic acid, stress, **63**:7

Attention

affective disorder, eye tracking, **66**:121
affective disorder, smooth pursuit eye movements, **66**:121
eye-tracking performance, first-episode psychosis, **64**:19
eye-tracking performance, schizophrenia, **64**:19
eye-tracking performance, schizophreniform disorder, **64**:19
eye tracking, affective disorder, **66**:121
eye tracking, schizophrenia, **66**:121
eye tracking, smooth pursuit eye movements, **66**:121
family studies, nonpsychotic relatives, **66**:131
family studies, schizophrenia, **66**:131
family studies, sex differences, **66**:131
family studies, vulnerability indicators, **66**:131
first-episode psychosis, eye-tracking performance, **64**:19
first-episode psychosis, schizophrenia and schizophreniform disorder, **64**:19
first-episode psychosis, smooth pursuit eye movements, **64**:19
gender, family studies, schizophrenia vulnerability indicators, **66**:131
Global/Local Task, laterality, **62**:111
Global/Local Task, left hemisphere deficit, **62**:111
Global/Local Task, reaction time, **62**:111
Global/Local Task, schizophrenia, **62**:111
laterality, Global/Local Task, **62**:111
laterality, reaction time, **62**:111
laterality, schizophrenia, **62**:111
left hemisphere deficit, Global/Local Task, **62**:111
left hemisphere deficit, reaction time, **62**:111
left hemisphere deficit, schizophrenia, **62**:111
medication withdrawal, negative priming, **62**:121
medication withdrawal, reaction time, **62**:121
medication withdrawal, schizophrenia, **62**:121
medication withdrawal, Stroop Task, **62**:121
negative priming, medication withdrawal, **62**:121
negative priming, reaction time, **62**:121
negative priming, schizophrenia, **62**:121
negative priming, Stroop Task, **62**:121
reaction time, Global/Local Task, **62**:111
reaction time, laterality, **62**:111
reaction time, left hemisphere deficit, **62**:111
reaction time, medication withdrawal, **62**:121
reaction time, negative priming, **62**:121
reaction time, schizophrenia, **62**:111, **62**:121
reaction time, Stroop Task, **62**:121
schizophrenia, eye-tracking performance, **64**:19, **66**:121
schizophrenia, family studies, **66**:131
schizophrenia, first-episode psychosis, **64**:19
schizophrenia, gender effects, **66**:131
schizophrenia, Global/Local Task, **62**:111
schizophrenia, high-risk study, **66**:121
schizophrenia, left hemisphere deficit, **62**:111
schizophrenia, medication withdrawal, **62**:121
schizophrenia, negative priming, **62**:121
schizophrenia, nonpsychotic relatives, **66**:131
schizophrenia, reaction time, **62**:111, **62**:121
schizophrenia, sex differences, **66**:131
schizophrenia, smooth pursuit eye movements, **64**:19, **66**:121
schizophrenia, Stroop Task, **62**:121
schizophrenia, vulnerability indicators, **66**:131
schizophreniform disorder, eye-tracking performance, **64**:19
schizophreniform disorder, smooth pursuit eye movements, **64**:19
smooth pursuit eye movements, affective disorder, **66**:121
smooth pursuit eye movements, first-episode psychosis, **64**:19
smooth pursuit eye movements, high-risk study, **66**:121
smooth pursuit eye movements, schizophrenia, **64**:19, **66**:121
smooth pursuit eye movements, schizophreniform disorder, **64**:19
Stroop Task, medication withdrawal, **62**:121
Stroop Task, negative priming, **62**:121
Stroop Task, reaction time, **62**:121
Stroop Task, schizophrenia, **62**:121
vulnerability indicators, family studies of schizophrenia, **66**:131
vulnerability indicators, nonpsychotic relatives, **66**:131

Attention deficit hyperactivity disorder

affective disorder, comorbidity, **62**:213
affective disorder, conduct disorder, **65**:79
c-Harvey-Ras gene, genetics, **63**:25
children, conduct disorder, **65**:79
children, whole blood serotonin, **65**:79
comorbidity, affective disorder, **62**:213
conduct disorder, whole blood serotonin, **65**:79
evoked potentials, oddball paradigm, **64**:179
genetics, c-Harvey-Ras gene, **63**:25
serotonin, conduct disorder, **65**:79
serotonin, whole blood, **65**:79

Autism

adrenocorticotropin 4-9 analogue, evoked potentials, **63**:33
evoked potentials, adrenocorticotropin 4-9 analogue, **63**:33
evoked potentials, ORG-2766, **63**:33
genetics, c-Harvey-Ras gene, **63**:25
genetics, serotonin receptor gene, **65**:33
hydroxyindoleacetic acid, genetics, **65**:33
hydroxyindoleacetic acid, serotonin receptor gene, **65**:33
ORG-2766, evoked potentials, **63**:33
serotonin, genetics, **65**:33
serotonin receptor gene, 5-hydroxyindoleacetic acid, **65**:33

Benzodiazepines

dopamine, generalized anxiety disorder, **65**:53
dopamine, homovanillic acid, **65**:53
dopamine, panic disorder, **65**:53
generalized anxiety disorder, dopamine, **65**:53
generalized anxiety disorder, homovanillic acid, **65**:53
homovanillic acid, dopamine, **65**:53
homovanillic acid, generalized anxiety disorder, **65**:53
homovanillic acid, panic disorder, **65**:53
panic disorder, dopamine, **65**:53
panic disorder, homovanillic acid, **65**:53

Bereavement
affective disorder, circadian rhythms, **62**:161
affective disorder, late-life depression, **62**:161
affective disorder, sleep impairment, **62**:161
affective disorder, Social Rhythm Metric, **62**:161
age, circadian rhythms, **62**:161
age, late-life depression, **62**:161
age, sleep impairment, **62**:161
age, Social Rhythm Metric, **62**:161
circadian rhythms, age, **62**:161
circadian rhythms, late-life depression, **62**:161
circadian rhythms, polysomnography, **62**:161
circadian rhythms, sleep impairment, **62**:161
late-life depression, age, **62**:161
late-life depression, circadian rhythms, **62**:161
late-life depression, sleep impairment, **62**:161
late-life depression, Social Rhythm Metric, **62**:161
polysomnography, late-life depression, **62**:161
sleep, age, **62**:161
sleep, circadian rhythms, **62**:161
sleep, late-life depression, **62**:161

Beta-endorphin
anorexia nervosa, **62**:65, **62**:97
antisocial personality disorder family history, prepubertal boys, **62**:203
bulimia nervosa, **62**:97
family history of substance abuse/dependence, **62**:203
immunology, anorexia nervosa, **62**:97
immunology, bulimia nervosa, **62**:97
prepubertal boys, family history of antisocial personality disorder, **62**:203
prepubertal boys, family history of substance abuse/dependence, **62**:203
substance abuse/dependence family history, prepubertal boys, **62**:203

Borderline personality
analgesia, self-injury, **63**:57
dissociation, analgesia, **63**:57
dissociation, pain, **63**:57
dissociation, self-injury, **63**:57
pain, dissociation, **63**:57
pain, self-injury, **63**:57
self-injury, analgesia, **63**:57
self-injury, dissociation, **63**:57
self-injury, pain, **63**:57

Brain tumors
frontal lobe, neuropsychology, **65**:15
frontal lobe, Wisconsin Card Sorting Test, **65**:15
neuropsychology, frontal lobe, **65**:15
neuropsychology, Wisconsin Card Sorting Test, **65**:15
Wisconsin Card Sorting Test, frontal lobe, **65**:15

Bulimia nervosa. *See* Eating disorders

Carbohydrate metabolism
anorexia nervosa, bulimia nervosa, **62**:85
bulimia nervosa, anorexia nervosa, **62**:85

Cataplexy
dissociative identity disorder, muscular weakness, **63**:231
multiple personality, muscular weakness, **63**:231
substance abuse/dependence, muscular weakness, **63**:231

Child psychiatry. *See also* Attention deficit hyperactivity disorder; Autism
affect regulation, Children's Affective Lability Scale, **65**:189
affective disorder, serotonin, **65**:79
apathy, Children's Motivation Scale, **63**:205
attention deficit hyperactivity disorder, evoked potential oddball paradigm, **64**:179
attention deficit hyperactivity disorder, serotonin, **65**:79
Children's Affective Lability Scale, psychometrics, **65**:189
Children's Motivation Scale, psychometrics, **63**:205
conduct disorder, serotonin, **65**:79
evoked potentials, attention deficit hyperactivity disorder, **64**:179
evoked potentials, oddball paradigm, **64**:179
psychometrics, Children's Affective Lability Scale, **65**:189
psychometrics, Children's Motivation Scale, **63**:205
serotonin, attention deficit hyperactivity disorder, **65**:79
serotonin, conduct disorder, **65**:79
serotonin, whole blood, adolescents and children, **65**:79

Cholecystokinin
adrenocorticotropic hormone, anorexia and bulimia nervosa, **62**:97
anorexia and bulimia nervosa, adrenocorticotropic hormone, **62**:97
anorexia and bulimia nervosa, beta-endorphin, **62**:97
anorexia and bulimia nervosa, corticotropin-releasing hormone, **62**:97
anorexia and bulimia nervosa, cortisol, **62**:97
anorexia and bulimia nervosa, immunology, **62**:97
anorexia and bulimia nervosa, phytohemoagglutinin, **62**:97
anorexia and bulimia nervosa, T-lymphocytes, **62**:97
anxiety, normal volunteers, **66**:59
anxiety, panic attacks, **66**:59
Anxiety Sensitivity Index, panic disorder, **62**:131
beta-endorphin, anorexia and bulimia nervosa, **62**:97
corticotropin-releasing hormone, anorexia and bulimia nervosa, **62**:97
cortisol, anorexia and bulimia nervosa, **62**:97
immunology, anorexia and bulimia nervosa, **62**:97
introversion, Minnesota Multiphasic Personality Inventory, **62**:131
introversion, panic disorder, **62**:131
Minnesota Multiphasic Personality Inventory, introversion, **62**:131
Minnesota Multiphasic Personality Inventory, panic disorder, **62**:131
panic, normal volunteers, **66**:59
panic attacks, normal volunteers, **66**:59
panic disorder, Anxiety Sensitivity Index, **62**:131
panic disorder, introversion, **62**:131
panic disorder, Minnesota Multiphasic Personality Inventory, **62**:131
panic disorder, personality, **62**:131

personality, introversion, **62**:131
personality, panic disorder, **62**:131
phytohemoagglutinin, anorexia and bulimia nervosa, **62**:97
T-lymphocytes, anorexia nervosa and bulimia nervosa, **62**:97

Cholinergic drugs
animal studies, anorexia nervosa, **62**:51
animal studies, beagle dogs, caloric restriction, **62**:51
animal studies, caloric restriction, **62**:51
anorexia nervosa, animal studies, beagle dogs, **62**:51
anorexia nervosa, growth hormone, **62**:51
anorexia nervosa, somatostatin, **62**:51
anorexia nervosa, thyrotropin-releasing hormone, **62**:51
beagle dogs, caloric restriction, **62**:51
growth hormone, anorexia nervosa, **62**:51
growth hormone, beagle dogs, caloric restriction, **62**:51
somatostatin, anorexia nervosa, **62**:51
somatostatin, beagle dogs, caloric restriction, **62**:51
thyrotropin-releasing hormone, anorexia nervosa, **62**:51
thyrotropin-releasing hormone, beagle dogs, caloric restriction, **62**:51

Circadian rhythms
affective disorder, age, **62**:161
affective disorder, bipolar subtype, **63**:161, **63**:219
affective disorder, late-life depression, **62**:161
affective disorder, melatonin, **63**:219
affective disorder, polysomnography, **62**:161
affective disorder, rapid cycling, **63**:161
affective disorder, sleep, **62**:161, **63**:161
affective disorder, sleep impairment, **62**:161
affective disorder, Social Rhythm Metric, **62**:161
age, affective disorder, **62**:161
age, bereavement, **62**:161
age, late-life depression, **62**:161
age, polysomnography, **62**:161
age, sleep impairment, **62**:161
age, Social Rhythm Metric, **62**:161
bereavement, age, **62**:161
bereavement, late-life depression, **62**:161
bereavement, polysomnography, **62**:161
bereavement, sleep impairment, **62**:161
bereavement, Social Rhythm Metric, **62**:161
bipolar affective disorder, **63**:161, **63**:219
bipolar affective disorder, melatonin, **63**:219
bipolar affective disorder, rapid cycling, **63**:161
bipolar affective disorder, sleep, **63**:161
depressed mood, estradiol, **62**:147
depressed mood, menstrual cycle, **62**:147
depressed mood, progesterone, **62**:147
depressed mood, prolactin, **62**:147
depressed mood, sleep deprivation, **62**:147
depressed mood, thyroid-stimulating hormone, **62**:147
estradiol, depressed mood, **62**:147
estradiol, menstrual cycle, **62**:147
estradiol, sleep deprivation, **62**:147
late-life depression, bereavement, **62**:161
late-life depression, polysomnography, **62**:161
late-life depression, sleep impairment, **62**:161
late-life depression, Social Rhythm Metric, **62**:161
melatonin, affective disorder, **63**:219
melatonin, bipolar affective disorder, **63**:219
menstrual cycle, depressed mood, **62**:147
menstrual cycle, estradiol, **62**:147
menstrual cycle, progesterone, **62**:147
menstrual cycle, prolactin, **62**:147
menstrual cycle, sleep deprivation, **62**:147
menstrual cycle, thyroid-stimulating hormone, **62**:147
polysomnography, affective disorder, **62**:161
polysomnography, age, **62**:161
polysomnography, bereavement, **62**:161
polysomnography, late-life depression, **62**:161
polysomnography, Social Rhythm Metric, **62**:161
progesterone, depressed mood, **62**:147
progesterone, menstrual cycle, **62**:147
progesterone, sleep deprivation, **62**:147
prolactin, depressed mood, **62**:147
prolactin, menstrual cycle, **62**:147
prolactin, sleep deprivation, **62**:147
rapid cycling, affective disorder, **63**:161
rapid cycling, bipolar affective disorder, **63**:161
sleep, affective disorder, **62**:161
sleep, age, **62**:161
sleep, bereavement, **62**:161
sleep, bipolar affective disorder, **63**:161
sleep, late-life depression, **62**:161
sleep, Social Rhythm Metric, **62**:161
sleep deprivation, depressed mood, **62**:147
sleep deprivation, early vs. late, **62**:147
sleep deprivation, estradiol, **62**:147
sleep deprivation, menstrual cycle, **62**:147
sleep deprivation, progesterone, **62**:147
sleep deprivation, prolactin, **62**:147
sleep deprivation, thyroid-stimulating hormone, **62**:147
Social Rhythm Metric, bereavement, **62**:161
Social Rhythm Metric, late-life depression, **62**:161
Social Rhythm Metric, polysomnography, **62**:161
Social Rhythm Metric, sleep impairment, **62**:161
thyroid-stimulating hormone, depressed mood, **62**:147
thyroid-stimulating hormone, menstrual cycle, **62**:147
thyroid-stimulating hormone, sleep deprivation, **62**:147

Circannual rhythms
affective disorder, age, **62**:265
affective disorder, seasonal depression, **62**:265
age, affective disorder, **62**:265
age, seasonal depression, **62**:265
demographic factors, South Africa, **66**:13
demographic factors, suicide, **66**:13
seasonal depression, affective disorder, **62**:265
seasonal depression, age, **62**:265
suicide, demographic factors, **66**:13
suicide, South Africa, **66**:13

Clozapine
animal model, dopamine, **62**:259
animal model, haloperidol, **62**:259
animal model, Sprague-Dawley rats, **62**:259

animal model, uptake of dopamine in platelets, **62**:259
dopamine, animal model, **62**:259
dopamine, haloperidol, **62**:259
dopamine, Sprague-Dawley rats, **62**:259
dopamine, uptake of dopamine in platelets, **62**:259
haloperidol, animal model, **62**:259
haloperidol, dopamine, **62**:259
haloperidol, Sprague-Dawley rats, **62**:259
haloperidol, uptake of dopamine in platelets, **62**:259
Sprague-Dawley rats, animal model, **62**:259
Sprague-Dawley rats, dopamine, **62**:259
Sprague-Dawley rats, haloperidol, **62**:259
Sprague-Dawley rats, uptake of dopamine in platelets, **62**:259
uptake of dopamine in platelets, animal model, **62**:259
uptake of dopamine in platelets, dopamine, **62**:259
uptake of dopamine in platelets, haloperidol, **62**:259
uptake of dopamine in platelets, Sprague-Dawley rats, **62**:259

Cocaine. *See also* Substance abuse/dependence
abstinence, craving, **65**:65
craving, abstinence, **65**:65
dopamine, craving, **65**:65
growth hormone, abstinence, **65**:65
growth hormone, craving, **65**:65
methylphenidate, substance abuse/dependence, **65**:65
prolactin, craving, **65**:65

Computed tomography
anorexia nervosa, **62**:105
cortical atrophy, age of onset of schizophrenia, **64**:47
cortical atrophy, homovanillic acid, methoxy-hydroxyphenylglycol, **64**:47
cortical atrophy, schizophrenia, treatment response prediction, **64**:47
homovanillic acid, cortical atrophy, sulcal widening, **64**:47
methoxy-hydroxyphenylglycol, cortical atrophy, sulcal widening, **64**:47
schizophrenia, age of onset, **64**:47
schizophrenia, cortical atrophy, sulcal widening, **64**:47
schizophrenia, treatment response prediction, **64**:47
sulcal widening, age of onset of schizophrenia, **64**:47
sulcal widening, homovanillic acid, methoxy-hydroxyphenylglycol, **64**:47
sulcal widening, treatment response prediction, schizophrenia, **64**:47
treatment response prediction, cortical atrophy, **64**:47
treatment response prediction, haloperidol, **64**:47
treatment response prediction, schizophrenia, **64**:47
treatment response prediction, sulcal widening, **64**:47

Corticotropin-releasing hormone
anorexia nervosa, **62**:65, **62**:75, **62**:97
bulimia nervosa, **62**:97
immunology, anorexia nervosa, **62**:97

Cortisol
activation-euphoria, amphetamine, **64**:1
affective disorder, aggression, anxiety, stress, **65**:143
aggression, affective disorder, **65**:143
amphetamine, activation-euphoria, **64**:1
anorexia and bulimia nervosa, immunology, **62**:97
anorexia nervosa, dexamethasone suppression test, **62**:75
anxiety, affective disorder, **65**:143
anxiety, stress, **63**:7, **65**:143
dexamethasone suppression test, anorexia nervosa, **62**:75
immunology, bulimia nervosa, **62**:97
meta-chlorophenylpiperazine, healthy volunteers, **62**:139
meta-chlorophenylpiperazine, panic disorder, **64**:77
meta-chlorophenylpiperazine, schizophrenia, **64**:147
ondansetron, activation-euphoria, **64**:1
ondansetron, amphetamine, **64**:1
panic disorder, meta-chlorophenylpiperazine, **64**:77
personality, aggression, **66**:33
schizophrenia, meta-chlorophenylpiperazine, **64**:147
stress, affective disorder, **65**:143
stress, anxiety, **63**:7, **65**:143

Cross-cultural
affective disorder, mortality rates, Taiwan, **62**:239
anorexia nervosa, Brazil, **62**:17
anorexia nervosa, Japan, **62**:11
Brazil, anorexia nervosa, **62**:17
bulimia nervosa, Japan, **62**:11
Japan, anorexia and bulimia nervosa, **62**:11
mortality rates, affective disorder, **62**:239
mortality rates, organic mental disorders, **62**:239
mortality rates, psychiatric inpatients, **62**:239
mortality rates, schizophrenia, **62**:239
mortality rates, substance abuse/dependence, **62**:239
mortality rates, Taiwan, **62**:239
organic mental disorders, mortality rates, Taiwan, **62**:239
psychiatric inpatients, mortality rates, Taiwan, **62**:239
schizophrenia, mortality rates, Taiwan, **62**:239
substance abuse/dependence, mortality rates, Taiwan, **62**:239
Taiwan, affective disorder, **62**:239
Taiwan, mortality rates, **62**:239
Taiwan, organic mental disorders, **62**:239
Taiwan, psychiatric inpatients, **62**:239
Taiwan, schizophrenia, **62**:239
Taiwan, substance abuse/dependence, **62**:239

Darier's Disease
schizophreniform psychosis, skin disorder, **64**:205
skin disorder, schizophreniform psychosis, **64**:205

Dementia
diagnostic accuracy of family history method, geriatric psychiatry, **62**:227
family history, diagnostic accuracy of method, **62**:227
family history, geriatric psychiatry, **62**:227
geriatric psychiatry, diagnostic accuracy of family history method, **62**:227
geriatric psychiatry, family history, **62**:227

Depression. *See* Affective disorder

Desmethylimipramine
growth hormone, orthostatic challenge, **63**:1
growth hormone, posttraumatic stress disorder, **63**:1
norepinephrine, orthostatic challenge, **63**:1

norepinephrine, posttraumatic stress disorder, **63**:1
orthostatic challenge, growth hormone, **63**:1
orthostatic challenge, norepinephrine, **63**:1
orthostatic challenge, posttraumatic stress disorder, **63**:1
posttraumatic stress disorder, growth hormone, **63**:1
posttraumatic stress disorder, norepinephrine, **63**:1
posttraumatic stress disorder, orthostatic challenge, **63**:1

Dexamethasone suppression test
adrenocorticotropic hormone, anorexia nervosa, **62**:75
affective disorder, endogenous subtype, **63**:83
affective disorder, polysomnography, **63**:83
affective disorder, sleep, **63**:83
affective disorder, symptom severity, **63**:83
anorexia nervosa, adrenocorticotropic hormone, **62**:75
anorexia nervosa, corticotropin-releasing hormone, **62**:75
anorexia nervosa, cortisol, **62**:75
corticotropin-releasing hormone, anorexia nervosa, **62**:75
cortisol, anorexia nervosa, **62**:75
endogenous subtype of affective disorder, polysomnography, **63**:83
endogenous subtype of affective disorder, symptom severity, **63**:83
polysomnography, affective disorder, endogenous subtype, **63**:83
sleep, affective disorder, endogenous subtype, **63**:83
symptom severity, affective disorder, endogenous subtype, **63**:83

Dopamine
abstinence, cocaine craving, **65**:65
affective disorder, bipolar subtype, **65**:179
affective disorder, sleep deprivation, **65**:179
affective disorder, psychomotor retardation, **64**:209
amineptine, affective disorder, bipolar subtype, **65**:179
amineptine, sleep deprivation, **65**:179
animal model, clozapine, **62**:259
animal model, haloperidol, **62**:259
animal model, Sprague-Dawley rats, **62**:259
animal model, uptake of dopamine in platelets, **62**:259
anxiety, benzodiazepines, **65**:53
anxiety, diazepam, **65**:53
anxiety, homovanillic acid, **65**:53
anxiety, psychomotor retardation, **64**:209
benzodiazepines, anxiety, **65**:53
benzodiazepines, generalized anxiety disorder, **65**:53
benzodiazepines, homovanillic acid, **65**:53
benzodiazepines, panic disorder, **65**:53
bipolar subtype, affective disorder, **65**:179
clozapine, animal model, Sprague-Dawley rats, **62**:259
clozapine, uptake of dopamine in platelets, **62**:259
cocaine, abstinence, **65**:65
cocaine, craving, **65**:65
cocaine, prolactin, **65**:65
diazepam, anxiety, **65**:53
diazepam, generalized anxiety disorder, **65**:53
diazepam, homovanillic acid, **65**:53
diazepam, panic disorder, **65**:53
DNA polymorphism, association study, **62**:221
DNA polymorphism, candidate gene, **62**:221
DNA polymorphism, monoamine oxidase, **62**:221
DNA polymorphism, schizophrenia, **62**:221
generalized anxiety disorder, benzodiazepines, **65**:53
generalized anxiety disorder, diazepam, **65**:53
generalized anxiety disorder, homovanillic acid, **65**:53
genetics, association study, **62**:221
genetics, candidate gene, **62**:221
genetics, DNA polymorphism, **62**:221
genetics, monoamine oxidase, **62**:221
genetics, schizophrenia, **62**:221
haloperidol, animal model, **62**:259
haloperidol, clozapine, **62**:259
haloperidol, Sprague-Dawley rats, **62**:259
haloperidol, uptake of dopamine in platelets, **62**:259
homovanillic acid, anxiety, **65**:53
homovanillic acid, benzodiazepines, **65**:53
homovanillic acid, diazepam, **65**:53
homovanillic acid, generalized anxiety disorder, **65**:53
homovanillic acid, panic disorder, **65**:53
methamphetamine, flashbacks, **63**:93
methamphetamine, paranoid-hallucinatory psychosis, **63**:93
methamphetamine, substance abuse/dependence, **63**:93
monoamine oxidase, association study, **62**:221
monoamine oxidase, candidate gene, **62**:221
monoamine oxidase, DNA polymorphism, **62**:221
monoamine oxidase, genetics, **62**:221
monoamine oxidase, schizophrenia, **62**:221
panic disorder, benzodiazepines, **65**:53
panic disorder, diazepam, **65**:53
panic disorder, homovanillic acid, **65**:53
paranoid-hallucinatory psychosis, flashbacks, **63**:93
paranoid-hallucinatory psychosis, methamphetamine, **63**:93
prolactin, cocaine craving, **65**:65
psychomotor retardation, affective disorder, **64**:209
psychomotor retardation, anxiety, **64**:209
schizophrenia, candidate gene, **62**:221
schizophrenia, DNA polymorphism, **62**:221
schizophrenia, genetics, **62**:221
schizophrenia, monoamine oxidase, **62**:221
sleep deprivation, affective disorder, **65**:179
sleep deprivation, amineptine, **65**:179
sleep deprivation, bipolar affective disorder, **65**:179
Sprague-Dawley rats, animal model, clozapine, **62**:259
Sprague-Dawley rats, haloperidol, **62**:259
Sprague-Dawley rats, uptake of dopamine in platelets, **62**:259
substance abuse/dependence, prolactin, **65**:65
uptake of dopamine in platelets, animal model, **62**:259
uptake of dopamine in platelets, clozapine, **62**:259
uptake of dopamine in platelets, haloperidol, **62**:259
uptake of dopamine in platelets, Sprague-Dawley rats, **62**:259

Eating disorders
adrenocorticotropic hormone, beta-endorphin, **62**:97
adrenocorticotropic hormone, cholecystokinin, **62**:97
adrenocorticotropic hormone, corticotropin-releasing hormone, **62**:75, **62**:97
adrenocorticotropic hormone, cortisol, **62**:75, **62**:97
adrenocorticotropic hormone, dexamethasone suppression test, **62**:75
adrenocorticotropic hormone, immunology, **62**:97

adrenocorticotropic hormone, phytohemoagglutinin, **62**:97
adrenocorticotropic hormone, T-lymphocytes, **62**:97
animal studies, beagle dogs, **62**:51
animal studies, caloric restriction, **62**:51
animal studies, cholinergic agonists and antagonists, **62**:51
animal studies, growth hormone, **62**:51
animal studies, somatostatin, **62**:51
animal studies, thyrotropin-releasing hormone, **62**:51
beagle dogs, animal studies, **62**:51
beagle dogs, caloric restriction, **62**:51
beagle dogs, cholinergic agonists and antagonists, **62**:51
beagle dogs, growth hormone, **62**:51
beagle dogs, somatostatin, **62**:51
beagle dogs, thyrotropin-releasing hormone, **62**:51
beta-endorphin, adrenocorticotropic hormone, **62**:97
beta-endorphin, cholecystokinin, **62**:97
beta-endorphin, corticotropin-releasing hormone, **62**:65, **62**:97
beta-endorphin, cortisol, **62**:97
beta-endorphin, immunology, **62**:97
beta-endorphin, neuropeptide Y, **62**:65
beta-endorphin, oxytocin, **62**:65
beta-endorphin, phytohemoagglutinin, **62**:97
beta-endorphin, T-lymphocytes, **62**:97
beta-endorphin, vasopressin, **62**:65
caloric restriction, animal studies, beagle dogs, **62**:51
caloric restriction, cholinergic agonists and antagonists, **62**:51
caloric restriction, growth hormone, **62**:51
caloric restriction, somatostatin, **62**:51
caloric restriction, thyrotropin-releasing hormone, **62**:51
carbohydrate metabolism, free fatty acids, **62**:85
carbohydrate metabolism, glucose tolerance, **62**:85
carbohydrate metabolism, insulin, **62**:85
carbohydrate metabolism, ketone bodies, **62**:85
cholecystokinin, adrenocorticotropic hormone, **62**:97
cholecystokinin, beta-endorphin, **62**:97
cholecystokinin, corticotropin-releasing hormone, **62**:97
cholecystokinin, cortisol, **62**:97
cholecystokinin, immunology, **62**:97
cholecystokinin, phytohemoagglutinin, **62**:97
cholecystokinin, T-lymphocytes, **62**:97
cholinergic agonists and antagonists, animal studies, beagle dogs, **62**:51
cholinergic agonists and antagonists, caloric restriction, **62**:51
cholinergic agonists and antagonists, growth hormone, **62**:51
cholinergic agonists and antagonists, somatostatin, **62**:51
cholinergic agonists and antagonists, thyrotropin-releasing hormone, **62**:51
computed tomography, **62**:105
corticotropin-releasing hormone, adrenocorticotropic hormone, **62**:75, **62**:97
corticotropin-releasing hormone, beta-endorphin, **62**:65, **62**:97
corticotropin-releasing hormone, cholecystokinin, **62**:97
corticotropin-releasing hormone, cortisol, **62**:75, **62**:97
corticotropin-releasing hormone, dexamethasone suppression test, **62**:75
corticotropin-releasing hormone, immunology, **62**:97
corticotropin-releasing hormone, neuropeptide Y, **62**:65
corticotropin-releasing hormone, oxytocin, **62**:65
corticotropin-releasing hormone, phytohemoagglutinin, **62**:97
corticotropin-releasing hormone, T-lymphocytes, **62**:97
corticotropin-releasing hormone, vasopressin, **62**:65
cortisol, adrenocorticotropic hormone, **62**:75, **62**:97
cortisol, beta-endorphin, **62**:97
cortisol, cholecystokinin, **62**:97
cortisol, corticotropin-releasing hormone, **62**:75, **62**:97
cortisol, dexamethasone suppression test, **62**:75
cortisol, immunology, **62**:97
cortisol, phytohemoagglutinin, **62**:97
cortisol, T-lymphocytes, **62**:97
cross-cultural, Brazil, **62**:17
cross-cultural, Japan, **62**:11
dexamethasone suppression test, adrenocorticotropic hormone, **62**:75
dexamethasone suppression test, corticotropin-releasing hormone, **62**:75
dexamethasone suppression test, cortisol, **62**:75
eating behavior, satiety, **62**:23
eating behavior, serotonin, **62**:23
epidemiology, risk factors, **62**:3
exercise, **62**:51, **62**:43
exercise, methoxy-hydroxyphenylglycol, **62**:43
exercise, norepinephrine, **62**:43
exercise, stress, **62**:43
exercise, test meals, **62**:43
free fatty acids, carbohydrate metabolism, **62**:85
free fatty acids, glucose tolerance, **62**:85
free fatty acids, insulin, **62**:85
free fatty acids, ketone bodies, **62**:85
glucose tolerance, carbohydrate metabolism, **62**:85
glucose tolerance, free fatty acids, **62**:85
glucose tolerance, insulin, **62**:85
glucose tolerance, ketone bodies, **62**:85
growth hormone, animal studies, beagle dogs, **62**:51
growth hormone, caloric restriction, **62**:51
growth hormone, cholinergic agonists and antagonists, **62**:51
growth hormone, meta-chlorophenylpiperazine, **62**:31
growth hormone, prolactin, **62**:31
growth hormone, serotonin, **62**:31
growth hormone, thyrotropin-releasing hormone, **62**:51
growth hormone, tryptophan, **62**:31
immunology, adrenocorticotropic hormone, **62**:97
immunology, beta-endorphin, **62**:97
immunology, cholecystokinin, **62**:97
immunology, corticotropin-releasing hormone, **62**:97
immunology, cortisol, **62**:97
immunology, phytohemoagglutinin, **62**:97
immunology, T-lymphocytes, **62**:97
insulin, carbohydrate metabolism, **62**:85
insulin, free fatty acids, **62**:85
insulin, ketone bodies, **62**:85
ketone bodies, carbohydrate metabolism, **62**:85
ketone bodies, free fatty acids, **62**:85
ketone bodies, glucose tolerance, **62**:85
ketone bodies, insulin, **62**:85
magnetic resonance imaging, **62**:105
meta-chlorophenylpiperazine, growth hormone, **62**:31

meta-chlorophenylpiperazine, prolactin, **62**:31
meta-chlorophenylpiperazine, serotonin, **62**:31
meta-chlorophenylpiperazine, tryptophan, **62**:31
methoxy-hydroxyphenylglycol, exercise, **62**:43
methoxy-hydroxyphenylglycol, stress, **62**:43
methoxy-hydroxyphenylglycol, test meals, **62**:43
neuropeptide Y, beta-endorphin, **62**:65
neuropeptide Y, corticotropin-releasing hormone, **62**:65
neuropeptide Y, oxytocin, **62**:65
neuropeptide Y, vasopressin, **62**:65
norepinephrine, **62**:51, **62**:43
norepinephrine, exercise, **62**:43
norepinephrine, methoxy-hydroxyphenylglycol, **62**:43
norepinephrine, stress, **62**:43
norepinephrine, test meals, **62**:43
oxytocin, beta-endorphin, **62**:65
oxytocin, corticotropin-releasing hormone, **62**:65
oxytocin, neuropeptide Y, **62**:65
oxytocin, vasopressin, **62**:65
phytohemoagglutinin, adrenocorticotropic hormone, **62**:97
phytohemoagglutinin, beta-endorphin, **62**:97
phytohemoagglutinin, cholecystokinin, **62**:97
phytohemoagglutinin, corticotropin-releasing hormone, **62**:97
phytohemoagglutinin, cortisol, **62**:97
phytohemoagglutinin, immunology, **62**:97
phytohemoagglutinin, T-lymphocytes, **62**:97
phytohemoagglutinin, T-lymphocytes, **62**:97
positron emission tomography, **62**:105
prolactin, growth hormone, **62**:31
prolactin, meta-chlorophenylpiperazine, **62**:31
prolactin, serotonin, **62**:31
prolactin, tryptophan, **62**:31
risk factors, epidemiology, **62**:3
satiety, eating behavior, **62**:23
satiety, serotonin, **62**:23
serotonin, eating behavior, **62**:23
serotonin, growth hormone, **62**:31
serotonin, meta-chlorophenylpiperazine, **62**:31
serotonin, prolactin, **62**:31
serotonin, satiety, **62**:23
serotonin, tryptophan, **62**:31
single photon emission computed tomography, **62**:105
somatostatin, animal studies, beagle dogs, **62**:51
somatostatin, caloric restriction, **62**:51
somatostatin, cholinergic agonists and antagonists, **62**:51
somatostatin, growth hormone, **62**:51
somatostatin, thyrotropin-releasing hormone, **62**:51
stress, exercise, **62**:43
stress, methoxy-hydroxyphenylglycol, **62**:43
stress, norepinephrine, **62**:43
stress, test meals, **62**:43
T-lymphocytes, adrenocorticotropic hormone, **62**:97
T-lymphocytes, beta-endorphin, **62**:97
T-lymphocytes, cholecystokinin, **62**:97
T-lymphocytes, corticotropin-releasing hormone, **62**:97
T-lymphocytes, cortisol, **62**:97
T-lymphocytes, immunology, **62**:97
T-lymphocytes, phytohemoagglutinin, **62**:97
test meals, exercise, **62**:43
test meals, methoxy-hydroxyphenylglycol, **62**:43
test meals, norepinephrine, **62**:43
test meals, stress, **62**:43
thyrotropin-releasing hormone, animal studies, beagle dogs, **62**:51
thyrotropin-releasing hormone, caloric restriction, **62**:51
thyrotropin-releasing hormone, cholinergic agonists and antagonists, **62**:51
thyrotropin-releasing hormone, growth hormone, **62**:51
thyrotropin-releasing hormone, somatostatin, **62**:51
tryptophan, growth hormone, **62**:31
tryptophan, meta-chlorophenylpiperazine, **62**:31
tryptophan, prolactin, **62**:31
tryptophan, serotonin, **62**:31
vasopressin, beta-endorphin, **62**:65
vasopressin, corticotropin-releasing hormone, **62**:65
vasopressin, neuropeptide Y, **62**:65
vasopressin, oxytocin, **62**:65

Electroconvulsive therapy
affective disorder, psychotic depression, **62**:191
affective disorder, seizure duration, **62**:191
affective disorder, seizure threshold, **62**:179
psychotic depression, seizure duration, **62**:191
seizure duration, affective disorder, **62**:191
seizure duration, psychotic depression, **62**:191
seizure threshold, affective disorder, **62**:179

Electroencephalography
affective disorder, electroconvulsive therapy, **62**:179
cognition, contingent negative variation, **66**:45
cognition, mental arithmetic, **66**:45
cognition, negative symptoms of schizophrenia, **66**:45
contingent negative variation, cognition, **66**:45
contingent negative variation, schizophrenia, **66**:45
electroconvulsive therapy, affective disorder, **62**:179
mental arithmetic, contingent negative variation, **66**:45
mental arithmetic, negative symptoms of schizophrenia, **66**:45
negative symptoms, schizophrenia, **66**:45
schizophrenia, cognition, **66**:45
schizophrenia, contingent negative variation, **66**:45
schizophrenia, mental arithmetic, **66**:45
schizophrenia, negative symptoms, **66**:45
schizophrenia, topographic brain mapping, **66**:45
topographic mapping, schizophrenia, **66**:45

Epidemiology
anorexia and bulimia nervosa, risk factors, **62**:3
risk factors, anorexia and bulimia nervosa, **62**:3

Erythrocytes
affective disorder, antidepressants, **66**:87
affective disorder, kinetic studies, **66**:87
affective disorder, serotonin, **66**:87
affective disorder, tryptophan, **66**:87
antidepressants, affective disorder, **66**:87
antidepressants, kinetics, **66**:87
antidepressants, serotonin, **66**:87
antidepressants, tryptophan, **66**:87

serotonin, affective disorder, **66**:87
serotonin, antidepressants, **66**:87
serotonin, kinetic studies, **66**:87
serotonin, tryptophan, **66**:87
tryptophan, affective disorder, **66**:87
tryptophan, antidepressants, **66**:87
tryptophan, kinetic studies, **66**:87
tryptophan, serotonin, **66**:87

Estradiol
circadian rhythms, depressed mood, **62**:147
circadian rhythms, sleep deprivation, **62**:147
depressed mood, circadian rhythms, **62**:147
depressed mood, sleep deprivation, **62**:147
menstrual cycle, circadian rhythms, **62**:147
menstrual cycle, depressed mood, **62**:147
menstrual cycle, sleep deprivation, **62**:147
sleep deprivation, circadian rhythms, **62**:147
sleep deprivation, depressed mood, **62**:147
sleep deprivation, early vs. late, **62**:147
sleep deprivation, menstrual cycle, **62**:147

Evoked potentials
adrenocorticotropin 4-9 analogue, autism, **63**:33
adrenocorticotropin 4-9 analogue, ORG-2766, **63**:33
alcohol abuse/dependence, dipole activity, **63**:47
alcohol abuse/dependence, serotonin, **63**:47
alcohol abuse/dependence, stimulus intensity, **63**:47
attention deficit hyperactivity disorder, oddball paradigm, **64**:179
auditory gating, P50 wave, **64**:121
auditory gating, schizophrenia, **64**:121
autism, adrenocorticotropin 4-9 analogue, **63**:33
autism, ORG-2766, **63**:33
child psychiatry, attention deficit hyperactivity disorder, **64**:179
dipole activity, alcohol abuse/dependence, **63**:47
dipole activity, stimulus intensity, **63**:47
oddball paradigm, attention deficit hyperactivity disorder, **64**:179
ORG-2766, autism, **63**:33
residual symptoms of schizophrenia, P300 wave, **65**:23
schizophrenia, auditory gating, **64**:121
schizophrenia, P300 wave, **65**:23
schizophrenia, P50 wave, **64**:121
schizophrenia, residual symptoms, **65**:23
schizophrenia, thought disorder, **65**:23
serotonin, alcohol abuse/dependence, **63**:47
serotonin, dipole activity, **63**:47
serotonin, stimulus intensity, **63**:47
stimulus intensity, alcohol abuse/dependence, **63**:47
stimulus intensity, dipole activity, **63**:47
stimulus intensity, serotonin, **63**:47
thought disorder, P300 wave, **65**:23
thought disorder, residual symptoms of schizophrenia, **65**:23

Eye movements
affective disorder, attention, **66**:121
attention, affective disorder, **66**:121
attention, first-episode psychosis, **64**:19
attention, high-risk study, **66**:121
attention, schizophrenia, **64**:19, **66**:121
attention, schizophreniform disorder, **64**:19
attention, smooth pursuit eye movements, **64**:19, **66**:121
schizophrenia, attention, **64**:19, **66**:121
schizophrenia, first-episode psychosis, **64**:19
schizophrenia, high-risk study, **66**:121
schizophrenia, smooth pursuit eye movements, **64**:19, **66**:121
schizophreniform disorder, attention, **64**:19
schizophreniform disorder, smooth pursuit eye movements, **64**:19
smooth pursuit eye movements, affective disorder, **66**:121
smooth pursuit eye movements, attention, **64**:19, **66**:121
smooth pursuit eye movements, first-episode psychosis, **64**:19
smooth pursuit eye movements, high-risk study, **66**:121
smooth pursuit eye movements, schizophrenia, **64**:19, **66**:121
smooth pursuit eye movements, schizophreniform disorder, **64**:19

Family history
geriatric psychiatry, diagnostic accuracy of family history method, **62**:227
dementia, diagnostic accuracy of family history method, **62**:227
affective disorder, diagnostic accuracy of family history method, **62**:227
diagnostic accuracy of family history method, geriatric psychiatry, **62**:227
diagnostic accuracy of family history method, dementia, **62**:227
diagnostic accuracy of family history method, affective disorder, **62**:227

Fragile X syndrome
cognition, depression, **64**:97
cognition, genetics, **64**:97
depression, cognition, **64**:97
depression, genetics, **64**:97
genetics, cognition, **64**:97
genetics, depression, **64**:97

Free fatty acids
anorexia nervosa, bulimia nervosa, **62**:85
bulimia nervosa, anorexia nervosa, **62**:85

Frontal lobe
brain tumors, neuropsychology, **65**:15
brain tumors, schizophrenia, **65**:15
brain tumors, Wisconsin Card Sorting Test, **65**:15
neuropsychology, brain tumors, **65**:15
neuropsychology, paranoid subtype, **64**:27
neuropsychology, schizophrenia, **64**:27, **65**:15
neuropsychology, Wisconsin Card Sorting Test, **64**:27, **65**:15
paranoid schizophrenia, neuropsychology, **64**:27
paranoid schizophrenia, Wisconsin Card Sorting Test, **64**:27
schizophrenia, neuropsychology, **64**:27, **65**:15
schizophrenia, paranoid subtype, **64**:27
schizophrenia, Wisconsin Card Sorting Test, **64**:27, **65**:15
Wisconsin Card Sorting Test, brain tumors, **65**:15
Wisconsin Card Sorting Test, paranoid schizophrenia, **64**:27
Wisconsin Card Sorting Test, schizophrenia, **64**:27, **65**:15

Gamma-aminobutyric acid
agoraphobia, panic disorder, **63**:223
panic disorder, agoraphobia, **63**:223

Gender differences
attention, family studies of schizophrenia, nonpsychotic relatives, **66**:131
neuropsychology, family studies of schizophrenia, nonpsychotic relatives, **66**:131
schizophrenia, vulnerability indicators, **66**:131

Generalized anxiety disorder
benzodiazepines, dopamine, **65**:53
benzodiazepines, homovanillic acid, **65**:53
diazepam, dopamine, **65**:53
diazepam, homovanillic acid, **65**:53
dopamine, benzodiazepines, **65**:53
dopamine, diazepam, **65**:53
dopamine, homovanillic acid, **65**:53
homovanillic acid, benzodiazepines, **65**:53
homovanillic acid, diazepam, **65**:53
homovanillic acid, dopamine, **65**:53

Genetics
affective disorder, bipolar subtype, **63**:17, **64**:91
affective disorder, candidate genes, **63**:17
affective disorder, chromosome-18 markers, **63**:17
affective disorder, linkage analysis, **63**:17
affective disorder, lithium, **63**:17, **64**:91
affective disorder, tyrosine hydroxylase gene, **64**:91
association study, candidate gene, **62**:221
association study, DNA polymorphism, **62**:221
association study, dopamine, **62**:221
association study, monoamine oxidase, **62**:221
association study, schizophrenia, **62**:221
attention deficit hyperactivity disorder, c-Harvey-Ras gene, **63**:25
autism, c-Harvey-Ras gene, **63**:25
autism, 5-hydroxyindoleacetic acid, **65**:33
autism, serotonin receptor gene, **65**:33
bipolar subtype, affective disorder, **63**:17, **64**:91
c-Harvey-Ras gene, attention deficit hyperactivity disorder, **63**:25
c-Harvey-Ras gene, autism, **63**:25
c-Harvey-Ras gene, schizophrenia, **63**:25
c-Harvey-Ras gene, Tourette's syndrome, **63**:25
candidate gene, DNA polymorphism, **62**:221
candidate gene, dopamine, **62**:221
candidate gene, monoamine oxidase, **62**:221
candidate genes, chromosome-18 markers, **63**:17
chromosome-18 markers, affective disorder, bipolar subtype, **63**:17
chromosome-18 markers, linkage analysis, **63**:17
chromosome-18 markers, lithium, **63**:17
cognition, Fragile X syndrome, **64**:97
depression, Fragile X syndrome, **64**:97
DNA polymorphism, association study, **62**:221
DNA polymorphism, candidate gene, **62**:221
DNA polymorphism, dopamine, **62**:221
DNA polymorphism, monoamine oxidase, **62**:221
DNA polymorphism, schizophrenia, **62**:221
dopamine, association study, **62**:221
dopamine, candidate gene, **62**:221
dopamine, DNA polymorphism, **62**:221
dopamine, monoamine oxidase, **62**:221
dopamine, schizophrenia, **62**:221
Fragile X syndrome, cognition, **64**:97
Fragile X syndrome, depression, **64**:97
hydroxyindoleacetic acid, autism, **65**:33
hydroxyindoleacetic acid, serotonin receptor gene, **65**:33
linkage analysis, affective disorder, **63**:17
linkage analysis, candidate genes, **63**:17
linkage analysis, chromosome-18 markers, **63**:17
lithium, affective disorder, bipolar subtype, **63**:17, **64**:91
monoamine oxidase, association study, **62**:221
monoamine oxidase, candidate gene, **62**:221
monoamine oxidase, DNA polymorphism, **62**:221
monoamine oxidase, dopamine, **62**:221
monoamine oxidase, schizophrenia, **62**:221
panic attacks, twins, **66**:69
panic disorder, twins, **66**:69
pseudoautosomal locus, schizophrenia, **62**:281
pseudoautosomal locus, sex chromosomes, **62**:281
schizophrenia, association study, **62**:221
schizophrenia, c-Harvey-Ras gene, **63**:25
schizophrenia, candidate gene, **62**:221
schizophrenia, DNA polymorphism, **62**:221
schizophrenia, dopamine, **62**:221
schizophrenia, monoamine oxidase, **62**:221
schizophrenia, pseudoautosomal locus, **62**:281
schizophrenia, sex chromosomes, **62**:281
serotonin, autism, **65**:33
serotonin, hydroxyindoleacetic acid, **65**:33
serotonin receptor gene, autism, **65**:33
serotonin receptor gene, hydroxyindoleacetic acid, **65**:33
sex chromosomes, pseudoautosomal locus, **62**:281
sex chromosomes, schizophrenia, **62**:281
Tourette's syndrome, c-Harvey-Ras gene, **63**:25
twins, panic attacks, **66**:69
twins, panic disorder, **66**:69
tyrosine hydroxylase gene, affective disorder, bipolar subtype, **64**:91
tyrosine hydroxylase gene, lithium, **64**:91

Geriatric psychiatry
affective disorder, late-life depression, **63**:183, **66**:23
dementia, diagnostic accuracy of family history method, **62**:227
dementia, family history, **62**:227
diagnostic accuracy of family history method, dementia, **62**:227
family history, dementia, **62**:227
family history, diagnostic accuracy of family history method, **62**:227
General Life Functioning Scale, late-life depression, **63**:183
interpersonal psychotherapy, late-life depression, **63**:183
late-life depression, General Life Functioning Scale, **63**:183
late-life depression, interpersonal psychotherapy, **63**:183
late-life depression, nortriptyline, **63**:183
late-life depression, outcome, **66**:23

late-life depression, quality of life, **63**:183, **63**:169
nortriptyline, General Life Functioning Scale, **63**:183
nortriptyline, late-life depression, **63**:183
nortriptyline, quality of life, **63**:183
outcome, late-life depression, **66**:23
quality of life, late-life depression, **63**:183
quality of life, late-life psychosis, **63**:169

Growth hormone
abstinence, cocaine craving, **65**:65
activation-euphoria, amphetamine, **64**:1
activation-euphoria, ondansetron, **64**:1
activation-euphoria, serotonin, **64**:1
aggression, personality, **66**:33
amphetamine, activation-euphoria, **64**:1
amphetamine, ondansetron, **64**:1
amphetamine, serotonin, **64**:1
animal models of anorexia nervosa, beagle dogs, caloric restriction, **62**:51
animal models of anorexia nervosa, cholinergic agonists and antagonists, **62**:51
anorexia nervosa, animal models, beagle dogs, caloric restriction, **62**:51
anorexia nervosa, cholinergic agonists and antagonists, **62**:51
anorexia nervosa, meta-chlorophenylpiperazine, **62**:31
anorexia nervosa, serotonin, **62**:31
beagle dogs, animal models of anorexia nervosa, caloric restriction, **62**:51
beagle dogs, cholinergic agonists and antagonists, **62**:51
cholinergic agonists and antagonists, animal models of anorexia nervosa, **62**:51
cocaine craving, abstinence, **65**:65
desmethylimipramine, norepinephrine, **63**:1
desmethylimipramine, orthostatic challenge, **63**:1
desmethylimipramine, posttraumatic stress disorder, **63**:1
meta-chlorophenylpiperazine, anorexia nervosa, **62**:31
meta-chlorophenylpiperazine, serotonin, tryptophan, **62**:31
methylphenidate, cocaine, **65**:65
norepinephrine, aggression, **66**:33
norepinephrine, desmethylimipramine, **63**:1
norepinephrine, orthostatic challenge, **63**:1
norepinephrine, personality, **66**:33
norepinephrine, posttraumatic stress disorder, **63**:1
ondansetron, activation-euphoria, **64**:1
ondansetron, amphetamine, **64**:1
ondansetron, blood pressure, **64**:1
ondansetron, serotonin, **64**:1
orthostatic challenge, desmethylimipramine, **63**:1
orthostatic challenge, norepinephrine, **63**:1
orthostatic challenge, posttraumatic stress disorder, **63**:1
personality, aggression, **66**:33
personality, norepinephrine, **66**:33
posttraumatic stress disorder, desmethylimipramine, **63**:1
posttraumatic stress disorder, norepinephrine, **63**:1
posttraumatic stress disorder, orthostatic challenge, **63**:1
serotonin, activation-euphoria, **64**:1
serotonin, amphetamine, **64**:1
serotonin, anorexia nervosa, **62**:31
serotonin, blood pressure, **64**:1
serotonin, meta-chlorophenylpiperazine, **62**:31
serotonin, ondansetron, **64**:1
serotonin, tryptophan, **62**:31
substance abuse/dependence, abstinence, **65**:65

Haloperidol
age of onset, schizophrenia, treatment response prediction, **64**:47
animal model, uptake of dopamine in platelets, **62**:259
computed tomography, cortical atrophy, schizophrenia, **64**:47
computed tomography, sulcal widening, schizophrenia, **64**:47
computed tomography, treatment response prediction, schizophrenia, **64**:47
cortical atrophy, schizophrenia, treatment response prediction, **64**:47
dopamine, animal model, Sprague-Dawley rats, **62**:259
dopamine, uptake of dopamine in platelets, **62**:259
schizophrenia, computed tomography, **64**:47
schizophrenia, cortical atrophy, **64**:47
schizophrenia, sulcal widening, **64**:47
schizophrenia, treatment response prediction, **64**:47
Sprague-Dawley rats, animal model, dopamine, **62**:259
Sprague-Dawley rats, uptake of dopamine in platelets, **62**:259
sulcal widening, schizophrenia, treatment response prediction, **64**:47
treatment response prediction, age of onset of schizophrenia, **64**:47
treatment response prediction, computed tomography, **64**:47
treatment response prediction, cortical atrophy, schizophrenia, **64**:47
treatment response prediction, sulcal widening, schizophrenia, **64**:47
uptake of dopamine in platelets, animal model, Sprague-Dawley rats, **62**:259

Homovanillic acid
antisocial personality disorder, family history in prepubertal boys, **62**:203
anxiety, benzodiazepines, **65**:53
anxiety, diazepam, **65**:53
anxiety, dopamine, **65**:53
anxiety, generalized anxiety disorder, **65**:53
anxiety, panic disorder, **65**:53
anxiety, stress, **63**:7
benzodiazepines, anxiety, **65**:53
benzodiazepines, dopamine, **65**:53
benzodiazepines, generalized anxiety disorder, **65**:53
benzodiazepines, panic disorder, **65**:53
computed tomography, cortical atrophy, **64**:47
computed tomography, haloperidol response, **64**:47
computed tomography, schizophrenia, **64**:47
computed tomography, sulcal widening, **64**:47
computed tomography, treatment response prediction, **64**:47
cortical atrophy, age of onset of schizophrenia, **64**:47
cortical atrophy, computed tomography, **64**:47
cortical atrophy, haloperidol treatment, **64**:47
cortical atrophy, schizophrenia, **64**:47
cortical atrophy, treatment response prediction, **64**:47
diazepam, anxiety, **65**:53
diazepam, dopamine, **65**:53
diazepam, generalized anxiety disorder, **65**:53
diazepam, panic disorder, **65**:53
dopamine, anxiety, **65**:53

dopamine, benzodiazepines, **65**:53
dopamine, diazepam, **65**:53
dopamine, generalized anxiety disorder, **65**:53
dopamine, panic disorder, **65**:53
family history of antisocial personality disorder in prepubertal boys, **62**:203
family history of substance abuse/dependence in prepubertal boys, **62**:203
generalized anxiety disorder, benzodiazepines, **65**:53
generalized anxiety disorder, diazepam, **65**:53
generalized anxiety disorder, dopamine, **65**:53
haloperidol treatment, age of onset of schizophrenia, **64**:47
haloperidol treatment, computed tomography, **64**:47
haloperidol treatment, cortical atrophy, **64**:47
haloperidol treatment, schizophrenia, **64**:47
haloperidol treatment, sulcal widening, **64**:47
haloperidol treatment, response prediction, **64**:47
infants, cerebrospinal fluid, **65**:129
infants, personality characteristics, **65**:129
infants, sociability, **65**:129
infants, twins, **65**:129
panic disorder, benzodiazepines, **65**:53
panic disorder, diazepam, **65**:53
panic disorder, dopamine, **65**:53
personality, infants, **65**:129
personality, twins, **65**:129
schizophrenia, age of onset, **64**:47
schizophrenia, computed tomography, **64**:47
schizophrenia, cortical atrophy, **64**:47
schizophrenia, haloperidol treatment, **64**:47
schizophrenia, sulcal widening, **64**:47
schizophrenia, treatment response prediction, **64**:47
sociability, cerebrospinal fluid measures, **65**:129
sociability, infants, **65**:129
sociability, twins, **65**:129
stress, anxiety, **63**:7
substance abuse/dependence, family history in prepubertal boys, **62**:203
sulcal widening, age of onset of schizophrenia, **64**:47
sulcal widening, computed tomography, **64**:47
sulcal widening, haloperidol treatment, **64**:47
sulcal widening, schizophrenia, **64**:47
sulcal widening, treatment response prediction, **64**:47
treatment response prediction, age of onset of schizophrenia, **64**:47
treatment response prediction, computed tomography, **64**:47
treatment response prediction, cortical atrophy, **64**:47
treatment response prediction, schizophrenia, **64**:47
treatment response prediction, sulcal widening, **64**:47
twins, cerebrospinal fluid, **65**:129
twins, infants, **65**:129
twins, personality, **65**:129
twins, sociability, **65**:129

Hydroxyindoleacetic acid

anxiety, stress, **63**:7
autism, genetics, **65**:33
autism, serotonin, **65**:33
autism, serotonin receptor gene, **65**:33
cerebrospinal fluid, infants, **65**:129
genetics, autism, **65**:33
genetics, serotonin receptor gene, **65**:33
infants, cerebrospinal fluid, **65**:129
infants, personality, **65**:129
infants, sociability, **65**:129
infants, twins, **65**:129
personality, cerebrospinal fluid, **65**:129
personality, infants, **65**:129
personality, sociability, **65**:129
personality, twins, **65**:129
serotonin, autism, **65**:33
serotonin, serotonin receptor gene, **65**:33
serotonin receptor gene, autism, **65**:33
sociability, cerebrospinal fluid, **65**:129
sociability, infants, **65**:129
sociability, personality, **65**:129
sociability, twins, **65**:129
stress, anxiety, **63**:7
twins, cerebrospinal fluid, **65**:129
twins, infants, **65**:129
twins, personality, **65**:129
twins, sociability, **65**:129

Imipramine

platelet imipramine binding, posttraumatic stress disorder, **63**:143
platelet imipramine binding, serotonin, **63**:143
posttraumatic stress disorder, platelet imipramine binding, **63**:143
posttraumatic stress disorder, serotonin, **63**:143
serotonin, platelet imipramine binding, **63**:143
serotonin, posttraumatic stress disorder, **63**:143

Immunology

acute phase proteins, affective disorder, **64**:161, **65**:159, **66**:1
acute phase proteins, schizophrenia, **66**:1
adrenocorticotropic hormone, cholecystokinin, **62**:97
adrenocorticotropic hormone, phytohemoagglutinin, **62**:97
adrenocorticotropic hormone, T-lymphocytes, **62**:97
affective disorder, acute phase proteins, **64**:161, **65**:159, **66**:1
affective disorder, albumin, **65**:159
affective disorder, antidepressants, **65**:159
affective disorder, beta-globulin, **65**:159
affective disorder, bipolar subtype, **66**:1
affective disorder, gamma-globulin, **65**:159
affective disorder, interleukins, **64**:161
affective disorder, psychotropic drugs, **66**:1
affective disorder, total serum protein, **65**:159
affective disorder, transferrin receptor, **64**:161
albumin, affective disorder, **65**:159
albumin, beta-globulin, **65**:159
albumin, gamma-globulin, **65**:159
albumin, total serum protein, **65**:159
anorexia and bulimia nervosa, T-lymphocytes, **62**:97
anorexia and bulimia nervosa, cholecystokinin, **62**:97
anorexia and bulimia nervosa, phytohemoagglutinin, **62**:97
antidepressants, acute phase proteins, **65**:159
antidepressants, albumin, **65**:159

antidepressants, beta-globulin, **65**:159
antidepressants, gamma-globulin, **65**:159
beta-endorphin, phytohemoagglutinin, **62**:97
beta-endorphin, T-lymphocytes, **62**:97
beta-globulin, acute phase proteins, **65**:159
beta-globulin, affective disorder, **65**:159
bipolar affective disorder, acute phase proteins, **66**:1
bipolar affective disorder, psychotropic drugs, **66**:1
cholecystokinin, bulimia nervosa, **62**:97
cholecystokinin, phytohemoagglutinin, **62**:97
cholecystokinin, T-lymphocytes, **62**:97
corticotropin-releasing hormone, anorexia nervosa, **62**:97
corticotropin-releasing hormone, bulimia nervosa, **62**:97
corticotropin-releasing hormone, phytohemoagglutinin, **62**:97
corticotropin-releasing hormone, T-lymphocytes, **62**:97
cortisol, anorexia nervosa, **62**:97
cortisol, bulimia nervosa, **62**:97
cortisol, phytohemoagglutinin, **62**:97
cortisol, T-lymphocytes, **62**:97
gamma-globulin, acute phase proteins, **65**:159
gamma-globulin, affective disorder, **65**:159
gamma-globulin, albumin, **65**:159
gamma-globulin, antidepressants, **65**:159
gamma-globulin, total serum protein, **65**:159
interferon-gamma, family studies, **66**:145
interferon-gamma, schizophrenia, **66**:145
interleukin-2, lymphocytes, **65**:171
interleukin-2, phytohemoagglutinin, **65**:171
interleukin-2, positive symptoms of schizophrenia, **65**:171
interleukin-2, schizophreniform disorder, **65**:171
interleukins, acute phase proteins, **64**:161
interleukins, affective disorder, **64**:161
interleukins, transferrin receptor, **64**:161
lymphocytes, interleukin-2, **65**:171
lymphocytes, phytohemoagglutinin, **65**:171
lymphocytes, schizophrenia, **65**:171
lymphocytes, schizophreniform disorder, **65**:171
phytohemoagglutinin, adrenocorticotropic hormone, **62**:97
phytohemoagglutinin, anorexia nervosa, **62**:97
phytohemoagglutinin, beta-endorphin, **62**:97
phytohemoagglutinin, bulimia nervosa, **62**:97
phytohemoagglutinin, cholecystokinin, **62**:97
phytohemoagglutinin, corticotropin-releasing hormone, **62**:97
phytohemoagglutinin, cortisol, **62**:97
phytohemoagglutinin, interleukin-2, **65**:171
phytohemoagglutinin, lymphocytes, **62**:97, **65**:171
phytohemoagglutinin, schizophrenia, **65**:171
phytohemoagglutinin, schizophreniform disorder, **65**:171
phytohemoagglutinin, T-lymphocytes, **62**:97
positive symptoms, schizophrenia, **65**:171
positive symptoms, schizophreniform disorder, **65**:171
psychotropic drugs, acute phase proteins, **66**:1
psychotropic drugs, affective disorder, **66**:1
psychotropic drugs, bipolar affective disorder, **66**:1
psychotropic drugs, schizophrenia, **66**:1
schizophrenia, acute phase proteins, **66**:1
schizophrenia, family studies, **66**:145
schizophrenia, interferon-gamma, **66**:145
schizophrenia, interleukin-2, **65**:171
schizophrenia, lymphocytes, **65**:171
schizophrenia, phytohemoagglutinin, **65**:171
schizophrenia, positive symptoms, **65**:171
schizophrenia, psychotropic drugs, **66**:1
schizophreniform disorder, interleukin-2, **65**:171
schizophreniform disorder, lymphocytes, **65**:171
schizophreniform disorder, phytohemoagglutinin, **65**:171
schizophreniform disorder, positive symptoms, **65**:171
T-lymphocytes, adrenocorticotropic hormone, **62**:97
T-lymphocytes, anorexia nervosa, **62**:97
T-lymphocytes, beta-endorphin, **62**:97
T-lymphocytes, bulimia nervosa, **62**:97
T-lymphocytes, cholecystokinin, **62**:97
T-lymphocytes, corticotropin-releasing hormone, **62**:97
T-lymphocytes, cortisol, **62**:97
T-lymphocytes, phytohemoagglutinin, **62**:97
total serum protein, acute phase proteins, **65**:159
total serum protein, affective disorder, **65**:159
total serum protein, albumin, **65**:159
total serum protein, antidepressants, **65**:159
total serum protein, beta-globulin, **65**:159
total serum protein, gamma-globulin, **65**:159
transferrin receptor, acute phase proteins, **64**:161
transferrin receptor, affective disorder, **64**:161
transferrin receptor, interleukins, **64**:161

Infants

homovanillic acid, cerebrospinal fluid, **65**:129
homovanillic acid, personality, **65**:129
homovanillic acid, sociability, **65**:129
homovanillic acid, twins, **65**:129
hydroxyindoleacetic acid, cerebrospinal fluid, **65**:129
hydroxyindoleacetic acid, personality, **65**:129
hydroxyindoleacetic acid, sociability, **65**:129
hydroxyindoleacetic acid, twins, **65**:129
methoxy-hydroxyphenylglycol, cerebrospinal fluid, **65**:129
methoxy-hydroxyphenylglycol, personality, **65**:129
methoxy-hydroxyphenylglycol, sociability, **65**:129
methoxy-hydroxyphenylglycol, twins, **65**:129
personality, homovanillic acid, **65**:129
personality, hydroxyindoleacetic acid, **65**:129
personality, methoxy-hydroxyphenylglycol, **65**:129
personality, sociability, **65**:129
personality, twins, **65**:129
sociability, homovanillic acid, **65**:129
sociability, hydroxyindoleacetic acid, **65**:129
sociability, methoxy-hydroxyphenylglycol, **65**:129
sociability, twins, **65**:129
twins, cerebrospinal fluid, **65**:129
twins, homovanillic acid, **65**:129
twins, hydroxyindoleacetic acid, **65**:129
twins, methoxy-hydroxyphenylglycol, **65**:129
twins, personality, **65**:129
twins, sociability, **65**:129

Inositol

affective disorder, calcium, **65**:45
affective disorder, second messengers, **65**:45
calcium, affective disorder, **65**:45

calcium, second messengers, **65**:45
second messengers, affective disorder, **65**:45
second messengers, calcium, **65**:45

Insulin
anorexia and bulimia nervosa, glucose tolerance, **62**:85
glucose tolerance, anorexia and bulimia nervosa, **62**:85

Interleukins
immunology, schizophrenia and schizophreniform disorder, **65**:171
lymphocytes, schizophrenia and schizophreniform disorder, **65**:171
schizophrenia, lymphocytes, **65**:171
schizophrenia, positive symptoms, **65**:171
schizophreniform disorder, lymphocytes, **65**:171
schizophreniform disorder, positive symptoms, **65**:171

Ketone bodies
anorexia nervosa, **62**:85
bulimia nervosa, **62**:85

Language
age of onset, schizophrenia, **63**:109
neuropsychology, age of onset of schizophrenia, **63**:109
neuropsychology, semantic network, **63**:109
schizophrenia, age of onset, **63**:109
schizophrenia, neuropsychology, **63**:109
schizophrenia, semantic network, **63**:109
semantic network, schizophrenia, **63**:109

Laterality
attention, Global/Local Task, **62**:111
attention, left hemisphere deficit, **62**:111
attention, reaction time, **62**:111
attention, schizophrenia, **62**:111
cognition, dichotic listening, **65**:1
cognition, neuropsychology, **65**:1
cognition, schizophrenia, **65**:1
dichotic listening, cognition, **65**:1
dichotic listening, neuropsychology, **65**:1
dichotic listening, schizophrenia, **65**:1
Global/Local Task, attention, **62**:111
Global/Local Task, left hemisphere deficit, **62**:111
Global/Local Task, reaction time, **62**:111
Global/Local Task, schizophrenia, **62**:111
hallucinations, attention, **62**:111
hallucinations, Global/Local Task, **62**:111
hallucinations, left hemisphere deficit, **62**:111
hallucinations, reaction time, **62**:111
hallucinations, schizophrenia, **62**:111
interhemispheric transfer, mirror-drawing, **64**:115
interhemispheric transfer, schizophrenia, **64**:115
left hemisphere deficit, attention, **62**:111
left hemisphere deficit, Global/Local Task, **62**:111
left hemisphere deficit, hallucinations, **62**:111
left hemisphere deficit, reaction time, **62**:111
left hemisphere deficit, schizophrenia, **62**:111
mirror-drawing, interhemispheric transfer, **64**:115
mirror-drawing, schizophrenia, **64**:115
neuropsychology, cognition, **65**:1
neuropsychology, dichotic listening, **65**:1
neuropsychology, schizophrenia, **65**:1
reaction time, attention, **62**:111
reaction time, Global/Local Task, **62**:111
reaction time, hallucinations, **62**:111
reaction time, left hemisphere deficit, **62**:111
reaction time, schizophrenia, **62**:111
schizophrenia, attention, **62**:111
schizophrenia, cognition, **65**:1
schizophrenia, dichotic listening, **65**:1
schizophrenia, Global/Local Task, **62**:111
schizophrenia, hallucinations, **62**:111
schizophrenia, interhemispheric transfer, **64**:115
schizophrenia, left hemisphere deficit, **62**:111
schizophrenia, mirror-drawing, **64**:115
schizophrenia, neuropsychology, **65**:1
schizophrenia, reaction time, **62**:111

Lithium
affective disorder, bipolar subtype, **63**:17, **64**:91
bipolar affective disorder, candidate genes, **63**:17
bipolar affective disorder, chromosome-18 markers, **63**:17
bipolar affective disorder, genetics, **63**:17, **64**:91
bipolar affective disorder, linkage analysis, **63**:17
bipolar affective disorder, tyrosine hydroxylase gene, **64**:91
candidate genes, affective disorder, **63**:17
candidate genes, bipolar affective disorder, **63**:17
candidate genes, chromosome-18 markers, **63**:17
candidate genes, linkage analysis, **63**:17
chromosome-18 markers, bipolar affective disorder, **63**:17
chromosome-18 markers, candidate genes, **63**:17
chromosome-18 markers, linkage analysis, **63**:17
genetics, bipolar affective disorder, **63**:17, **64**:91
genetics, candidate genes, **63**:17
genetics, chromosome-18 markers, **63**:17
genetics, linkage analysis, **63**:17
genetics, tyrosine hydroxylase gene, **64**:91
linkage analysis, bipolar subtype, **63**:17
linkage analysis, candidate genes, **63**:17
linkage analysis, chromosome-18 markers, **63**:17
tyrosine hydroxylase gene, bipolar affective disorder, **64**:91

Magnetic resonance imaging
anorexia nervosa, **62**:105

Melatonin
affective disorder, bipolar subtype, **63**:219
affective disorder, circadian rhythms, **63**:219
bipolar affective disorder, circadian rhythms, **63**:219
circadian rhythms, affective disorder, bipolar subtype, **63**:219

Menstrual cycle
anxiety, Daily Symptom Report, **65**:97
anxiety, depressed mood, **65**:97
anxiety, premenstrual dysphoric disorder, **65**:97
Daily Symptom Report, anxiety, **65**:97

Daily Symptom Report, depressed mood, **65**:97
Daily Symptom Report, premenstrual dysphoric disorder, **65**:97
depressed mood, anxiety, **65**:97
depressed mood, Daily Symptom Report, **65**:97
depressed mood, premenstrual dysphoric disorder, **65**:97
premenstrual dysphoric disorder, anxiety, **65**:97
premenstrual dysphoric disorder, Daily Symptom Report, **65**:97
premenstrual dysphoric disorder, depressed mood, **65**:97

Meta-chlorophenylpiperazine
anorexia nervosa, growth hormone, **62**:31
anorexia nervosa, prolactin, **62**:31
anorexia nervosa, serotonin, **62**:31
anorexia nervosa, tryptophan, **62**:31
body temperature, schizophrenia, **64**:147
cortisol, panic disorder, **64**:77
cortisol, schizophrenia, **64**:147
cortisol, serotonin, **62**:139, **64**:147, **64**:77
growth hormone, anorexia nervosa, **62**:31
panic disorder, cortisol, **64**:77
panic disorder, serotonin, **64**:77
prolactin, anorexia nervosa, **62**:31
prolactin, schizophrenia, **64**:147
prolactin, serotonin, **62**:139, **64**:147
schizophrenia, body temperature, **64**:147
schizophrenia, serotonin, **64**:147
serotonin, anorexia nervosa, **62**:31
serotonin, body temperature, **64**:147
serotonin, cortisol, **62**:139, **64**:147, **64**:77
serotonin, growth hormone, **62**:31
serotonin, panic disorder, **64**:77
serotonin, prolactin, **62**:139, **62**:31, **64**:147
serotonin, schizophrenia, **64**:147
serotonin, tryptophan, **62**:31
tryptophan, anorexia nervosa, **62**:31
tryptophan, serotonin, **62**:31

Methamphetamine
dopamine, paranoid-hallucinatory psychosis, **63**:93
flashbacks, paranoid-hallucinatory psychosis, **63**:93
methoxy-hydroxyphenylglycol, norepinephrine, **63**:93
methoxy-hydroxyphenylglycol, paranoid-hallucinatory psychosis, **63**:93
norepinephrine, methoxy-hydroxyphenylglycol, **63**:93
norepinephrine, paranoid-hallucinatory psychosis, **63**:93
paranoid-hallucinatory psychosis, dopamine, **63**:93
paranoid-hallucinatory psychosis, flashbacks, **63**:93
paranoid-hallucinatory psychosis, methoxy-hydroxyphenylglycol, **63**:93
paranoid-hallucinatory psychosis, norepinephrine, **63**:93

Methoxy-hydroxyphenylglycol
affective disorder, family history, **62**:171
affective disorder, symptom severity, **62**:171
affective disorder, unipolar subtype, **62**:171
affective disorder, urinary levels, **62**:171
anorexia and bulimia nervosa, exercise, **62**:43
anorexia and bulimia nervosa, norepinephrine, **62**:43
anorexia and bulimia nervosa, stress, **62**:43
anorexia and bulimia nervosa, test meals, **62**:43
antisocial personality disorder, family history in prepubertal boys, **62**:203
anxiety, vanillylmandelic acid, **63**:7
computed tomography, cortical atrophy, **64**:47
computed tomography, schizophrenia, **64**:47
computed tomography, sulcal widening, **64**:47
computed tomography, treatment response prediction, **64**:47
cortisol, stress, **63**:7
depressive spectrum disease, family history, **62**:171
exercise, anorexia and bulimia nervosa, **62**:43
exercise, norepinephrine, **62**:43
exercise, stress, **62**:43
family history, affective disorder, **62**:171
haloperidol, computed tomography, **64**:47
haloperidol, schizophrenia, **64**:47
haloperidol, treatment response prediction, **64**:47
infants, cerebrospinal fluid, **65**:129
infants, personality, **65**:129
infants, sociability, **65**:129
infants, twins, **65**:129
methamphetamine, flashbacks, **63**:93
methamphetamine, norepinephrine, **63**:93
methamphetamine, paranoid-hallucinatory psychosis, **63**:93
norepinephrine, anorexia and bulimia nervosa, **62**:43
norepinephrine, exercise, **62**:43
norepinephrine, methamphetamine, **63**:93
norepinephrine, paranoid-hallucinatory psychosis, **63**:93
norepinephrine, personality, **65**:61
norepinephrine, reward dependence traits, **65**:61
norepinephrine, stress, **62**:43
norepinephrine, substance abuse/dependence, **63**:93
norepinephrine, Tridimensional Personality Questionnaire, **65**:61
paranoid-hallucinatory psychosis, flashbacks, **63**:93
paranoid-hallucinatory psychosis, methamphetamine, **63**:93
paranoid-hallucinatory psychosis, norepinephrine, **63**:93
personality, human newborns, **65**:129
personality, norepinephrine, **65**:61
personality, reward dependence traits, **65**:61
personality, sociability, **65**:129
personality, twins, **65**:129
prepubertal boys, family history of antisocial personality disorder, **62**:203
prepubertal boys, family history of substance abuse/dependence, **62**:203
reward dependence traits, norepinephrine, **65**:61
reward dependence traits, Tridimensional Personality Questionnaire, **65**:61
schizophrenia, age of onset, **64**:47
schizophrenia, computed tomography, **64**:47
schizophrenia, cortical atrophy, **64**:47
schizophrenia, haloperidol, **64**:47
schizophrenia, sulcal widening, **64**:47
schizophrenia, treatment response prediction, **64**:47
sociability, infants, **65**:129
sociability, twins, **65**:129
stress, anorexia and bulimia nervosa, **62**:43
stress, exercise, **62**:43

stress, norepinephrine, **62**:43
stress, vanillylmandelic acid, **63**:7
substance abuse/dependence, family history in prepubertal boys, **62**:203
substance abuse/dependence, methamphetamine, **63**:93
substance abuse/dependence, norepinephrine, **63**:93
substance abuse/dependence, paranoid-hallucinatory psychosis, **63**:93
treatment response prediction, schizophrenia, **64**:47
Tridimensional Personality Questionnaire, norepinephrine, **65**:61
Tridimensional Personality Questionnaire, reward dependence traits, **65**:61
twins, infants, **65**:129
vanillylmandelic acid, stress, **63**:7

Methylphenidate
cocaine, abstinence, craving, **65**:65

Migraine
affective disorder, bipolar subtype, **65**:73
affective disorder, phenolsulfotransferase, **65**:73
affective disorder, unipolar subtype, **65**:73
bipolar affective disorder, phenolsulfotransferase, **65**:73
obsessive-compulsive disorder, phenolsulfotransferase, **65**:73
phenolsulfotransferase, affective disorder, **65**:73
phenolsulfotransferase, bipolar affective disorder, **65**:73
phenolsulfotransferase, obsessive-compulsive disorder, **65**:73
phenolsulfotransferase, platelets, **65**:73
phenolsulfotransferase, unipolar depression, **65**:73
unipolar depression, phenolsulfotransferase, **65**:73

Monoamine oxidase
affective disorder, platelets, **62**:273
affective disorder, suicide attempts, **62**:273
DNA polymorphism, association study, **62**:221
DNA polymorphism, candidate gene, **62**:221
DNA polymorphism, dopamine, **62**:221
DNA polymorphism, genetics, **62**:221
DNA polymorphism, schizophrenia, **62**:221
dopamine, candidate gene, **62**:221
dopamine, DNA polymorphism, **62**:221
dopamine, genetics, **62**:221
dopamine, schizophrenia, **62**:221
genetics, association study, **62**:221
genetics, DNA polymorphism, **62**:221
genetics, dopamine, **62**:221
genetics, schizophrenia, **62**:221
platelets, affective disorder, **62**:273
platelets, seasonal depression, **62**:273
platelets, suicide attempts, **62**:273
schizophrenia, candidate gene, **62**:221
schizophrenia, DNA polymorphism, **62**:221
schizophrenia, dopamine, **62**:221
schizophrenia, genetics, **62**:221
seasonal depression, platelets, **62**:273
seasonal depression, suicide attempts, **62**:273
suicide attempts, affective disorder, **62**:273
suicide attempts, platelets, **62**:273
suicide attempts, seasonal depression, **62**:273

Monoamine oxidase inhibitors
imipramine binding, posttraumatic stress disorder, **63**:143
phenelzine, platelet imipramine binding, **63**:143
phenelzine, posttraumatic stress disorder, **63**:143
platelet imipramine binding, posttraumatic stress disorder, **63**:143
posttraumatic stress disorder, platelet imipramine binding, **63**:143
serotonin, platelet imipramine binding, **63**:143
serotonin, posttraumatic stress disorder, **63**:143

Mortality rates
affective disorder, cross-cultural, Taiwan, **62**:239
cross-cultural, affective disorder, **62**:239
cross-cultural, organic mental disorders, **62**:239
cross-cultural, psychiatric inpatients, **62**:239
cross-cultural, schizophrenia, **62**:239
cross-cultural, substance abuse/dependence, **62**:239
cross-cultural, Taiwan, **62**:239
organic mental disorders, cross-cultural, Taiwan, **62**:239
schizophrenia, cross-cultural, Taiwan, **62**:239
substance abuse/dependence, cross-cultural, Taiwan, **62**:239

Multiple personality
cataplexy, dissociative identity disorder, **63**:231
muscular weakness, dissociative identity disorder, **63**:231
muscular weakness, substance abuse/dependence, **63**:231
substance abuse/dependence, muscular weakness, **63**:231

Neuroleptic malignant syndrome
diaphoresis, polydipsia, serum osmolality, schizophrenia, **64**:137
polydipsia, diaphoresis, serum osmolality, schizophrenia, **64**:137
schizophrenia, diaphoresis, polydipsia, serum osmolality, **64**:137
serum osmolality, diaphoresis, polydipsia, schizophrenia, **64**:137

Neurological soft signs
family history, gender, **64**:105
family history, obstetric complications, **64**:105
family history, schizophrenia, **64**:105
gender, family history, **64**:105
gender, obstetric complications, **64**:105
gender, schizophrenia, **64**:105
obstetric complications, family history, **64**:105
obstetric complications, gender, **64**:105
obstetric complications, schizophrenia, **64**:105
schizophrenia, family history, **64**:105
schizophrenia, gender, **64**:105
schizophrenia, obstetric complications, **64**:105

Neuropeptides
anorexia nervosa, beta-endorphin, **62**:65
anorexia nervosa, neuropeptide Y, **62**:65

anorexia nervosa, vasopressin, oxytocin, **62**:65
antisocial personality disorder family history, beta-endorphin, **62**:203
beta-endorphin, anorexia nervosa, **62**:65
beta-endorphin, family history of antisocial personality disorder, **62**:203
beta-endorphin, family history of substance abuse/dependence, **62**:203
beta-endorphin, prepubertal boys, **62**:203
corticotropin-releasing hormone, anorexia nervosa, **62**:65
corticotropin-releasing hormone, beta-endorphin, **62**:65
corticotropin-releasing hormone, vasopressin, oxytocin, **62**:65
neuropeptide Y, anorexia nervosa, **62**:65
oxytocin, anorexia nervosa, **62**:65
prepubertal boys, beta-endorphin, **62**:203
substance abuse/dependence family history, beta-endorphin, **62**:203
vasopressin, anorexia nervosa, **62**:65

Neuropsychology

affective disorder, bipolar subtype, **65**:113
affective disorder, lack of insight, **65**:113
age of onset, schizophrenia, **63**:109
alcohol abuse/dependence, comorbidity with schizophrenia, **64**:35
attention, family studies, **66**:131
attention, gender, **66**:131
attention, negative priming, **62**:121
attention, nonpsychotic relatives of schizophrenic patients, **66**:131
attention, schizophrenia, **62**:121
attention, schizophrenia, **66**:131
attention, Stroop Task, **62**:121
attention, vulnerability indicators, **66**:131
bipolar subtype, affective disorder, **65**:113
bipolar subtype, lack of insight, **65**:113
brain tumors, frontal lobe, **65**:15
brain tumors, Wisconsin Card Sorting Test, **65**:15
cognition, dichotic listening, **65**:1
cognition, laterality, **65**:1
cognition, schizophrenia, **65**:1
comorbidity, alcohol abuse/dependence, **64**:35
comorbidity, schizophrenia, **64**:35
dichotic listening, cognition, **65**:1
dichotic listening, laterality, **65**:1
dichotic listening, schizophrenia, **65**:1
family studies, attention, **66**:131
family studies, gender, **66**:131
family studies, nonpsychotic relatives, **66**:131
family studies, schizophrenia, **66**:131
family studies, sex differences, **66**:131
family studies, vulnerability indicators, **66**:131
frontal lobe, brain tumors, **65**:15
frontal lobe, paranoid subtype, **64**:27
frontal lobe, schizophrenia, **64**:27, **65**:15
frontal lobe, Wisconsin Card Sorting Test, **64**:27, **65**:15
gender, family studies, **66**:131
gender, schizophrenia, **66**:131
gender, vulnerability indicators, **66**:131
lack of insight, affective disorder, bipolar subtype, **65**:113
language, schizophrenia, **63**:109
laterality, dichotic listening, **65**:1
laterality, schizophrenia, **65**:1
medication withdrawal, negative priming, **62**:121
medication withdrawal, schizophrenia, **62**:121
medication withdrawal, Stroop Task, **62**:121
negative priming, schizophrenia, **62**:121
negative priming, Stroop Task, **62**:121
nonpsychotic relatives, family studies, **66**:131
nonpsychotic relatives, schizophrenia, **66**:131
nonpsychotic relatives, sex differences, **66**:131
nonpsychotic relatives, vulnerability indicators, **66**:131
orienting response, Wisconsin Card Sorting Test, **65**:107
paranoid subtype, schizophrenia, frontal lobe, **64**:27
paranoid subtype, schizophrenia, Wisconsin Card Sorting Test, **64**:27
reaction time, Stroop Task, **62**:121
schizophrenia, age of onset, **63**:109
schizophrenia, comorbid alcohol abuse/dependence, **64**:35
schizophrenia, dichotic listening, **65**:1
schizophrenia, family studies, **66**:131
schizophrenia, frontal lobe, **64**:27, **65**:15
schizophrenia, gender, **66**:131
schizophrenia, language, **63**:109
schizophrenia, laterality, **65**:1
schizophrenia, medication withdrawal, **62**:121
schizophrenia, negative priming, **62**:121
schizophrenia, nonpsychotic relatives, **66**:131
schizophrenia, paranoid subtype, **64**:27
schizophrenia, semantic network, **63**:109
schizophrenia, sex differences, **66**:131
schizophrenia, Stroop Task, **62**:121
schizophrenia, vulnerability indicators, **66**:131
schizophrenia, Wisconsin Card Sorting Test, **64**:27, **65**:15, **65**:107
semantic network, language, **63**:109
semantic network, schizophrenia, **63**:109
sex differences, family studies, **66**:131
sex differences, nonpsychotic relatives, **66**:131
sex differences, schizophrenia, **66**:131
sex differences, vulnerability indicators, **66**:131
skin conductance, Wisconsin Card Sorting Test, **65**:107
Stroop Task, attention, **62**:121
Stroop Task, medication withdrawal, **62**:121
Stroop Task, negative priming, **62**:121
Stroop Task, reaction time, **62**:121
Stroop Task, schizophrenia, **62**:121
vulnerability indicators, family studies, **66**:131
vulnerability indicators, gender, **66**:131
vulnerability indicators, nonpsychotic relatives, **66**:131
vulnerability indicators, schizophrenia, **66**:131
vulnerability indicators, sex differences, **66**:131
Wisconsin Card Sorting Test, brain tumors, **65**:15
Wisconsin Card Sorting Test, frontal lobe, **64**:27, **65**:15, **65**:107
Wisconsin Card Sorting Test, paranoid schizophrenia, **64**:27
Wisconsin Card Sorting Test, schizophrenia, **64**:27, **65**:107, **65**:15

Norepinephrine
affective disorder, anxiety, **64**:209
affective disorder, psychomotor retardation, **64**:209
aggression, personality, **66**:33
anorexia and bulimia nervosa, exercise, **62**:43
anorexia and bulimia nervosa, methoxy-hydroxyphenylglycol, **62**:43
anorexia and bulimia nervosa, stress, **62**:43
anorexia and bulimia nervosa, test meals, **62**:43
anxiety, affective disorder, **64**:209
anxiety, psychomotor retardation, **64**:209
desmethylimipramine, growth hormone, **63**:1
desmethylimipramine, orthostatic challenge, **63**:1
desmethylimipramine, posttraumatic stress disorder, **63**:1
exercise, anorexia and bulimia nervosa, **62**:43
exercise, methoxy-hydroxyphenylglycol, **62**:43
exercise, stress, **62**:43
growth hormone, aggression, **66**:33
growth hormone, desmethylimipramine, **63**:1
growth hormone, orthostatic challenge, **63**:1
growth hormone, posttraumatic stress disorder, **63**:1
methamphetamine, flashbacks, **63**:93
methamphetamine, methoxy-hydroxyphenylglycol, **63**:93
methamphetamine, paranoid-hallucinatory psychosis, **63**:93
methoxy-hydroxyphenylglycol, anorexia and bulimia nervosa, **62**:43
methoxy-hydroxyphenylglycol, exercise, **62**:43
methoxy-hydroxyphenylglycol, methamphetamine, **63**:93
methoxy-hydroxyphenylglycol, paranoid-hallucinatory psychosis, **63**:93
methoxy-hydroxyphenylglycol, personality, **65**:61
methoxy-hydroxyphenylglycol, reward dependence traits, **65**:61
methoxy-hydroxyphenylglycol, stress, **62**:43
methoxy-hydroxyphenylglycol, substance abuse/dependence, **63**:93
methoxy-hydroxyphenylglycol, Tridimensional Personality Questionnaire, **65**:61
orthostatic challenge, desmethylimipramine, **63**:1
orthostatic challenge, growth hormone, **63**:1
orthostatic challenge, posttraumatic stress disorder, **63**:1
paranoid-hallucinatory psychosis, flashbacks, **63**:93
paranoid-hallucinatory psychosis, methamphetamine, **63**:93
paranoid-hallucinatory psychosis, methoxy-hydroxyphenylglycol, **63**:93
paranoid-hallucinatory psychosis, substance abuse/dependence, **63**:93
personality, aggression, **66**:33
personality, methoxy-hydroxyphenylglycol, **65**:61
personality, reward dependence traits, **65**:61
posttraumatic stress disorder, desmethylimipramine, **63**:1
posttraumatic stress disorder, growth hormone, **63**:1
posttraumatic stress disorder, orthostatic challenge, **63**:1
psychomotor retardation, affective disorder, **64**:209
psychomotor retardation, anxiety, **64**:209
reward dependence traits, methoxy-hydroxyphenylglycol, **65**:61
reward dependence traits, Tridimensional Personality Questionnaire, **65**:61
stress, anorexia and bulimia nervosa, **62**:43
stress, exercise, **62**:43
stress, methoxy-hydroxyphenylglycol, **62**:43
substance abuse/dependence, methamphetamine, **63**:93
substance abuse/dependence, methoxy-hydroxyphenylglycol, **63**:93
substance abuse/dependence, paranoid-hallucinatory psychosis, **63**:93
Tridimensional Personality Questionnaire, methoxy-hydroxyphenylglycol, **65**:61
Tridimensional Personality Questionnaire, reward dependence traits, **65**:61

Obsessive-compulsive disorder
anxiety, harm avoidance, **65**:185
anxiety, Tridimensional Personality Questionnaire, **65**:185
compulsive buying, Compulsive Buying Scale, **64**:59
compulsive buying, fluvoxamine, **64**:59
compulsive buying, selective serotonin reuptake inhibitors, **64**:59
Compulsive Buying Scale, fluvoxamine, **64**:59
Compulsive Buying Scale, selective serotonin reuptake inhibitors, **64**:59
fluvoxamine, compulsive buying, **64**:59
fluvoxamine, Compulsive Buying Scale, **64**:59
harm avoidance, anxiety, **65**:185
harm avoidance, Tridimensional Personality Questionnaire, **65**:185
migraine, phenolsulfotransferase, **65**:73
personality, harm avoidance, **65**:185
phenolsulfotransferase, affective disorder, bipolar subtype, **65**:73
phenolsulfotransferase, migraine, **65**:73
phenolsulfotransferase, platelets, **65**:73
phenolsulfotransferase, unipolar depression, **65**:73
selective serotonin reuptake inhibitors, compulsive buying, **64**:59
selective serotonin reuptake inhibitors, Compulsive Buying Scale, **64**:59
Tridimensional Personality Questionnaire, anxiety, **65**:185
Tridimensional Personality Questionnaire, harm avoidance, **65**:185

Obstetric complications
family history, schizophrenia, **64**:11
family history, season of birth, **64**:11
schizophrenia, family history, **64**:11
schizophrenia, season of birth, **64**:11
season of birth, family history, **64**:11
season of birth, schizophrenia, **64**:11

Ondansetron
activation-euphoria, amphetamine, **64**:1
amphetamine, activation-euphoria, **64**:1
amphetamine, prolactin, cortisol, growth hormone, blood pressure, **64**:1
amphetamine, serotonin, **64**:1
blood pressure, activation-euphoria, **64**:1
blood pressure, amphetamine, **64**:1
cortisol, activation-euphoria, **64**:1
cortisol, amphetamine, **64**:1

growth hormone, activation-euphoria, **64**:1
growth hormone, amphetamine, **64**:1
prolactin, activation-euphoria, **64**:1
prolactin, amphetamine, **64**:1
serotonin, amphetamine, **64**:1

Organic psychoses
cross-cultural, mortality rates, Taiwan, **62**:239
mortality rates, cross-cultural, Taiwan, **62**:239

Oxytocin
anorexia nervosa, beta-endorphin, **62**:65
anorexia nervosa, corticotropin-releasing hormone, **62**:65
anorexia nervosa, neuropeptide Y, **62**:65
anorexia nervosa, vasopressin, **62**:65
beta-endorphin, anorexia nervosa, **62**:65
corticotropin-releasing hormone, anorexia nervosa, **62**:65
neuropeptide Y, anorexia nervosa, **62**:65
vasopressin, anorexia nervosa, **62**:65

Pain
analgesia, borderline personality disorder, **63**:57
analgesia, dissociation, **63**:57
analgesia, self-injury, **63**:57
borderline personality disorder, analgesia, **63**:57
borderline personality disorder, dissociation, **63**:57
borderline personality disorder, self-injury, **63**:57
dissociation, analgesia, **63**:57
dissociation, borderline personality disorder, **63**:57
dissociation, self-injury, **63**:57
self-injury, analgesia, **63**:57
self-injury, borderline personality disorder, **63**:57
self-injury, dissociation, **63**:57

Panic attacks
cholecystokinin, normal volunteers, **66**:97

Panic disorder
agoraphobia, gamma-aminobutyric acid, **63**:223
Anxiety Sensitivity Index, cholecystokinin, **62**:131
benzodiazepines, anxiety, **65**:53
benzodiazepines, dopamine, **65**:53
benzodiazepines, homovanillic acid, **65**:53
cardiovascular morbidity, electrocardiogram, **66**:167
cardiovascular morbidity, QRS complex, **66**:167
cholecystokinin, Anxiety Sensitivity Index, **62**:131
cholecystokinin, introversion, **62**:131
cholecystokinin, Minnesota Multiphasic Personality Inventory, **62**:131
cholecystokinin, personality, **62**:131
cortisol, meta-chlorophenylpiperazine, **64**:77
diazepam, dopamine, **65**:53
diazepam, homovanillic acid, **65**:53
dopamine, benzodiazepines, **65**:53
dopamine, diazepam, **65**:53
dopamine, homovanillic acid, **65**:53
electrocardiogram, cardiovascular morbidity, **66**:167
electrocardiogram, QRS complex, **66**:167
electrocardiogram, spectral analysis, **66**:167
gamma-aminobutyric acid, agoraphobia, **63**:223
genetics, panic attacks, **66**:69
genetics, twins, **66**:69
homovanillic acid, benzodiazepines, **65**:53
homovanillic acid, diazepam, **65**:53
homovanillic acid, dopamine, **65**:53
introversion, cholecystokinin, **62**:131
introversion, Minnesota Multiphasic Personality Inventory, **62**:131
meta-chlorophenylpiperazine, serotonin, **64**:77
Minnesota Multiphasic Personality Inventory, cholecystokinin, **62**:131
Minnesota Multiphasic Personality Inventory, introversion, **62**:131
panic attacks, genetics, **66**:69
panic attacks, twins, **66**:69
personality, Anxiety Sensitivity Index, **62**:131
personality, cholecystokinin, **62**:131
personality, introversion, **62**:131
psychophysiology, electrocardiogram, **66**:167
serotonin, meta-chlorophenylpiperazine, **64**:77
serotonin, respiration, **64**:83
serotonin, tryptophan depletion, **64**:83
spectral analysis, electrocardiogram, **66**:167
tryptophan depletion, respiration, **64**:83
tryptophan depletion, serotonin, **64**:83
twins, panic attacks, **66**:69

Personality
affective disorder, bipolar subtype, **64**:69
aggression, growth hormone, prolactin, cortisol, testosterone, **66**:33
aggression, norepinephrine, **66**:33
anxiety, harm avoidance, **65**:185
anxiety, Tridimensional Personality Questionnaire, **65**:185
Anxiety Sensitivity Index, cholecystokinin, **62**:131
Anxiety Sensitivity Index, panic disorder, **62**:131
bipolar subtype, affective disorder, **64**:69
cholecystokinin, Anxiety Sensitivity Index, **62**:131
cholecystokinin, introversion, **62**:131
cholecystokinin, Minnesota Multiphasic Personality Inventory, **62**:131
cortisol, aggression, **66**:33
growth hormone, aggression, **66**:33
harm avoidance, anxiety, **65**:185
harm avoidance, obsessive-compulsive disorder, **65**:185
harm avoidance, Tridimensional Personality Questionnaire, **65**:185
homovanillic acid, cerebrospinal fluid, **65**:129
homovanillic acid, infants, **65**:129
homovanillic acid, sociability, **65**:129
homovanillic acid, twins, **65**:129
hydroxyindoleacetic acid, cerebrospinal fluid, **65**:129
hydroxyindoleacetic acid, infants, **65**:129
hydroxyindoleacetic acid, sociability, **65**:129
hydroxyindoleacetic acid, twins, **65**:129
infants, hydroxyindoleacetic acid, homovanillic acid, methoxy-hydroxyphenylglycol, **65**:129
infants, sociability, **65**:129
infants, twins, **65**:129
introversion, Minnesota Multiphasic Personality Inventory, **62**:131

introversion, panic disorder, **62**:131
methoxy-hydroxyphenylglycol, cerebrospinal fluid, **65**:129
methoxy-hydroxyphenylglycol, infants, **65**:129
methoxy-hydroxyphenylglycol, reward dependence traits, **65**:61
methoxy-hydroxyphenylglycol, sociability, **65**:129
methoxy-hydroxyphenylglycol, Tridimensional Personality Questionnaire, **65**:61
methoxy-hydroxyphenylglycol, twins, **65**:129
Minnesota Multiphasic Personality Inventory, cholecystokinin, **62**:131
Minnesota Multiphasic Personality Inventory, introversion, **62**:131
Minnesota Multiphasic Personality Inventory, panic disorder, **62**:131
norepinephrine, aggression, **66**:33
norepinephrine, reward dependence traits, **65**:61
norepinephrine, Tridimensional Personality Questionnaire, **65**:61
obsessive-compulsive disorder, harm avoidance, **65**:185
obsessive-compulsive disorder, Tridimensional Personality Questionnaire, **65**:185
panic disorder, Anxiety Sensitivity Index, **62**:131
panic disorder, introversion, **62**:131
panic disorder, Minnesota Multiphasic Personality Inventory, **62**:131
prolactin, aggression, **66**:33
reward dependence traits, methoxy-hydroxyphenylglycol, **65**:61
reward dependence traits, norepinephrine, **65**:61
reward dependence traits, Tridimensional Personality Questionnaire, **65**:61
sociability, homovanillic acid, **65**:129
sociability, hydroxyindoleacetic acid, **65**:129
sociability, infants, **65**:129
sociability, methoxy-hydroxyphenylglycol, **65**:129
sociability, twins, **65**:129
testosterone, aggression, **66**:33
Tridimensional Personality Questionnaire, harm avoidance, **65**:185
Tridimensional Personality Questionnaire, methoxy-hydroxyphenylglycol, **65**:61
Tridimensional Personality Questionnaire, norepinephrine, **65**:61
Tridimensional Personality Questionnaire, obsessive-compulsive disorder, **65**:185
Tridimensional Personality Questionnaire, reward dependence traits, **65**:61
twins, homovanillic acid, **65**:129
twins, hydroxyindoleacetic acid, **65**:129
twins, infants, **65**:129
twins, methoxy-hydroxyphenylglycol, **65**:129
twins, sociability, **65**:129

Phytohemoagglutinin
anorexia and bulimia nervosa, immunology, **62**:97
immunology, anorexia and bulimia nervosa, **62**:97

Phenelzine
imipramine binding, posttraumatic stress disorder, **63**:143
imipramine binding, serotonin, **63**:143
monoamine oxidase inhibitor inhibitor, posttraumatic stress disorder, **63**:143
posttraumatic stress disorder, platelet imipramine binding, **63**:143
posttraumatic stress disorder, serotonin, **63**:143
serotonin, platelet imipramine binding, **63**:143
serotonin, posttraumatic stress disorder, **63**:143

Phenolsulfotransferase
affective disorder, bipolar and unipolar subtypes, **65**:73
affective disorder, migraine, **65**:73
bipolar affective disorder, migraine, **65**:73
migraine, affective disorder, **65**:73
migraine, bipolar and unipolar depression, **65**:73
migraine, obsessive-compulsive disorder, **65**:73
obsessive-compulsive disorder, migraine, **65**:73
unipolar depression, migraine, **65**:73

Phospholipids
bipolar affective disorder, skin fibroblasts, **63**:133
schizophrenia, skin fibroblasts, **63**:133
skin fibroblasts, bipolar affective disorder, **63**:133
skin fibroblasts, schizophrenia, **63**:133

Polysomnography. *See also* Sleep
affective disorder, age, **62**:161
affective disorder, circadian rhythms, **62**:161
affective disorder, dexamethasone suppression test, **63**:83
affective disorder, endogenous subtype, **63**:83
affective disorder, sleep impairment, **62**:161
affective disorder, Social Rhythm Metric, **62**:161
affective disorder, symptom severity, **63**:83
affective disorder, thyrotropin-releasing hormone, **63**:83
age, affective disorder, **62**:161
age, circadian rhythms, **62**:161
age, sleep impairment, **62**:161
age, Social Rhythm Metric, **62**:161
bereavement, circadian rhythms, **62**:161
bereavement, late-life depression, **62**:161
bereavement, sleep impairment, **62**:161
bereavement, Social Rhythm Metric, **62**:161
circadian rhythms, affective disorder, **62**:161
circadian rhythms, age, **62**:161
circadian rhythms, bereavement, **62**:161
circadian rhythms, late-life depression, **62**:161
circadian rhythms, Social Rhythm Metric, **62**:161
dexamethasone suppression test, affective disorder, endogenous subtype, **63**:83
dexamethasone suppression test, symptom severity, **63**:83
endogenous subtype, affective disorder, **63**:83
endogenous subtype, dexamethasone suppression test, **63**:83
endogenous subtype, symptom severity, **63**:83
endogenous subtype, thyrotropin-releasing hormone, **63**:83
late-life depression, circadian rhythms, **62**:161
late-life depression, sleep impairment, **62**:161
late-life depression, Social Rhythm Metric, **62**:161
sleep impairment, affective disorder, **62**:161
sleep impairment, age, **62**:161
sleep impairment, bereavement, **62**:161

sleep impairment, late-life depression, **62**:161
sleep impairment, Social Rhythm Metric, **62**:161
Social Rhythm Metric, affective disorder, **62**:161
Social Rhythm Metric, age, **62**:161
Social Rhythm Metric, bereavement, **62**:161
Social Rhythm Metric, late-life depression, **62**:161
thyrotropin-releasing hormone, affective disorder, endogenous subtype, **63**:83
thyrotropin-releasing hormone, symptom severity, **63**:83

Positron emission tomography
anorexia nervosa, **62**:105

Posttraumatic stress disorder
acoustic startle reflex, prepulse inhibition, **64**:169
acoustic startle reflex, startle amplitude, **64**:169
desmethylimipramine, growth hormone, **63**:1
desmethylimipramine, norepinephrine, **63**:1
desmethylimipramine, orthostatic challenge, **63**:1
eyeblink reflex, acoustic startle reflex, **64**:169
growth hormone, desmethylimipramine, **63**:1
growth hormone, orthostatic challenge, **63**:1
imipramine binding in platelets, monoamine oxidase inhibitor, **63**:143
imipramine binding in platelets, phenelzine, **63**:143
imipramine binding in platelets, serotonin, **63**:143
monoamine oxidase inhibitor, phenelzine, **63**:143
monoamine oxidase inhibitor, platelet imipramine binding, **63**:143
monoamine oxidase inhibitor, serotonin, **63**:143
norepinephrine, desmethylimipramine, **63**:1
norepinephrine, orthostatic challenge, **63**:1
orthostatic challenge, desmethylimipramine, **63**:1
orthostatic challenge, growth hormone, **63**:1
orthostatic challenge, norepinephrine, **63**:1
phenelzine, platelet imipramine binding, **63**:143
phenelzine, serotonin, **63**:143
prepulse inhibition, acoustic startle reflex, **64**:169
psychophysiology, acoustic startle reflex, **64**:169
psychophysiology, eyeblink reflex, **64**:169
psychophysiology, prepulse inhibition, **64**:169
psychophysiology, startle amplitude, **64**:169
serotonin, monoamine oxidase inhibitor, **63**:143
serotonin, phenelzine, **63**:143
serotonin, platelet imipramine binding, **63**:143

Premenstrual syndrome
anxiety, Daily Symptom Report, **65**:97
anxiety, depressed mood, **65**:97
anxiety, menstrual cycle, **65**:97
Daily Symptom Report, anxiety, **65**:97
Daily Symptom Report, depressed mood, **65**:97
Daily Symptom Report, menstrual cycle, **65**:97
depressed mood, anxiety, **65**:97
depressed mood, Daily Symptom Report, **65**:97
depressed mood, menstrual cycle, **65**:97
menstrual cycle, anxiety, **65**:97
menstrual cycle, Daily Symptom Report, **65**:97
menstrual cycle, depressed mood, **65**:97

Progesterone
circadian rhythms, menstrual cycle, **62**:147
depressed mood, circadian rhythms, **62**:147
depressed mood, sleep deprivation, **62**:147
menstrual cycle, circadian rhythms, **62**:147
menstrual cycle, depressed mood, **62**:147
menstrual cycle, sleep deprivation, **62**:147
sleep deprivation, menstrual cycle, **62**:147

Prolactin
abstinence, cocaine craving, **65**:65
abstinence, substance abuse/dependence, **65**:65
activation-euphoria, amphetamine, **64**:1
activation-euphoria, ondansetron, **64**:1
activation-euphoria, serotonin, **64**:1
aggression, personality, **66**:33
amphetamine, activation-euphoria, **64**:1
amphetamine, ondansetron, **64**:1
amphetamine, serotonin, **64**:1
anorexia nervosa, meta-chlorophenylpiperazine, **62**:31
anorexia nervosa, serotonin, **62**:31
circadian rhythms, depressed mood, **62**:147
circadian rhythms, menstrual cycle, **62**:147
circadian rhythms, sleep deprivation, **62**:147
cocaine, abstinence, **65**:65
cocaine, craving, **65**:65
cocaine, dopamine, **65**:65
depressed mood, circadian rhythms, **62**:147
depressed mood, menstrual cycle, **62**:147
depressed mood, sleep deprivation, **62**:147
dopamine, cocaine, **65**:65
early vs. late sleep deprivation, **62**:147
menstrual cycle, circadian rhythms, **62**:147
menstrual cycle, depressed mood, **62**:147
menstrual cycle, sleep deprivation, **62**:147
meta-chlorophenylpiperazine, anorexia nervosa, **62**:31
meta-chlorophenylpiperazine, schizophrenia, **64**:147
meta-chlorophenylpiperazine, serotonin, **62**:31, **62**:139, **64**:147
methylphenidate, cocaine, **65**:65
methylphenidate, substance abuse/dependence, **65**:65
ondansetron, activation-euphoria, **64**:1
ondansetron, amphetamine, **64**:1
ondansetron, serotonin, **64**:1
personality, aggression, **66**:33
schizophrenia, meta-chlorophenylpiperazine, **64**:147
schizophrenia, serotonin, **64**:147
serotonin, activation-euphoria, **64**:1
serotonin, amphetamine, **64**:1
serotonin, anorexia nervosa, **62**:31
serotonin, meta-chlorophenylpiperazine, **62**:31, **62**:139, **64**:147
serotonin, ondansetron, **64**:1
serotonin, schizophrenia, **64**:147
sleep deprivation, circadian rhythms, **62**:147
sleep deprivation, depressed mood, **62**:147
sleep deprivation, early vs. late, **62**:147
sleep deprivation, menstrual cycle, **62**:147
substance abuse/dependence, cocaine, **65**:65
substance abuse/dependence, dopamine, **65**:65
tryptophan, anorexia nervosa, **62**:31
tryptophan, meta-chlorophenylpiperazine, **62**:31

Psychomotor activity
affective disorder, dopamine, **64**:209
affective disorder, norepinephrine, **64**:209
anxiety, dopamine, **64**:209
anxiety, norepinephrine, **64**:209
dopamine, affective disorder, **64**:209
dopamine, anxiety, **64**:209
norepinephrine, affective disorder, **64**:209
norepinephrine, anxiety, **64**:209

Psychophysiology
acoustic startle reflex, posttraumatic stress disorder, **64**:169
electrocardiogram, panic disorder, **66**:111
electrocardiogram, QRS complex, **66**:111
electrocardiogram, spectral analysis, **66**:111
eyeblink reflex, posttraumatic stress disorder, **64**:169
orienting response, schizophrenia, **65**:107
panic disorder, electrocardiogram, **66**:111
posttraumatic stress disorder, acoustic startle reflex, **64**:169
posttraumatic stress disorder, eyeblink reflex, **64**:169
posttraumatic stress disorder, prepulse inhibition, **64**:169
posttraumatic stress disorder, startle amplitude, **64**:169
prepulse inhibition, posttraumatic stress disorder, **64**:169
schizophrenia, skin conductance orienting response, **65**:107
skin conductance orienting response, schizophrenia, **65**:107
spectral analysis, electrocardiogram, **66**:111
startle amplitude, posttraumatic stress disorder, **64**:169

Schizoaffective disorder
age, Quality of Well-Being Scale, **63**:169
positive symptoms, age, **63**:169
positive symptoms, Quality of Well-Being Scale, **63**:169
Quality of Well-Being Scale, positive symptoms, **63**:169

Schizophrenia
acute phase proteins, immunology, **66**:1
acute phase proteins, psychotropic drugs, **66**:1
age, positive symptoms, **63**:169
age, Quality of Well-Being Scale, **63**:169
age of onset, computed tomography, **64**:47
age of onset, cortical atrophy, **64**:47
age of onset, homovanillic acid, **64**:47
age of onset, language, **63**:109
age of onset, methoxy-hydroxyphenylglycol, **64**:47
age of onset, neuropsychology, **63**:109
age of onset, semantic network, **63**:109
age of onset, sulcal widening, **64**:47
age of onset, treatment response prediction, **64**:47
attention, affective disorder, **66**:121
attention, eye-tracking performance, **64**:19, **66**:121
attention, family studies, **66**:131
attention, first-episode psychosis, **64**:19
attention, gender, **66**:131
attention, Global/Local Task, **62**:111
attention, hallucinations, **62**:111
attention, high-risk study, **66**:121
attention, laterality, **62**:111
attention, left hemisphere deficit, **62**:111
attention, medication withdrawal, **62**:121
attention, negative priming, **62**:121
attention, neuropsychology, **62**:121, **66**:131
attention, nonpsychotic relatives, **66**:131
attention, reaction time, **62**:111, **62**:121
attention, schizophreniform disorder, **64**:19
attention, sex differences, **66**:131
attention, smooth pursuit eye movements, **64**:19, **66**:121
attention, Stroop Task, **62**:121
attention, vulnerability indicators, **66**:131
Brief Psychiatric Rating Scale symptom factors, sleep latency, **66**:111
Brief Psychiatric Rating Scale symptom factors, thinking disturbance, **66**:111
c-Harvey-Ras gene, genetics, **63**:25
cognition, contingent negative variation, **66**:45
cognition, dichotic listening, **65**:1
cognition, electroencephalography, **66**:45
cognition, laterality, **65**:1
cognition, mental arithmetic, **66**:45
cognition, negative symptoms, **66**:45
cognition, neuropsychology, **65**:1
cognition, outpatients, **62**:251
cognition, social function, **62**:251, **63**:77
cognition, topographic brain mapping, **66**:45
comorbidity, alcohol abuse/dependence, **64**:35
computed tomography, age of onset, **64**:47
computed tomography, cortical atrophy, **64**:47
computed tomography, haloperidol, **64**:47
computed tomography, homovanillic acid, **64**:47
computed tomography, methoxy-hydroxyphenylglycol, **64**:47
computed tomography, sulcal widening, **64**:47
computed tomography, treatment response prediction, **64**:47
contingent negative variation, cognition, **66**:45
contingent negative variation, electroencephalography, **66**:45
contingent negative variation, mental arithmetic, **66**:45
contingent negative variation, negative symptoms, **66**:45
contingent negative variation, topographic brain mapping, **66**:45
cortical atrophy, age of onset, **64**:47
cortical atrophy, computed tomography, **64**:47
cortical atrophy, haloperidol, **64**:47
cortical atrophy, homovanillic acid, **64**:47
cortical atrophy, methoxy-hydroxyphenylglycol, **64**:47
cortical atrophy, treatment response prediction, **64**:47
cortisol, meta-chlorophenylpiperazine, **64**:147
cortisol, temperature, **64**:147
cross-cultural, Taiwan, mortality rates, **62**:239
Darier's Disease, skin disorder, **64**:205
diaphoresis, neuroleptic malignant syndrome, **64**:137
diaphoresis, polydipsia, **64**:137
diaphoresis, serum osmolality, **64**:137
dichotic listening, cognition, **65**:1
dichotic listening, laterality, **65**:1
dichotic listening, neuropsychology, **65**:1
DNA polymorphism, association study, **62**:221
DNA polymorphism, candidate gene, **62**:221
DNA polymorphism, dopamine, **62**:221
DNA polymorphism, monoamine oxidase, **62**:221
dopamine, DNA polymorphism, **62**:221
dopamine, genetics, **62**:221

electroencephalography, cognition, **66**:45
electroencephalography, contingent negative variation, **66**:45
electroencephalography, mental arithmetic, **66**:45
electroencephalography, negative symptoms, **66**:45
electroencephalography, topographic mapping, **66**:45
evoked potentials, auditory gating, **64**:121
evoked potentials, P300 wave, **65**:23
evoked potentials, P50 wave, **64**:121
evoked potentials, residual symptoms, **65**:23
evoked potentials, thought disorder, **65**:23
eye-tracking performance, attention, **64**:19
eye-tracking performance, first-episode psychosis, **64**:19
eye-tracking performance, schizophreniform disorder, **64**:19
eye tracking, attention, **66**:121
eye tracking, high-risk study, **66**:121
eye tracking, smooth pursuit eye movements, **66**:121
family history, gender, **64**:105
family history, neurological soft signs, **64**:105
family history, obstetric complications, **64**:11, **64**:105
family history, season of birth, **64**:11
family studies, attention, **66**:131
family studies, gender, **66**:131
family studies, immunology, **66**:145
family studies, interferon-gamma, **66**:145
family studies, neuropsychology, **66**:131
family studies, nonpsychotic relatives, **66**:131
family studies, sex differences, **66**:131
family studies, vulnerability indicators, **66**:131
first-episode psychosis, attention, **64**:19
first-episode psychosis, eye-tracking performance, **64**:19
first-episode psychosis, smooth pursuit eye movements, **64**:19
frontal lobe, neuropsychology, **64**:27, **65**:15
frontal lobe, paranoid subtype, **64**:27
frontal lobe, Wisconsin Card Sorting Test, **64**:27, **65**:15
gender, attention, **66**:131
gender, family studies, **64**:105, **66**:131
gender, neurological soft signs, **64**:105
gender, neuropsychology, **66**:131
gender, nonpsychotic relatives, **66**:131
gender, obstetric complications, **64**:105
gender, vulnerability indicators, **66**:131
genetics, association study, **62**:221
genetics, c-Harvey-Ras gene, **63**:25
genetics, candidate gene, **62**:221
genetics, DNA polymorphism, **62**:221
genetics, dopamine, **62**:221
genetics, monoamine oxidase, **62**:221
genetics, pseudoautosomal locus, **62**:281
genetics, sex chromosomes, **62**:281
hallucinations, attention, **62**:111
hallucinations, Global/Local Task, **62**:111
hallucinations, laterality, **62**:111
hallucinations, left hemisphere deficit, **62**:111
hallucinations, reaction time, **62**:111
haloperidol, homovanillic acid, **64**:47
haloperidol, methoxy-hydroxyphenylglycol, **64**:47
haloperidol, treatment response prediction, **64**:47
haloperidol withdrawal, serotonin, **63**:123
high-risk study, attention, **66**:121
high-risk study, eye tracking, **66**:121
high-risk study, smooth pursuit eye movements, **66**:121
homovanillic acid, haloperidol, **64**:47
homovanillic acid, treatment response prediction, **64**:47
hyponatremia, neuroleptic dosage, **63**:227
hyponatremia, water intoxication, **63**:227
immunology, acute phase proteins, **66**:1
immunology, family studies, **66**:145
immunology, interferon-gamma, **66**:145
immunology, interleukin-2, **65**:171
immunology, lymphocytes, **65**:171
immunology, phytohemoagglutinin, **65**:171
immunology, positive symptoms, **65**:171
immunology, psychotropic drugs, **66**:1
immunology, schizophreniform disorder, **65**:171
inpatients vs. outpatients, quality of life, **66**:153
interferon-gamma, family studies, **66**:145
interferon-gamma, immunology, **66**:145
interhemispheric transfer, mirror-drawing, **64**:115
interleukin-2, immunology, **65**:171
interleukin-2, lymphocytes, **65**:171
interleukin-2, phytohemoagglutinin, **65**:171
interleukin-2, positive symptoms, **65**:171
interleukin-2, schizophreniform disorder, **65**:171
language, age of onset, **63**:109
language, neuropsychology, **63**:109
laterality, attention, **62**:111
laterality, cognition, **65**:1
laterality, dichotic listening, **65**:1
laterality, Global/Local Task, **62**:111
laterality, hallucinations, **62**:111
laterality, mirror-drawing, **64**:115
laterality, neuropsychology, **65**:1
laterality, reaction time, **62**:111
left hemisphere deficit, attention, **62**:111
left hemisphere deficit, Global/Local Task, **62**:111
left hemisphere deficit, hallucinations, **62**:111
left hemisphere deficit, reaction time, **62**:111
lymphocytes, immunology, **65**:171
lymphocytes, interleukin-2, **65**:171
lymphocytes, phytohemoagglutinin, **65**:171
lymphocytes, positive symptoms, **65**:171
lymphocytes, schizophreniform disorder, **65**:171
mental arithmetic, cognition, **66**:45
mental arithmetic, contingent negative variation, **66**:45
mental arithmetic, electroencephalography, **66**:45
mental arithmetic, negative symptoms, **66**:45
mental arithmetic, topographic mapping, **66**:45
meta-chlorophenylpiperazine, cortisol, **64**:147
meta-chlorophenylpiperazine, prolactin, **64**:147
meta-chlorophenylpiperazine, serotonin, **64**:147
meta-chlorophenylpiperazine, temperature, **64**:147
methoxy-hydroxyphenylglycol, treatment response prediction, **64**:47
monoamine oxidase, association study, **62**:221
monoamine oxidase, candidate gene, **62**:221
monoamine oxidase, DNA polymorphism, **62**:221
monoamine oxidase, dopamine, **62**:221
monoamine oxidase, genetics, **62**:221

mortality rates, cross-cultural, Taiwan, **62**:239
negative symptoms, Negative Symptom Assessment, **63**:67
negative priming, attention, **62**:121
negative priming, medication withdrawal, **62**:121
negative priming, neuropsychology, **62**:121
negative priming, reaction time, **62**:121
negative priming, Stroop Task, **62**:121
negative symptoms, Brief Psychiatric Rating Scale retardation factor, **63**:67
negative symptoms, cognition, **66**:45
negative symptoms, contingent negative variation, **66**:45
negative symptoms, electroencephalography, **66**:45
negative symptoms, mental arithmetic, **66**:45
negative symptoms, topographic mapping, **66**:45
neuroleptic dosage, hyponatremia, **63**:227
neuroleptic dosage, water intoxication, **63**:227
neuroleptic malignant syndrome, diaphoresis, **64**:137
neuroleptic malignant syndrome, polydipsia, **64**:137
neuroleptic malignant syndrome, serum osmolality, **64**:137
neurological soft signs, family history, **64**:105
neurological soft signs, gender, **64**:105
neurological soft signs, obstetric complications, **64**:105
neuropsychology, age of onset, **63**:109
neuropsychology, attention, **62**:121, **66**:131
neuropsychology, dichotic listening, **65**:1
neuropsychology, family studies, **66**:131
neuropsychology, frontal lobe, **64**:27, **65**:15
neuropsychology, gender, **66**:131
neuropsychology, language, **63**:109
neuropsychology, laterality, **65**:1
neuropsychology, medication withdrawal, **62**:121
neuropsychology, negative priming, **62**:121
neuropsychology, nonpsychotic relatives, **66**:131
neuropsychology, paranoid subtype, **64**:27
neuropsychology, reaction time, **62**:121
neuropsychology, semantic network, **63**:109
neuropsychology, sex differences, **66**:131
neuropsychology, Stroop Task, **62**:121
neuropsychology, vulnerability indicators, **66**:131
neuropsychology, Wisconsin Card Sorting Test, **64**:27, **65**:15, **65**:107
nonpsychotic relatives, attention, **66**:131
nonpsychotic relatives, neuropsychology, **66**:131
nonpsychotic relatives, vulnerability indicators, **66**:131
obstetric complications, family history, **64**:11, **64**:105
obstetric complications, neurological soft signs, **64**:105
obstetric complications, season of birth, **64**:11
orienting response, psychophysiology, **65**:107
P300 wave, evoked potentials, **65**:23
P300 wave, residual symptoms, **65**:23
P300 wave, thought disorder, **65**:23
paranoid subtype, frontal lobe, **64**:27
paranoid subtype, neuropsychology, **64**:27
paranoid subtype, Wisconsin Card Sorting Test, **64**:27
phospholipid fatty acids, skin fibroblasts, **63**:133
phytohemoagglutinin, immunology, **65**:171
phytohemoagglutinin, interleukin-2, **65**:171
phytohemoagglutinin, lymphocytes, **65**:171
phytohemoagglutinin, positive symptoms, **65**:171
phytohemoagglutinin, schizophreniform disorder, **65**:171
polydipsia, diaphoresis, **64**:137
polydipsia, neuroleptic malignant syndrome, **64**:137
polydipsia, serum osmolality, **64**:137
positive symptoms, age, **63**:169
positive symptoms, immunology, **65**:171
positive symptoms, interleukin-2, **65**:171
positive symptoms, lymphocytes, **65**:171
positive symptoms, phytohemoagglutinin, **65**:171
positive symptoms, Quality of Well-Being Scale, **63**:169
positive symptoms, schizophreniform disorder, **65**:171
prolactin, meta-chlorophenylpiperazine, **64**:147
prolactin, serotonin, **64**:147
prolactin, temperature, **64**:147
pseudoautosomal locus, genetics, **62**:281
pseudoautosomal locus, sex chromosomes, **62**:281
psychophysiology, orienting response, **65**:107
psychophysiology, skin conductance, **65**:107
psychotropic drugs, acute phase proteins, **66**:1
psychotropic drugs, immunology, **66**:1
quality of life, inpatients vs. outpatients, **66**:153
Quality of Well-Being Scale, age, **63**:169
Quality of Well-Being Scale, positive symptoms, **63**:169
reaction time, attention, **62**:111, **62**:121
reaction time, Global/Local Task, **62**:111
reaction time, hallucinations, **62**:111
reaction time, laterality, **62**:111
reaction time, left hemisphere deficit, **62**:111
reaction time, medication withdrawal, **62**:121
reaction time, negative priming, **62**:121
reaction time, neuropsychology, **62**:121
reaction time, Stroop Task, **62**:121
residual symptoms, evoked potentials, **65**:23
residual symptoms, P300 wave, **65**:23
residual symptoms, thought disorder, **65**:23
schizophreniform disorder, attention, **64**:19
schizophreniform disorder, eye-tracking performance, **64**:19
schizophreniform disorder, immunology, **65**:171
schizophreniform disorder, interleukin-2, **65**:171
schizophreniform disorder, lymphocytes, **65**:171
schizophreniform disorder, phytohemoagglutinin, **65**:171
schizophreniform disorder, positive symptoms, **65**:171
schizophreniform disorder, smooth pursuit eye movements, **64**:19
season of birth, family history, **64**:11
season of birth, obstetric complications, **64**:11
semantic network, age of onset, **63**:109
semantic network, language, **63**:109
semantic network, neuropsychology, **63**:109
serotonin, cortisol, **64**:147
serotonin, meta-chlorophenylpiperazine, **64**:147
serotonin, platelets, **63**:123
serotonin, prolactin, **64**:147
serotonin, temperature, **64**:147
serum osmolality, diaphoresis, **64**:137
serum osmolality, neuroleptic malignant syndrome, **64**:137
serum osmolality, polydipsia, **64**:137
sex chromosomes, genetics, **62**:281
sex chromosomes, pseudoautosomal locus, **62**:281
sex differences, attention, **66**:131
sex differences, neuropsychology, **66**:131

skin conductance, psychophysiology, **65**:107
skin fibroblasts, phospholipid fatty acids, **63**:133
sleep, Brief Psychiatric Rating Scale symptom factors, **66**:111
sleep, thinking disturbance, **66**:111
sleep latency, Brief Psychiatric Rating Scale symptom factors, **66**:111
sleep latency, thinking disturbance, **66**:111
smooth pursuit eye movements, attention, **64**:19, **66**:121
smooth pursuit eye movements, first-episode psychosis, **64**:19
smooth pursuit eye movements, high-risk study, **66**:121
smooth pursuit eye movements, schizophreniform disorder, **64**:19
social function, cognition, **62**:251, **63**:77
social function, outpatients, **62**:251
Stroop Task, attention, **62**:121
Stroop Task, medication withdrawal, **62**:121
Stroop Task, negative priming, **62**:121
Stroop Task, neuropsychology, **62**:121
Stroop Task, reaction time, **62**:121
sulcal widening, age of onset, **64**:47
sulcal widening, computed tomography, **64**:47
sulcal widening, homovanillic acid, **64**:47
sulcal widening, methoxy-hydroxyphenylglycol, **64**:47
sulcal widening, treatment response prediction, **64**:47
temperature, cortisol, **64**:147
temperature, meta-chlorophenylpiperazine, **64**:147
temperature, prolactin, **64**:147
temperature, serotonin, **64**:147
thinking disturbance, sleep latency, **66**:111
thought disorder, evoked potentials, **65**:23
thought disorder, P300 wave, **65**:23
thought disorder, residual symptoms, **65**:23
topographic mapping, cognition, **66**:45
topographic mapping, contingent negative variation, **66**:45
topographic mapping, electroencephalography, **66**:45
topographic mapping, mental arithmetic, **66**:45
topographic mapping, negative symptoms, **66**:45
treatment response prediction, age of onset, **64**:47
treatment response prediction, computed tomography, **64**:47
treatment response prediction, cortical atrophy, **64**:47
treatment response prediction, haloperidol, **64**:47
treatment response prediction, homovanillic acid, **64**:47
treatment response prediction, methoxy-hydroxyphenylglycol, **64**:47
treatment response prediction, sulcal widening, **64**:47
vulnerability indicators, attention, **66**:131
vulnerability indicators, family studies, **66**:131
vulnerability indicators, neuropsychology, **66**:131
vulnerability indicators, nonpsychotic relatives, **66**:131
water intoxication, hyponatremia, **63**:227
water intoxication, neuroleptic dosage, **63**:227
Wisconsin Card Sorting Test, frontal lobe, **64**:27, **65**:15
Wisconsin Card Sorting Test, neuropsychology, **65**:107
Wisconsin Card Sorting Test, paranoid subtype, **64**:27

Schizophreniform psychosis. *See* Schizophrenia

Seasonal depression. *See also* Affective disorder; Circannual rhythms
monoamine oxidase, platelets, **62**:273
monoamine oxidase, suicide attempts, **62**:273
suicide attempts, monoamine oxidase, platelets, **62**:273

Serotonin
activation-euphoria, amphetamine, **64**:1
activation-euphoria, blood pressure, **64**:1
activation-euphoria, cortisol, **64**:1
activation-euphoria, growth hormone, **64**:1
activation-euphoria, ondansetron, **64**:1
activation-euphoria, prolactin, **64**:1
affective disorder, adolescents, **65**:79
affective disorder, aggression, **65**:143
affective disorder, antidepressants, **66**:73, **66**:87
affective disorder, anxiety, **65**:143
affective disorder, children, **65**:79
affective disorder, cortisol, **65**:143
affective disorder, diagnostic subtype, **65**:143
affective disorder, erythrocytes, **63**:151, **66**:87
affective disorder, kinetic analysis, **63**:151, **66**:87
affective disorder, paroxetine binding in platelets, **66**:73
affective disorder, serotonin receptors, **66**:73
affective disorder, stress, **65**:143
affective disorder, suicidal thoughts, **66**:73
affective disorder, tryptophan, **63**:151, **66**:87
aggression, affective disorder, **65**:143
aggression, cortisol, **65**:143
alcohol abuse/dependence, dipole activity, **63**:47
alcohol abuse/dependence, evoked potentials, **63**:47
alcohol abuse/dependence, stimulus intensity, **63**:47
amphetamine, activation-euphoria, **64**:1
amphetamine, blood pressure, **64**:1
amphetamine, cortisol, **64**:1
amphetamine, growth hormone, **64**:1
amphetamine, ondansetron, **64**:1
amphetamine, prolactin, **64**:1
animal models, antisense oligonucleotide, **63**:197
animal models, hippocampus, **63**:197
animal models, learned helplessness, **63**:197
animal models, Sprague-Dawley rats, **63**:197
anorexia nervosa, eating behavior, **62**:23
anorexia nervosa, growth hormone, **62**:31
anorexia nervosa, meta-chlorophenylpiperazine, **62**:31
anorexia nervosa, prolactin, **62**:31
anorexia nervosa, satiety, **62**:23
anorexia nervosa, tryptophan, **62**:31
antidepressants, affective disorder, **66**:73, **66**:87
antidepressants, erythrocytes, **66**:87
antidepressants, kinetics, **66**:87
antidepressants, paroxetine binding in platelets, **66**:73
antidepressants, serotonin receptors, **66**:73
antidepressants, suicidal thoughts, **66**:73
antidepressants, tryptophan, **66**:87
antisense oligonucleotide, animal models, **63**:197
antisense oligonucleotide, hippocampus, **63**:197
antisense oligonucleotide, learned helplessness, **63**:197
antisense oligonucleotide, Sprague-Dawley rats, **63**:197
anxiety, cortisol, **65**:143
anxiety, panic disorder, **64**:83
anxiety, respiration, **64**:83
anxiety, tryptophan depletion, **64**:83

attention deficit hyperactivity disorder, conduct disorder, **65**:79
autism, genetics, **65**:33
autism, hydroxyindoleacetic acid, **65**:33
autism, serotonin receptor gene, **65**:33
blood pressure, activation-euphoria, **64**:1
blood pressure, amphetamine, **64**:1
blood pressure, cortisol, **64**:1
blood pressure, growth hormone, **64**:1
blood pressure, ondansetron, **64**:1
blood pressure, prolactin, **64**:1
bulimia nervosa, eating behavior, **62**:23
bulimia nervosa, satiety, **62**:23
conduct disorder, attention deficit hyperactivity disorder, **65**:79
cortisol, activation-euphoria, **64**:1
cortisol, affective disorder, **65**:143
cortisol, aggression, **65**:143
cortisol, amphetamine, **64**:1
cortisol, anxiety, **65**:143
cortisol, blood pressure, **64**:1
cortisol, diagnostic subtype, **65**:143
cortisol, growth hormone, **64**:1
cortisol, meta-chlorophenylpiperazine, **62**:139, **64**:77, **64**:147
cortisol, ondansetron, **64**:1
cortisol, panic disorder, **64**:77
cortisol, prolactin, **62**:139, **64**:1, **64**:147
cortisol, schizophrenia, **64**:147
cortisol, stress, **65**:143
cortisol, temperature, **64**:147
dipole activity, alcohol abuse/dependence, **63**:47
dipole activity, evoked potentials, **63**:47
dipole activity, stimulus intensity, **63**:47
eating behavior, anorexia and bulimia nervosa, **62**:23
eating behavior, satiety, **62**:23
erythrocytes, affective disorder, **63**:151, **66**:87
erythrocytes, antidepressants, **66**:87
erythrocytes, kinetic analysis, **63**:151, **66**:87
erythrocytes, tryptophan, **63**:151, **66**:87
evoked potentials, alcohol abuse/dependence, **63**:47
evoked potentials, dipole activity, **63**:47
evoked potentials, stimulus intensity, **63**:47
genetics, autism, **65**:33
genetics, hydroxyindoleacetic acid, **65**:33
genetics, serotonin receptor gene, **65**:33
growth hormone, activation-euphoria, **64**:1
growth hormone, amphetamine, **64**:1
growth hormone, anorexia nervosa, **62**:31
growth hormone, blood pressure, **64**:1
growth hormone, cortisol, **64**:1
growth hormone, meta-chlorophenylpiperazine, **62**:31
growth hormone, ondansetron, **64**:1
growth hormone, prolactin, **62**:31, **64**:1
growth hormone, tryptophan, **62**:31
haloperidol withdrawal, platelets, **63**:123
haloperidol withdrawal, schizophrenia, **63**:123
hippocampus, animal models, **63**:197
hippocampus, antisense oligonucleotide, **63**:197
hippocampus, learned helplessness, **63**:197
hippocampus, Sprague-Dawley rats, **63**:197
hydroxyindoleacetic acid, autism, **65**:33
hydroxyindoleacetic acid, genetics, **65**:33
hydroxyindoleacetic acid, serotonin receptor gene, **65**:33
imipramine binding, monoamine oxidase inhibitor, **63**:143
imipramine binding, phenelzine, **63**:143
imipramine binding, posttraumatic stress disorder, **63**:143
kinetic analysis, affective disorder, **63**:151, **66**:87
kinetic analysis, erythrocytes, **63**:151, **66**:87
kinetic analysis, tryptophan, **63**:151, **66**:87
kinetic analysis, antidepressants, **66**:87
learned helplessness, animal models, **63**:197
learned helplessness, antisense oligonucleotide, **63**:197
learned helplessness, hippocampus, **63**:197
learned helplessness, Sprague-Dawley rats, **63**:197
meta-chlorophenylpiperazine, anorexia nervosa, **62**:31
meta-chlorophenylpiperazine, cortisol, **62**:139, **64**:77, **64**:147
meta-chlorophenylpiperazine, growth hormone, **62**:31
meta-chlorophenylpiperazine, panic disorder, **64**:77
meta-chlorophenylpiperazine, prolactin, **62**:31, **62**:139, **64**:147
meta-chlorophenylpiperazine, schizophrenia, **64**:147
meta-chlorophenylpiperazine, temperature, **64**:147
meta-chlorophenylpiperazine, tryptophan, **62**:31
monoamine oxidase inhibitor, imipramine binding, **63**:143
monoamine oxidase inhibitor, phenelzine, **63**:143
monoamine oxidase inhibitor, platelet imipramine binding, **63**:143
monoamine oxidase inhibitor, posttraumatic stress disorder, **63**:143
ondansetron, activation-euphoria, **64**:1
ondansetron, amphetamine, **64**:1
ondansetron, blood pressure, **64**:1
ondansetron, cortisol, **64**:1
ondansetron, growth hormone, **64**:1
ondansetron, prolactin, **64**:1
panic disorder, cortisol, **64**:77
panic disorder, meta-chlorophenylpiperazine, **64**:77
panic disorder, respiration, **64**:83
panic disorder, tryptophan depletion, **64**:83
paroxetine binding in platelets, affective disorder, **66**:73
paroxetine binding in platelets, antidepressants, **66**:73
paroxetine binding in platelets, serotonin receptors, **66**:73
paroxetine binding in platelets, suicidal thoughts, **66**:73
phenelzine, imipramine binding, **63**:143
phenelzine, platelet imipramine binding, **63**:143
phenelzine, posttraumatic stress disorder, **63**:143
platelet imipramine binding, monoamine oxidase inhibitor, **63**:143
platelet imipramine binding, phenelzine, **63**:143
platelet imipramine binding, posttraumatic stress disorder, **63**:143
platelets, haloperidol withdrawal, **63**:123
platelets, schizophrenia, **63**:123
posttraumatic stress disorder, imipramine binding, **63**:143
posttraumatic stress disorder, monoamine oxidase inhibitor, **63**:143

posttraumatic stress disorder, phenelzine, **63**:143
posttraumatic stress disorder, platelet imipramine binding, **63**:143
prolactin, activation-euphoria, **64**:1
prolactin, amphetamine, **64**:1
prolactin, anorexia nervosa, **62**:31
prolactin, blood pressure, **64**:1
prolactin, cortisol, **62**:139, **64**:1, **64**:147
prolactin, growth hormone, **62**:31, **64**:1
prolactin, meta-chlorophenylpiperazine, **62**:31, **62**:139, **64**:147
prolactin, ondansetron, **64**:1
prolactin, schizophrenia, **64**:147
prolactin, temperature, **64**:147
prolactin, tryptophan, **62**:31
respiration, anxiety, **64**:83
respiration, panic disorder, **64**:83
respiration, tryptophan depletion, **64**:83
satiety, anorexia and bulimia nervosa, **62**:23
satiety, eating behavior, **62**:23
schizophrenia, cortisol, **64**:147
schizophrenia, haloperidol withdrawal, **63**:123
schizophrenia, meta-chlorophenylpiperazine, **64**:147
schizophrenia, platelets, **63**:123
schizophrenia, prolactin, **64**:147
schizophrenia, temperature, **64**:147
serotonin receptor gene, autism, **65**:33
serotonin receptor gene, genetics, **65**:33
serotonin receptor gene, hydroxyindoleacetic acid, **65**:33
Sprague-Dawley rats, animal models, **63**:197
Sprague-Dawley rats, antisense oligonucleotide, **63**:197
Sprague-Dawley rats, hippocampus, **63**:197
Sprague-Dawley rats, learned helplessness, **63**:197
stimulus intensity, alcohol abuse/dependence, **63**:47
stimulus intensity, dipole activity, **63**:47
stimulus intensity, evoked potentials, **63**:47
stress, affective disorder, **65**:143
stress, aggression, **65**:143
stress, anxiety, **65**:143
stress, cortisol, **65**:143
stress, diagnostic subtype, **65**:143
suicidal thoughts, affective disorder, **66**:73
suicidal thoughts, antidepressants, **66**:73
suicidal thoughts, paroxetine binding in platelets, **66**:73
suicidal thoughts, serotonin receptors, **66**:73
temperature, cortisol, **64**:147
temperature, meta-chlorophenylpiperazine, **64**:147
temperature, prolactin, **64**:147
temperature, schizophrenia, **64**:147
tryptophan, affective disorder, **63**:151, **66**:87
tryptophan, anorexia nervosa, **62**:31
tryptophan, antidepressants, **66**:87
tryptophan, erythrocytes, **63**:151, **66**:87
tryptophan, growth hormone, **62**:31
tryptophan, kinetic analysis, **63**:151, **66**:87
tryptophan, meta-chlorophenylpiperazine, **62**:31
tryptophan, prolactin, **62**:31
tryptophan depletion, anxiety, **64**:83
tryptophan depletion, panic disorder, **64**:83
tryptophan depletion, respiration, **64**:83

Single photon emission computed tomography
anorexia nervosa, **62**:105

Sleep
affective disorder, age, **62**:161
affective disorder, bereavement, **62**:161
affective disorder, bipolar subtype, **63**:161, **65**:121
affective disorder, circadian rhythms, **62**:161, **63**:161
affective disorder, dexamethasone suppression test, **63**:83
affective disorder, endogenous subtype, **63**:83
affective disorder, late-life depression, **62**:161
affective disorder, manic symptomatology, **65**:121
affective disorder, polysomnography, **62**:161, **63**:83
affective disorder, rapid cycling form, **63**:161
affective disorder, sleep duration, **65**:121
affective disorder, sleep impairment, **62**:161
affective disorder, Social Rhythm Metric, **62**:161
affective disorder, symptom severity, **63**:83
affective disorder, thyrotropin-releasing hormone, **63**:83
age, affective disorder, **62**:161
age, bereavement, **62**:161
age, circadian rhythms, **62**:161
age, late-life depression, **62**:161
age, polysomnography, **62**:161
age, sleep impairment, **62**:161
age, Social Rhythm Metric, **62**:161
bereavement, affective disorder, **62**:161
bereavement, age, **62**:161
bereavement, circadian rhythms, **62**:161
bereavement, late-life depression, **62**:161
bereavement, polysomnography, **62**:161
bereavement, sleep impairment, **62**:161
bereavement, Social Rhythm Metric, **62**:161
bipolar affective disorder, rapid cycling, **63**:161
bipolar affective disorder, manic symptomatology, **65**:121
bipolar affective disorder, circadian rhythms, **63**:161
bipolar affective disorder, sleep duration, **65**:121
Brief Psychiatric Rating Scale symptom factors, schizophrenia, **66**:111
Brief Psychiatric Rating Scale symptom factors, sleep latency, **66**:111
Brief Psychiatric Rating Scale symptom factor, thinking disturbance, **66**:111
circadian rhythms, affective disorder, **62**:161, **63**:161
circadian rhythms, age, **62**:161
circadian rhythms, bereavement, **62**:161
circadian rhythms, bipolar affective disorder, **63**:161
circadian rhythms, late-life depression, **62**:161
circadian rhythms, polysomnography, **62**:161
circadian rhythms, sleep impairment, **62**:161
circadian rhythms, Social Rhythm Metric, **62**:161
dexamethasone suppression test, affective disorder, **63**:83
dexamethasone suppression test, endogenous subtype, **63**:83
dexamethasone suppression test, polysomnography, **63**:83
dexamethasone suppression test, symptom severity, **63**:83
late-life depression, bereavement, **62**:161
late-life depression, circadian rhythms, **62**:161

late-life depression, polysomnography, **62**:161
late-life depression, sleep impairment, **62**:161
late-life depression, Social Rhythm Metric, **62**:161
manic symptomatology, affective disorder, **65**:121
manic symptomatology, sleep duration, **65**:121
polysomnography, affective disorder, **62**:161, **63**:83
polysomnography, age, **62**:161
polysomnography, bereavement, **62**:161
polysomnography, circadian rhythms, **62**:161
polysomnography, dexamethasone suppression test, **63**:83
polysomnography, late-life depression, **62**:161
polysomnography, symptom severity, **63**:83
polysomnography, thyrotropin-releasing hormone, **63**:83
schizophrenia, Brief Psychiatric Rating Scale symptom factors, **66**:111
schizophrenia, sleep latency, **66**:111
schizophrenia, thinking disturbance, **66**:111
sleep duration, affective disorder, **65**:121
sleep duration, bipolar affective disorder, **65**:121
sleep duration, manic symptomatology, **65**:121
sleep impairment, affective disorder, **62**:161
sleep impairment, age, **62**:161
sleep impairment, bereavement, **62**:161
sleep impairment, circadian rhythms, **62**:161
sleep impairment, late-life depression, **62**:161
sleep impairment, polysomnography, **62**:161
sleep impairment, Social Rhythm Metric, **62**:161
sleep latency, Brief Psychiatric Rating Scale symptom factors, **66**:111
sleep latency, schizophrenia, **66**:111
sleep latency, thinking disturbance, **66**:111
Social Rhythm Metric, affective disorder, **62**:161
Social Rhythm Metric, age, **62**:161
Social Rhythm Metric, bereavement, **62**:161
Social Rhythm Metric, circadian rhythms, **62**:161
Social Rhythm Metric, late-life depression, **62**:161
Social Rhythm Metric, polysomnography, **62**:161
Social Rhythm Metric, sleep impairment, **62**:161
thinking disturbance, Brief Psychiatric Rating Scale symptom factors, **66**:111
thinking disturbance, schizophrenia, **66**:111
thinking disturbance, sleep latency, **66**:111
thyrotropin-releasing hormone, affective disorder, **63**:83
thyrotropin-releasing hormone, endogenous subtype, **63**:83
thyrotropin-releasing hormone, polysomnography, **63**:83
thyrotropin-releasing hormone, symptom severity, **63**:83

Sleep deprivation

affective disorder, amineptine, **65**:179
affective disorder, bipolar subtype, **65**:179
affective disorder, dopamine, **65**:179
amineptine, affective disorder, **65**:179
amineptine, bipolar subtype, **65**:179
amineptine, dopamine, **65**:179
animal studies, rapid eye movement sleep, **66**:97
animal studies, slow wave sleep, **66**:97
animal studies, Sprague-Dawley rats, **66**:97
bipolar subtype, affective disorder, **65**:179
circadian rhythms, depressed mood, **62**:147
circadian rhythms, early vs. late, **62**:147
circadian rhythms, estradiol, **62**:147
circadian rhythms, menstrual cycle, **62**:147
circadian rhythms, progesterone, **62**:147
circadian rhythms, prolactin, **62**:147
circadian rhythms, thyroid-stimulating hormone, **62**:147
depressed mood, circadian rhythms, **62**:147
depressed mood, early vs. late, **62**:147
depressed mood, estradiol, **62**:147
depressed mood, menstrual cycle, **62**:147
depressed mood, progesterone, **62**:147
depressed mood, prolactin, **62**:147
depressed mood, thyroid-stimulating hormone, **62**:147
dopamine, affective disorder, **65**:179
dopamine, amineptine, **65**:179
early vs. late, circadian rhythms, **62**:147
early vs. late, depressed mood, **62**:147
early vs. late, estradiol, **62**:147
early vs. late, menstrual cycle, **62**:147
early vs. late, progesterone, **62**:147
early vs. late, prolactin, **62**:147
early vs. late, thyroid-stimulating hormone, **62**:147
estradiol, circadian rhythms, **62**:147
estradiol, depressed mood, **62**:147
estradiol, early vs. late, **62**:147
estradiol, menstrual cycle, **62**:147
estradiol, progesterone, **62**:147
estradiol, prolactin, **62**:147
estradiol, thyroid-stimulating hormone, **62**:147
menstrual cycle, circadian rhythms, **62**:147
menstrual cycle, depressed mood, **62**:147
menstrual cycle, early vs. late, **62**:147
menstrual cycle, estradiol, **62**:147
menstrual cycle, progesterone, **62**:147
menstrual cycle, prolactin, **62**:147
menstrual cycle, thyroid-stimulating hormone, **62**:147
progesterone, circadian rhythms, **62**:147
progesterone, depressed mood, **62**:147
progesterone, early vs. late, **62**:147
progesterone, estradiol, **62**:147
progesterone, menstrual cycle, **62**:147
progesterone, prolactin, **62**:147
progesterone, thyroid-stimulating hormone, **62**:147
prolactin, circadian rhythms, **62**:147
prolactin, depressed mood, **62**:147
prolactin, early vs. late, **62**:147
prolactin, estradiol, **62**:147
prolactin, menstrual cycle, **62**:147
prolactin, progesterone, **62**:147
prolactin, thyroid-stimulating hormone, **62**:147
rapid eye movement sleep, animal studies, **66**:97
rapid eye movement sleep, slow wave sleep, **66**:97
rapid eye movement sleep, Sprague-Dawley rats, **66**:97
slow wave sleep, animal studies, **66**:97
slow wave sleep, rapid eye movement sleep, **66**:97
slow wave sleep, Sprague-Dawley rats, **66**:97
Sprague-Dawley rats, animal studies, **66**:97
Sprague-Dawley rats, rapid eye movement sleep, **66**:97
Sprague-Dawley rats, slow wave sleep, **66**:97

thyroid-stimulating hormone, circadian rhythms, **62**:147
thyroid-stimulating hormone, depressed mood, **62**:147
thyroid-stimulating hormone, early vs. late, **62**:147
thyroid-stimulating hormone, estradiol, **62**:147
thyroid-stimulating hormone, menstrual cycle, **62**:147
thyroid-stimulating hormone, progesterone, **62**:147
thyroid-stimulating hormone, prolactin, **62**:147

Somatostatin
animal studies, anorexia nervosa, **62**:51
animal studies, beagle dogs, **62**:51
animal studies, caloric restriction, **62**:51
anorexia nervosa, animal studies, beagle dogs, **62**:51
anorexia nervosa, caloric restriction, **62**:51
anorexia nervosa, cholinergic agonists and antagonists, **62**:51
beagle dogs, anorexia nervosa, **62**:51
beagle dogs, caloric restriction, **62**:51
caloric restriction, animal studies, beagle dogs, **62**:51
caloric restriction, anorexia nervosa, **62**:51
cholinergic agonists and antagonists, animal studies, beagle dogs, **62**:51
cholinergic agonists and antagonists, anorexia nervosa, **62**:51

Stress
cortisol, **63**:7
homovanillic acid, **63**:7
hydroxyindoleacetic acid, **63**:7
methoxy-hydroxyphenylglycol, **63**:7
vanillylmandelic acid, **63**:7

Substance abuse/dependence
abstinence, cocaine, **65**:65
abstinence, craving, **65**:65
abstinence, dopamine, **65**:65
abstinence, growth hormone, **65**:65
abstinence, methylphenidate, **65**:65
abstinence, prolactin, **65**:65
beta-endorphin, family history, **62**:203
cataplexy, dissociative identity disorder, **63**:231
cataplexy, multiple personality, **63**:231
cataplexy, muscular weakness, **63**:231
cocaine, abstinence, **65**:65
cocaine, craving, **65**:65
cocaine, dopamine, **65**:65
cocaine, growth hormone, **65**:65
cocaine, methylphenidate, **65**:65
cocaine, prolactin, **65**:65
craving, abstinence, **65**:65
craving, cocaine, **65**:65
craving, dopamine, **65**:65
craving, growth hormone, **65**:65
craving, methylphenidate, **65**:65
craving, prolactin, **65**:65
cross-cultural, mortality rates, Taiwan, **62**:239
dissociative identity disorder, cataplexy, **63**:231
dissociative identity disorder, muscular weakness, **63**:231
dopamine, cocaine, **65**:65
dopamine, growth hormone, **65**:65
dopamine, methamphetamine, paranoid-hallucinatory psychosis, **63**:93
dopamine, methylphenidate, **65**:65
dopamine, prolactin, **65**:65
family history, prepubertal boys, **62**:203
flashbacks, methamphetamine, **63**:93
flashbacks, paranoid-hallucinatory psychosis, **63**:93
growth hormone, abstinence, **65**:65
growth hormone, cocaine craving, **65**:65
growth hormone, dopamine, **65**:65
growth hormone, methylphenidate, **65**:65
growth hormone, prolactin, **65**:65
homovanillic acid, family history, **62**:203
methamphetamine, dopamine, **63**:93
methamphetamine, methoxy-hydroxyphenylglycol, **63**:93
methamphetamine, norepinephrine, **63**:93
methamphetamine, paranoid-hallucinatory psychosis, **63**:93
methoxy-hydroxyphenylglycol, family history, **62**:203
methoxy-hydroxyphenylglycol, methamphetamine, paranoid-hallucinatory psychosis, **63**:93
methylphenidate, abstinence, **65**:65
methylphenidate, cocaine craving, **65**:65
methylphenidate, dopamine, **65**:65
methylphenidate, growth hormone, **65**:65
methylphenidate, prolactin, **65**:65
mortality rates, cross-cultural, Taiwan, **62**:239
multiple personality, cataplexy, **63**:231
multiple personality, muscular weakness, **63**:231
muscular weakness, cataplexy, **63**:231
muscular weakness, dissociative identity disorder, **63**:231
muscular weakness, multiple personality, **63**:231
neuropeptides, family history, **62**:203
norepinephrine, methamphetamine, paranoid-hallucinatory psychosis, **63**:93
paranoid-hallucinatory psychosis, dopamine, **63**:93
paranoid-hallucinatory psychosis, flashbacks, **63**:93
paranoid-hallucinatory psychosis, methamphetamine, **63**:93
paranoid-hallucinatory psychosis, methoxy-hydroxyphenylglycol, **63**:93
paranoid-hallucinatory psychosis, norepinephrine, **63**:93
prepubertal boys, family history, **62**:203
prolactin, abstinence, **65**:65
prolactin, cocaine craving, **65**:65
prolactin, dopamine, **65**:65
prolactin, growth hormone, **65**:65
prolactin, methylphenidate, **65**:65

Suicide
circannual rhythms, demographic factors, **66**:13
circannual rhythms, South Africa, **66**:13
demographic factors, circannual rhythms, **66**:13
demographic factors, South Africa, **66**:13

Testosterone
aggression, personality, **66**:33
personality, aggression, **66**:33

Thyroid-stimulating hormone
circadian rhythms, depressed mood, **62**:147
circadian rhythms, menstrual cycle, **62**:147

depressed mood, circadian rhythms, **62**:147
depressed mood, menstrual cycle, **62**:147
depressed mood, sleep deprivation, **62**:147
menstrual cycle, circadian rhythms, **62**:147
menstrual cycle, depressed mood, **62**:147
menstrual cycle, sleep deprivation, **62**:147
sleep deprivation, circadian rhythms, **62**:147
sleep deprivation, depressed mood, **62**:147
sleep deprivation, early vs. late, **62**:147
sleep deprivation, menstrual cycle, **62**:147

Thyrotropin-releasing hormone
affective disorder, endogenous subtype, **63**:83
affective disorder, polysomnography, **63**:83
affective disorder, sleep, **63**:83
affective disorder, symptom severity, **63**:83
animal studies, anorexia nervosa, **62**:51
animal studies, beagle dogs, caloric restriction, **62**:51
anorexia nervosa, animal studies, beagle dogs, **62**:51
beagle dogs, caloric restriction, **62**:51
cholinergic agonists and antagonists, animal studies,, beagle dogs, **62**:51
cholinergic agonists and antagonists, anorexia nervosa, **62**:51
polysomnography, affective disorder, endogenous subtype, **63**:83
polysomnography, depressive symptom severity, **63**:83
sleep, affective disorder, endogenous subtype, **63**:83
sleep, depressive symptom severity, **63**:83
sleep, polysomnography, **63**:83

Tourette's syndrome
c-Harvey-Ras gene, genetics, **63**:25
genetics, c-Harvey-Ras gene, **63**:25

Tryptophan
affective disorder, antidepressants, **66**:87
affective disorder, erythrocytes, **63**:151, **66**:87
affective disorder, kinetic analysis, **63**:151, **66**:87
affective disorder, serotonin, **63**:151, **66**:87
anorexia nervosa, growth hormone, **62**:31
anorexia nervosa, meta-chlorphenylpiperazine, **62**:31
anorexia nervosa, prolactin, **62**:31
anorexia nervosa, serotonin, **62**:31
antidepressants, affective disorder, **66**:87
antidepressants, erythrocytes, **66**:87
antidepressants, kinetics, **66**:87
antidepressants, serotonin, **66**:87
anxiety, respiration, **64**:83
anxiety, serotonin, **64**:83
erythrocytes, affective disorder, **63**:151, **66**:87
erythrocytes, antidepressants, **66**:87
erythrocytes, kinetic analysis, **66**:151, **66**:87
erythrocytes, serotonin, **63**:151, **66**:87
growth hormone, anorexia nervosa, **62**:31
growth hormone, meta-chlorphenylpiperazine, **62**:31
growth hormone, prolactin, **62**:31
growth hormone, serotonin, **62**:31
kinetic analysis, affective disorder, **63**:151, **66**:87
kinetic analysis, antidepressants, **66**:87
kinetic analysis, erythrocytes, **63**:151, **66**:87
kinetic analysis, serotonin, **63**:151, **66**:87
meta-chlorphenylpiperazine, anorexia nervosa, **62**:31
meta-chlorphenylpiperazine, growth hormone, **62**:31
meta-chlorphenylpiperazine, prolactin, **62**:31
meta-chlorphenylpiperazine, serotonin, **62**:31
panic disorder, anxiety, **64**:83
panic disorder, respiration, **64**:83
panic disorder, serotonin, **64**:83
prolactin, anorexia nervosa, **62**:31
prolactin, growth hormone, **62**:31
prolactin, meta-chlorphenylpiperazine, **62**:31
prolactin, serotonin, **62**:31
respiration, anxiety, **64**:83
respiration, panic disorder, **64**:83
respiration, serotonin, **64**:83
serotonin, affective disorder, **63**:151, **66**:87
serotonin, anorexia nervosa, **62**:31
serotonin, antidepressants, **66**:87
serotonin, anxiety, **64**:83
serotonin, erythrocytes, **63**:151, **66**:87
serotonin, growth hormone, **62**:31
serotonin, kinetic analysis, **63**:151, **66**:87
serotonin, meta-chlorphenylpiperazine, **62**:31
serotonin, panic disorder, **64**:83
serotonin, prolactin, **62**:31
serotonin, respiration, **64**:83

Vanillylmandelic acid
anxiety, methoxy-hydroxyphenylglycol, **63**:7
methoxy-hydroxyphenylglycol, anxiety, stress, **63**:7
stress, methoxy-hydroxyphenylglycol, **63**:7

Vasopressin
anorexia nervosa, neuropeptides, **62**:65
neuropeptides, anorexia nervosa, **62**:65

Water intoxication
hyponatremia, neuroleptic dosage, **63**:227
hyponatremia, schizophrenia, **63**:227
neuroleptic dosage, hyponatremia, **63**:227
neuroleptic dosage, schizophrenia, **63**:227
schizophrenia, hyponatremia, **63**:227
schizophrenia, neuroleptic dosage, **63**:227

UMI

SHOULD READ AUTHOR INDEX 1996-1997

ELSEVIER

Psychiatry Research: Neuroimaging 68 (1997) 185–186

PSYCHIATRY RESEARCH NEUROIMAGING

Author Index for 1996

Abraham, H.D., **67**:173
Ågren, H., **67**:1
Alpert, M., **67**:59
Amering, M., **68**:41
Andreasen, N.C., **67**:145
Antoni, G., **67**:1
Arndt, S., **67**:145
Asenbaum, S., **68**:23
Aylward, E.H., **68**:65

Badawi, R., **68**:111
Baischer, W., **68**:41
Bakish, D., **68**:31
Barkely, J., **68**:31
Barta, P.E., **67**:155, **68**:65
Bartels, M., **67**:135
Bartzokis, G., **67**:189
Becker, T., **67**:135
Beckmann, H., **67**:135, **68**:87, **68**:99
Berger, P., **68**:41
Biersack, H.-J., **68**:1
Black, K.J., **67**:203
Bookstein, F.L., **67**:81
Bormans, G., **68**:11
Boyko, O.B., **67**:215, **68**:55
Branchey, M., **67**:39
Brodaty, H., **68**:133
Brücke, T., **68**:23
Brunberg, J.A., **67**:81
Brunsden, B.S., **67**:203
Bubeck, B., **68**:125
Bucci, P., **67**:113
Buckley, P.F., **67**:123
Buydens-Branchey, L., **67**:39
Byrum, C.E., **67**:215

Challakere, K., **67**:99
Charles, H.C., **67**:215
Chase, G.A., **68**:65
Chasten, K., **67**:39
Chitilla, V.R., **67**:215
Christensen, G.E., **67**:203
Cizadlo, T., **67**:145
Compton-Toth, B., **67**:17
Danos, P., **68**:1
Dantendorfer, K., **68**:41
Davidson, P.B., **67**:59
De Groot, T., **68**:11
Demisch, S., **68**:125
DeQuardo, J.R., **67**:81
Dery, K., **67**:189
Donovan, B., **67**:17
Downhill, J., **67**:145
Duffy, F.H., **67**:173
Dupont, P., **68**:11
Dupont, R.M., **67**:99

Elkis, H., **67**:123
Elmer, K., **67**:135
Farde, L., **67**:161, **67**:163

Fasth, K.J., **67**:1
Fenton, G.W., **68**:111
Fenwick, P.B.C., **68**:111
Fowler, J.S., **67**:11
Frazier, J.A., **68**:77
Friedman, L., **67**:123

Gado, M.H., **67**:203
Galderisi, S., **67**:113
Garada, B., **67**:59
Garnett, M.L., **67**:17
Gatley, S.J., **67**:11
Gaur, R., **68**:133
Giedd, J.N., **68**:77
Gillespie, H., **67**:29
Gjedde, A., **67**:159
Gössler, R., **68**:23
Goyer, P.F., **67**:17
Grant, C., **67**:29
Grant, I., **67**:99
Green, W.D.K., **67**:81
Grodd, W., **67**:135
Grünwald, F., **68**:1

Haindl, W., **68**:132
Halldin, C., **67**:163
Halpern, S., **67**:99
Hamburger, S.D., **68**:77
Harris, G.J., **68**:65
Hartvig, P., **67**:1
Heckers, S., **67**:135
Higashima, M., **67**:49
Hisada, K., **67**:49
Hitzemann, R., **67**:11
Hollister, L., **67**:29
Holman, B.L., **67**:59

Iidaka, T., **68**:143
Imhof, H., **68**:41
Itoh, M., **67**:71

Jacobsen, L.K., **68**:77

Kasper, S., **68**:1, **68**:23
Katschnig, H., **68**:41
Kaufman, B., **67**:123
Kawasaki, Y., **67**:49
Kim, D., **67**:215
Klemm, E., **68**:1
Knott, V.J., **68**:31
Koder, D., **68**:133
Koshino, Y., **67**:49
Kramer, J., **68**:41
Krishnan, K.R.R., **67**:215, **68**:55
Küfferle, B., **68**:23

Laack, K., **67**:189
Lamoureux, G., **67**:99
Långström, B., **67**:1
Lauer, M., **68**:87, **68**:99
Lee, H.S., **67**:123
Lehr, P.P., **67**:99
Leisure, G., **67**:17
Lenane, M.C., **68**:77
Lewis, P., **68**:111
Lin, D.Y., **67**:203
Lindström, L., **67**:1
Logan, J., **67**:11
Lumsden, J., **68**:111
Lundberg, T., **67**:1
Lundqvist, H., **67**:1
Lusk-Mikkelsen, S., **68**:31
Lys, C., **67**:123

Maayan, M.L., **67**:39
MacFall, J.R., **67**:215
MacGregor, R.R., **67**:11
Maeda, Y., **67**:49
Maehara, T., **68**:143

Maes, M., **68**:11
Maisey, M.N., **68**:111
Maj, M., **67**:113
Marder, S.R., **67**:189
Matsuda, H., **67**:49, **68**:143
Matsui, H., **67**:71
McCormick, R., **67**:17
McDonald, W.M., **68**:55
Meares, S., **68**:133
Meguro, K., **67**:71
Meltzer, H.Y., **67**:123
Mignone, M.L., **67**:113
Mintz, J., **67**:189
Miraldi, F., **67**:17
Möller, H.-J., **68**:1
Morris, E., **67**:17
Mortelmans, L., **68**:11
Mucci, A., **67**:113
Mullani, N., **67**:29
Muswick, G., **67**:17

Nakajima, T., **68**:143
Nelson, D., **67**:17
Nordström, A.-L., **67**:161
Nuechterlein, K.H., **67**:189
Nyberg, S., **67**:163

O'Leary, D., **67**:145
Okazaki, A., **68**:143

Passe, T., **67**:215
Pearlson, G.D., **67**:155, **68**:65
Perugini, M., **68**:31
Peuskens, J., **68**:11
Podreka, I., **68**:23
Powers, R.E., **67**:155, **68**:65
Prayer, D., **68**:41

Rabins, P.V., **68**:65
Rajagopalan, P., **67**:215
Rajapakse, J.C., **68**:77
Rajarethinam, R., **67**:145
Rapoport, J.L., **68**:77
Reed, R.J., **67**:99
Reibring, L., **67**:1
Reith, J., **67**:159
Rose, J.S., **67**:39
Rosier, A., **68**:11
Rourke, S.B., **67**:99

Sachdev, P., **68**:133
Sakai, N., **67**:49
Sasaki, H., **67**:71
Sauer, H., **68**:125
Schiepers, C., **68**:11
Schildkraut, J.J., **67**:59
Schlyer, D.J., **67**:11
Schneider, F., **67**:135
Schneider, M., **67**:135
Schoder, M., **68**:41
Schröder, J., **68**:125
Schulz, S.C., **67**:17
Schwartz, R.B., **67**:59
Semple, W.E., **67**:17
Sharkoff, J., **67**:17
Sheline, Y.I., **67**:203
Shiraishi, H., **68**:143
Smith, J.S., **67**:215
Stapleton, J.M., **67**:39
Steffens, D.C., **68**:55
Steinberger, K., **68**:41
Suzuki, M., **67**:49
Suzuki, Y., **68**:143

Tancredi, L., **67**:29
Tandon, R., **67**:81
Tauscher, J., **68**:23
Tien, A.Y., **67**:155
Topitz-Schratzberger, A., **68**:23
Tune, L.E., **67**:155, **68**:65
Tupler, L.A., **68**:55

Upchurch, L., **67**:215

Vaituzis, A.C., **68**:77
Valentine, A., **67**:29
Vandenberghe, R., **68**:11
Vannier, M.W., **67**:203
Vasile, R.G., **67**:59
Verbruggen, A., **68**:11
Vesely, C., **68**:23
Volkow, N.D., **67**:11, **67**:29

Wagner, H.N., **67**:155
Walker, A., **68**:133
Wang, G.-J., **67**:11
Werrell, A., **67**:39
Windhaber, J., **68**:41
Wolf, A.P., **67**:11
Wong, D., **67**:155, **67**:159
Wong, M.T.H., **68**:111

Xanthakos, S., **67**:215

Yamaguchi, N., **67**:49
Yamaguchi, S., **67**:71
Yamaguchi, T., **67**:71
Yamazaki, H., **67**:71

UMI

SHOULD READ SUBJECT INDEX 1996-1997

ELSEVIER

Psychiatry Research: Neuroimaging 68 (1997) 187–202

PSYCHIATRY
RESEARCH
NEUROIMAGING

Subject index for 1996

Affective disorder
age, frontal cortex, **67**:59
age, single photon emission computed tomography, **67**:59
age, temporal lobe, **67**:59
cerebral blood flow, frontal lobe, **68**:143
computed tomography, frontal lobe, sulcal prominence, **67**:123
computed tomography, ventricle-brain ratio, **67**:123
frontal lobe, age, **67**:59
frontal lobe, computed tomography, **67**:123
frontal lobe, geriatric depression, **67**:59
frontal lobe, single photon emission computed tomography, **67**:59, **68**:1, **68**:143
geriatric depression, frontal cortex, **67**:59
geriatric depression, single photon emission computed tomography, **67**:59
geriatric depression, temporal lobe, **67**:59
major depression, computed tomography, **67**:123
major depression, frontal cortex, **67**:123
major depression, sulcal prominence, **67**:123
major depression, ventricle-brain ratio, **67**:123
single photon emission computed tomography, age, **67**:59
single photon emission computed tomography, frontal lobe, **67**:59, **68**:1, **68**:143
single photon emission computed tomography, geriatric depression, **67**:59
single photon emission computed tomography, temporal lobe, **67**:59, **68**:1
sulcal prominence, computed tomography, **67**:123
temporal lobe, age, **67**:59
temporal lobe, geriatric depression, **67**:59
temporal lobe, single photon emission computed tomography, **67**:59, **68**:1
unipolar subtype, computed tomography, **67**:123
unipolar subtype, frontal cortex, **67**:123
unipolar subtype, sulcal prominence, **67**:123
unipolar subtype, ventricle-brain ratio, **67**:123
ventricle-brain ratio, computed tomography, **67**:123

Age
Alzheimer's Disease, cognitive impairment, magnetic resonance imaging, **68**:65
Alzheimer's Disease, temporal lobe, **68**:65
affective disorder, frontal cortex, **67**:59
affective disorder, single photon emission computed tomography, **67**:59
affective disorder, temporal lobe, **67**:59
altanserin, positron emission tomography, **68**:11
altanserin, receptor loss with age, **68**:11
altanserin, serotonin, **68**:11
basal ganglia, iron content, **68**:55
basal ganglia, magnetic resonance imaging, **68**:55
cerebellum, multi-infarct dementia, **67**:71
cerebellum, positron emission tomography, **67**:71
cerebellum, wandering behavior, **67**:71
dementia, cerebellum, **67**:71
dementia, frontal cortex, **67**:71
dementia, positron emission tomography, **67**:71
dementia, wandering behavior, **67**:71
dopamine, receptor binding, striatum, **67**:11
frontal cortex, affective disorder, **67**:59
frontal cortex, dementia, **67**:71
frontal cortex, geriatric depression, **67**:59
frontal cortex, multi-infarct dementia, **67**:71
frontal cortex, positron emission tomography, **67**:71
frontal cortex, single photon emission computed tomography, **67**:59
frontal cortex, wandering behavior, **67**:71
geriatric depression, frontal cortex, **67**:59
geriatric depression, single photon emission computed tomogrphy, **67**:59
geriatric depression, temporal lobe, **67**:59
globus pallidus, magnetic resonance imaging, **68**:55
iron content, basal ganglia, **68**:55
iron content, magnetic resonance imaging, **68**:55
magnetic resonance imaging, basal ganglia, **68**:55
magnetic resonance imaging, globus pallidus, **68**:55
magnetic resonance imaging, iron content, **68**:55
magnetic resonance imaging, putamen, **68**:55
magnetic resonance imaging, schizophrenia, **67**:189
magnetic resonance imaging, temporal lobe, **67**:189
multi-infarct dementia, cerebellum, **67**:71
multi-infarct dementia, frontal cortex, **67**:71
multi-infarct dementia, positron emission tomography, **67**:71
multi-infarct dementia, wandering behavior, **67**:71
positron emission tomography, altanserin, **68**:11
positron emission tomography, cerebellum, **67**:71
positron emission tomography, dementia, **67**:71

positron emission tomography, dopamine, **67**:11
positron emission tomography, frontal cortex, **67**:71
positron emission tomography, methylspiroperidol, **67**:11
positron emission tomography, multi-infarct dementia, **67**:71
positron emission tomography, raclopride, **67**:11
positron emission tomography, receptor binding, **67**:11, **68**:11
positron emission tomography, receptor loss with age, **68**:11
positron emission tomography, serotonin, **68**:11
positron emission tomography, striatum, **67**:11
positron emission tomography, wandering behavior, **67**:71
putamen, magnetic resonance imaging, **68**:55
raclopride, dopamine, **67**:11
raclopride, positron emission tomography, **67**:11
raclopride, receptor binding, **67**:11
raclopride, striatum, **67**:11
receptor binding, altanserin, **68**:11
receptor binding, dopamine, **67**:11
receptor binding, methylspiroperidol, **67**:11
receptor binding, positron emission tomography, **67**:11, **68**:11
receptor binding, raclopride, **67**:11
receptor binding, serotonin, **68**:11
receptor binding, striatum, **67**:11
receptor loss with age, positron emission tomography, **68**:11
schizophrenia, age of onset, **67**:189
schizophrenia, late age of onset, magnetic resonance imaging, **68**:65
schizophrenia, magnetic resonance imaging, **67**:189, **68**:65
schizophrenia, temporal lobe, **67**:189, **68**:65
serotonin, positron emission tomography, **68**:11
serotonin, receptor binding, **68**:11
serotonin, receptor loss with age, **68**:11
single photon emission computed tomography, affective disorder, **67**:59
single photon emission computed tomography, frontal cortex, **67**:59
single photon emission computed tomography, geriatric depression, **67**:59
single photon emission computed tomography, temporal lobe, **67**:59
striatum, dopamine, **67**:11
striatum, methylspiroperidol, **67**:11
striatum, positron emission tomography, **67**:11
striatum, raclopride, **67**:11
temporal lobe, affective disorder, **67**:59
temporal lobe, age of onset, **67**:189
temporal lobe, Alzheimer's Disease, **68**:65
temporal lobe, geriatric depression, **67**:59
temporal lobe, magnetic resonance imaging, **67**:189, **68**:65
temporal lobe, schizophrenia, **67**:189, **68**:65
temporal lobe, single photon emission computed tomography, **67**:59
temporal lobe length, magnetic resonance imaging, **67**:189
wandering behavior, cerebellum, **67**:71
wandering behavior, frontal cortex, **67**:71
wandering behavior, multi-infarct dementia, **67**:71
wandering behavior, positron emission tomography, **67**:71

Alcohol abuse/dependence. *See also* Substance abuse/dependence

abstinence, neuropsychology, **67**:99
abstinence, Raven's progressive-matrices, **67**:99
abstinence, single photon emission computed tomography, **67**:99
iodoamphetamine, single photon emission computed tomography, **67**:99
neuropsychology, abstinence, **67**:99
neuropsychology, single photon emission computed tomography, **67**:99
Raven's progressive-matrices, abstinence, **67**:99
Raven's progressive-matrices, single photon emission computed tomography, **67**:99
single photon emission computed tomography, abstinence, **67**:99
single photon emission computed tomography, iodoamphetamine, **67**:99
single photon emission computed tomography, neuropsychology, **67**:99
single photon emission computed tomography, Raven's progressive-matrices, **67**:99
single photon emission computed tomography, smoking, **67**:99
smoking, single photon emission computed tomography, **67**:99

Alzheimer's Disease

cerebral blood flow, longitudinal course, **68**:133
cerebral blood flow, neuropsychological tests, **68**:133
cognitive impairment, magnetic resonance imaging, **68**:65
longitudinal course, cerebral blood flow, **68**:133
longitudinal course, neuropsychological tests, **68**:133
longitudinal course, single photon emission computed tomography, **68**:133
magnetic resonance imaging, volumetry, **68**:65
magnetic resonance imaging, temporal lobe, **68**:65
neuropsychological tests, cerebral blood flow, **68**:133
neuropsychological tests, longitudinal course, **68**:133
neuropsychological tests, single photon emission computed tomography, **68**:133
single photon emission computed tomography, longitudinal course, **68**:133
single photon emission computed tomography, neuropsychological tests, **68**:133
single photon emission computed tomography, Tc-hexamethy propyleneamine oxime, **68**:133
temporal lobe, magnetic resonance imaging, **68**:65

Anxiety

electroencephalography, magnetic resonance imaging, **68**:41
electroencephalography, panic disorder, **68**:31, **68**:41
electroencephalography, topographic mapping, **68**:31
magnetic resonance imaging, electroencephalography, **68**:41
magnetic resonance imaging, panic disorder, **68**:41
magnetic resonance imaging, septohippocampal system, **68**:41
panic disorder, electroencephalography, **68**:31, **68**:41
panic disorder, magnetic resonance imaging, **68**:41
panic disorder, septohippocampal system, **68**:41

septohippocampal system, magnetic resonance imaging, **68**:41
septohippocampal system, panic disorder, **68**:41

Attention
continuous performance test, parietal cortex, positron emission tomography, **67**:17
continuous performance test, posttraumatic stress disorder, **67**:17
continuous performance test, substance abuse, **67**:17
parietal cortex, continuous performance test, **67**:17
parietal cortex, positron emission tomography, **67**:17
parietal cortex, posttraumatic stress disorder, **67**:17
parietal cortex, substance abuse, **67**:17
positron emission tomography, continuous performance test, **67**:17
positron emission tomography, parietal cortex, **67**:17
positron emission tomography, posttraumatic stress disorder, **67**:17
positron emission tomography, substance abuse, **67**:17
posttraumatic stress disorder, continuous performance test, **67**:17
posttraumatic stress disorder, parietal cortex, positron emission tomography, **67**:17
substance abuse, continuous performance test, **67**:17
substance abuse, parietal cortex, positron emission tomography, **67**:17

Basal ganglia *See also* Striatum
age, magnetic resonance imaging, **68**:55
dopamine, iodobenzamide, **68**:23
dopamine, obsessive-compulsive disorder, **68**:23
dopamine, psychotic patients, **68**:23
dopamine, receptor binding, **68**:23
dopamine, risperidone, **68**:23
dopamine, schizophrenia, **68**:23
dopamine, single photon emission computed tomography, **68**:23
globus pallidus, age, **68**:55
globus pallidus, magnetic resonance imaging, **68**:55
iodobenzamide, dopamine, **68**:23
iodobenzamide, obsessive-compulsive disorder, **68**:23
iodobenzamide, psychotic patients, **68**:23
iodobenzamide, receptor binding, **68**:23
iodobenzamide, risperidone, **68**:23
iodobenzamide, schizophrenia, **68**:23
iodobenzamide, single photon emission computed tomography, **68**:23
iron content, magnetic resonance imaging, **68**:55
magnetic resonance imaging, age, **68**:55
magnetic resonance imaging, globus pallidus, **68**:55
magnetic resonance imaging, iron content, **68**:55
magnetic resonance imaging, putamen, **68**:55
marijuana intoxication, positron emission tomography, **67**:29
obsessive-compulsive disorder, dopamine, **68**:23
obsessive-compulsive disorder, iodobenzamide, **68**:23
obsessive-compulsive disorder, risperidone, **68**:23
obsessive-compulsive disorder, single photon emission computed tomography, **68**:23
positron emission tomography, fluorodeoxyglucose, **67**:29
positron emission tomography, marijuana intoxication, **67**:29
positron emission tomography, substance abuse, **67**:29
positron emission tomography, tetrahydrocannabinol, **67**:29
psychotic patients, dopamine, **68**:23
psychotic patients, iodobenzamide, **68**:23
psychotic patients, risperidone, **68**:23
psychotic patients, single photon emission computed tomography, **68**:23
putamen, age, **68**:55
putamen, magnetic resonance imaging, **68**:55
receptor binding, dopamine, **68**:23
receptor binding, iodobenzamide, **68**:23
receptor binding, obsessive-compulsive disorder, **68**:23
receptor binding, psychotic patients, **68**:23
receptor binding, risperidone, **68**:23
receptor binding, schizophrenia, **68**:23
receptor binding, single photon emission computed tomography, **68**:23
risperidone, iodobenzamide, **68**:23
risperidone, obsessive-compulsive disorder, **68**:23
risperidone, psychotic patients, **68**:23
risperidone, receptor binding, **68**:23
risperidone, schizophrenia, **68**:23
risperidone, single photon emission computed tomography, **68**:23
schizophrenia, dopamine, **68**:23
schizophrenia, iodobenzamide, **68**:23
schizophrenia, receptor binding, **68**:23
schizophrenia, risperidone, **68**:23
schizophrenia, single photon emission computed tomography, **68**:23
single photon emission computed tomography, dopamine, **68**:23
single photon emission computed tomography, iodobenzamide, **68**:23
single photon emission computed tomography, obsessive-compulsive disorder, **68**:23
single photon emission computed tomography, psychotic patients, **68**:23
single photon emission computed tomography, receptor binding, **68**:23
single photon emission computed tomography, risperidone, **68**:23
single photon emission computed tomography, schizophrenia, **68**:23
substance abuse, positron emission tomography, **67**:29
tetrahydrocannabinol, positron emission tomography, **67**:29

Benzodiazepine
diazepam binding, frontal lobe, **68**:125
diazepam binding, schizophrenia, **68**:125
diazepam binding, single photon emission computed tomography, **68**:125
frontal lobe, diazepam binding, **68**:125
frontal lobe, schizophrenia, **68**:125
frontal lobe, single photon emission computed tomography, **68**:125

single photon emission computed tomography, diazepam binding, **68**:125
single photon emission computed tomography, schizophrenia, **68**:125
schizophrenia, diazepam binding, **68**:125
schizophrenia, frontal lobe, **68**:125
schizophrenia, single photon emission computed tomography, **68**:125

Cerebellum

age, multi-infarct dementia, **67**:71
age, positron emission tomography, **67**:71
age, wandering behavior, **67**:71
dementia, multi-infarct, **67**:71
dementia, positron emission tomography, **67**:71
dementia, wandering behavior, **67**:71
marijuana intoxication, positron emission tomography, **67**:29
multi-infarct dementia, age, **67**:71
multi-infarct dementia, positron emission tomography, **67**:71
multi-infarct dementia, wandering behavior, **67**:71
positron emission tomography, age, **67**:71
positron emission tomography, dementia, **67**:71
positron emission tomography, fluorodeoxyglucose, **67**:29, **67**:71
positron emission tomography, marijuana intoxication, **67**:29
positron emission tomography, multi-infarct dementia, **67**:71
positron emission tomography, substance abuse, **67**:29
positron emission tomography, tetrahydrocannabinol, **67**:29
positron emission tomography, wandering behavior, **67**:71
substance abuse, positron emission tomography, **67**:29
tetrahydrocannabinol, positron emission tomography, **67**:29
wandering behavior, age, **67**:71
wandering behavior, multi-infarct dementia, **67**:71
wandering behavior, positron emission tomography, **67**:71

Cerebral blood flow. See also Single photon emission computed tomography, Positron emission tomography

affective disorder, frontal lobe, **68**:143
Alzheimer's Disease, longitudinal course, **68**:133
Alzheimer's Disease, neuropsychological tests, **68**:133
attention, parietal cortex, **67**:17
attention, posttraumatic stress disorder, **67**:17
attention, substance abuse, **67**:17
continuous performance test, parietal cortex, **67**:17
continuous performance test, posttraumatic stress disorder, **67**:17
continuous performance test, substance abuse, **67**:17
frontal lobe, affective disorder, **68**:143
neuropsychological tests, Alzheimer's Disease, **68**:133
parietal cortex, attention, **67**:17
parietal cortex, continuous performance test, **67**:17
parietal cortex, posttraumatic stress disorder, **67**:17
parietal cortex, substance abuse, **67**:17
posttraumatic stress disorder, attention, **67**:17
posttraumatic stress disorder, continuous performance test, **67**:17
posttraumatic stress disorder, parietal cortex, **67**:17
substance abuse, attention, **67**:17
substance abuse, continuous performance test, **67**:17
substance abuse, parietal cortex, **67**:17

Childhood schizophrenia

corpus callosum, magnetic resonance imaging, **68**:77
white matter sparing, magnetic resonance imaging, **68**:77

Clozapine

dopamine, frontal cortex, **67**:1
dopamine, positron emission tomography, **67**:1
dopamine, receptor binding, **67**:1
dopamine, striatum, **67**:1
electroencephalography, healthy subjects, **67**:113
electroencephalography, multilead mapping, **67**:113
frontal cortex, dopamine, **67**:1
frontal cortex, positron emission tomography, **67**:1
frontal cortex, receptor binding, **67**:1
frontal cortex, serotonin, **67**:1
healthy subjects, electroencephalographic brain mapping, **67**:113
healthy subjects, pharmaco-electroencephalography, **67**:113
pharmaco-electroencephalography, healthy subjects, **67**:113
positron emission tomography, dopamine, **67**:1
positron emission tomography, frontal cortex, **67**:1
positron emission tomography, receptor binding, **67**:1
positron emission tomography, serotonin, **67**:1
positron emission tomography, striatum, **67**:1
receptor binding, dopamine, **67**:1
receptor binding, frontal cortex, **67**:1
receptor binding, positron emission tomography, **67**:1
receptor binding, serotonin, **67**:1
receptor binding, striatum, **67**:1
serotonin, frontal cortex, **67**:1
serotonin, positron emission tomography, **67**:1
serotonin, receptor binding, **67**:1
striatum, dopamine, **67**:1
striatum, positron emission tomography, **67**:1
striatum, receptor binding, **67**:1

Computed tomography

affective disorder, frontal cortex, **67**:123
affective disorder, sulcal prominence, **67**:123
affective disorder, ventricle-brain ratio, **67**:123
frontal cortex, affective disorder, **67**:123
frontal cortex, schizophrenia, **67**:123
schizophrenia, frontal cortex, **67**:123
schizophrenia, sulcal prominence, **67**:123
schizophrenia, ventricle-brain ratio, **67**:123
sulcal prominence, affective disorder, **67**:123
sulcal prominence, schizophrenia, **67**:123
ventricle-brain ratio, affective disorder, **67**:123
ventricle-brain ratio, schizophrenia, **67**:123

Corpus callosum

age, childhood onset schizophrenia, **68**:77
childhood schizophrenia, magnetic resonance imaging, **68**:77
magnetic resonance imaging, childhood schizophrenia, **68**:77
magnetic resonance imaging, schizophrenia, **67**:81, **68**:77

magnetic resonance imaging, shape analysis, **67**:81
schizophrenia, childhood onset, **68**:77
schizophrenia, magnetic resonance imaging, **67**:81, **68**:77

Dementia. *See also* Alzheimer's Disease
cerebellum, positron emission tomography, **67**:71
frontal cortex, positron emission tomography, **67**:71
frontal cortex, wandering behavior, **67**:71
multi-infarct, positron emission tomography, **67**:71
multi-infarct, wandering behavior, **67**:71
positron emission tomography, age, **67**:71
positron emission tomography, cerebellum, **67**:71
positron emission tomography, fluorodeoxyglucose, **67**:71
positron emission tomography, frontal cortex, **67**:71
positron emission tomography, multi-infarct, **67**:71
positron emission tomography, wandering behavior, **67**:71
wandering behavior, cerebellum, **67**:71
wandering behavior, frontal cortex, **67**:71
wandering behavior, positron emission tomography, **67**:71

Depression. *See* Affective disorder

Dopamine
age, methylspiroperidol, **67**:11
age, positron emission tomography, **67**:11
age, raclopride, **67**:11
age, receptor binding, **67**:11
age, striatum, **67**:11
basal ganglia, iodobenzamide, **68**:23
basal ganglia, obsessive-compulsive disorder, **68**:23
basal ganglia, psychotic patients, **68**:23
basal ganglia, receptor binding, **68**:23
basal ganglia, risperidone, **68**:23
basal ganglia, schizophrenia, **68**:23
basal ganglia, single photon emission computed tomography, **68**:23
clozapine, frontal cortex, **67**:1
clozapine, positron emission tomography, **67**:1
clozapine, receptor binding, **67**:1
clozapine, striatum, **67**:1
frontal cortex, clozapine, **67**:1
frontal cortex, positron emission tomography, **67**:1
frontal cortex, receptor binding, **67**:1
haloperidol, positron emission tomography, **67**:163
haloperidol, raclopride, **67**:163
haloperidol, receptor binding, **67**:163
haloperidol, schizophrenia, **67**:163
haloperidol, striatum, **67**:163
iodobenzamide, basal ganglia, **68**:23
iodobenzamide, obsessive-compulsive disorder, **68**:23
iodobenzamide, psychotic patients, **68**:23
iodobenzamide, receptor binding, **68**:23
iodobenzamide, risperidone, **68**:23
iodobenzamide, schizophrenia, **68**:23
iodobenzamide, single photon emission computed tomography, **68**:23
methylspiperone, positron emission tomography, **67**:159
methylspiperone, receptor binding, **67**:159
methylspiperone, schizophrenia, **67**:159
methylspiroperidol, age, **67**:11
methylspiroperidol, positron emission tomography, **67**:11
methylspiroperidol, raclopride, **67**:11
methylspiroperidol, receptor binding, **67**:11
methylspiroperidol, striatum, **67**:11
obsessive-compulsive disorder, basal ganglia, **68**:23
obsessive-compulsive disorder, iodobenzamide, **68**:23
obsessive-compulsive disorder, receptor binding, **68**:23
obsessive-compulsive disorder, risperidone, **68**:23
obsessive-compulsive disorder, single photon emission computed tomography, **68**:23
positron emission tomography, age, **67**:11
positron emission tomography, clozapine, **67**:1
positron emission tomography, frontal cortex, **67**:1
positron emission tomography, haloperidol, **67**:163
positron emission tomography, methylspiperone, **67**:159
positron emission tomography, methylspiroperidol, **67**:11
positron emission tomography, raclopride, **67**:11, **67**:163
positron emission tomography, receptor binding, **67**:1, **67**:11, **67**:155, **67**:159, **67**:163
positron emission tomography, schizophrenia, **67**:155, **67**:159, **67**:163
positron emission tomography, striatum, **67**:1, **67**:11, **67**:155, **67**:163
psychotic patients, basal ganglia, **68**:23
psychotic patients, iodobenzamide, **68**:23
psychotic patients, receptor binding, **68**:23
psychotic patients, risperidone, **68**:23
psychotic patients, single photon emission computed tomography, **68**:23
raclopride, age, **67**:11
raclopride, positron emission tomography, **67**:11, **67**:163
raclopride, receptor binding, **67**:11, **67**:163
raclopride, schizophrenia, **67**:163
raclopride, striatum, **67**:11, **67**:163
receptor binding, age, **67**:11
receptor binding, basal ganglia, **68**:23
receptor binding, clozapine, **67**:1
receptor binding, frontal cortex, **67**:1
receptor binding, haloperidol, **67**:163
receptor binding, iodobenzamide, **68**:23
receptor binding, methylspiperone, **67**:159
receptor binding, methylspiroperidol, **67**:11
receptor binding, obsessive-compulsive disorder, **68**:23
receptor binding, positron emission tomography, **67**:1, **67**:11, **67**:155, **67**:159, **67**:163
receptor binding, psychotic patients, **68**:23
receptor binding, raclopride, **67**:11, **67**:163
receptor binding, risperidone, **68**:23
receptor binding, schizophrenia, **67**:155, **67**:159, **67**:163, **68**:23
receptor binding, single photon emission computed tomography, **68**:23
receptor binding, striatum, **67**:1, **67**:11, **67**:155, **67**:163
risperidone, basal ganglia, **68**:23
risperidone, iodobenzamide, **68**:23
risperidone, obsessive-compulsive disorder, **68**:23
risperidone, psychotic patients, **68**:23

risperidone, receptor binding, **68**:23
risperidone, schizophrenia, **68**:23
risperidone, single photon emission computed tomography, **68**:23
schizophrenia, basal ganglia, **68**:23
schizophrenia, haloperidol, **67**:163
schizophrenia, iodobenzamide, **68**:23
schizophrenia, methylspiperone, **67**:159
schizophrenia, positron emission tomography, **67**:155, **67**:159, **67**:163
schizophrenia, raclopride, **67**:163
schizophrenia, receptor binding, **67**:155, **67**:159, **67**:163, **68**:23
schizophrenia, risperidone, **68**:23
schizophrenia, single photon emission computed tomography, **68**:23
schizophrenia, striatum, **67**:155, **67**:163
serotonin, receptor binding, **67**:1
single photon emission computed tomography, basal ganglia, **68**:23
single photon emission computed tomography, iodobenzamide, **68**:23
single photon emission computed tomography, obsessive-compulsive disorder, **68**:23
single photon emission computed tomography, psychotic patients, **68**:23
single photon emission computed tomography, receptor binding, **68**:23
single photon emission computed tomography, risperidone, **68**:23
single photon emission computed tomography, schizophrenia, **68**:23
striatum, age, **67**:11
striatum, clozapine, **67**:1
striatum, haloperidol, **67**:163
striatum, methylspiroperidol, **67**:11
striatum, positron emission tomography, **67**:1, **67**:11, **67**:155, **67**:163
striatum, raclopride, **67**:11, **67**:163
striatum, receptor binding, **67**:1, **67**:11, **67**:155, **67**:163
striatum, schizophrenia, **67**:155, **67**:163

Electroencephalography *See also* Evoked potentials

anxiety, multilead mapping, **68**:31
clozapine, healthy subjects, **67**:113
clozapine, multilead mapping, **67**:113
cortical disinhibition, hallucinogen, **67**:173
cortical disinhibition, lysergic acid diethylamide, **67**:173
cortical disinhibition, perceptual disorder, **67**:173
cortical disinhibition, substance abuse, **67**:173
hallucinogen, cortical disinhibition, **67**:173
hallucinogen, perceptual disorder, **67**:173
healthy subjects, clozapine, **67**:113
healthy subjects, multilead mapping, **67**:113
lysergic acid diethylamide, cortical disinhibition, **67**:173
lysergic acid diethylamide, perceptual disorder, **67**:173
panic disorder, multilead mapping, **68**:31
perceptual disorder, cortical disinhibition, **67**:173
perceptual disorder, hallucinogen, **67**:173
perceptual disorder, lysergic acid diethylamide, **67**:173
perceptual disorder, substance abuse, **67**:173
pharmaco-electroencephalography, clozapine, **67**:113
pharmaco-electroencephalography, healthy subjects, **67**:113
substance abuse, cortical disinhibition, **67**:173
substance abuse, hallucinogen, **67**:173
substance abuse, lysergic acid diethylamide, **67**:173
substance abuse, perceptual disorder, **67**:173

Evoked potentials

cortical disinhibition, hallucinogen, **67**:173
cortical disinhibition, lysergic acid diethylamide, **67**:173
hallucinogen, cortical disinhibition, **67**:173
hallucinogen, multilead mapping, **67**:173
hallucinogen, perceptual disorder, **67**:173
lysergic acid diethylamide, cortical disinhibition, **67**:173
lysergic acid diethylamide, multilead mapping, **67**:173
lysergic acid diethylamide, perceptual disorder, **67**:173
perceptual disorder, hallucinogen, **67**:173
perceptual disorder, lysergic acid diethylamide, **67**:173
substance abuse, hallucinogen, **67**:173
substance abuse, lysergic acid diethylamide, **67**:173

Frontal lobe

affective disorder, computed tomography, **67**:123
affective disorder, single photon emission computed tomography, **67**:59, **68**:1, **68**:143
affective disorder, sulcal prominence, **67**:123
affective disorder, age, **67**:59
age, affective disorder, **67**:59
age, positron emission tomography, **67**:71
age, single photon emission computed tomography, **67**:59
age, wandering behavior, **67**:71
benzodiazepine receptor distribution, schizophrenia, **68**:125
benzodiazepine receptor distribution, single photon emission tomography, **68**:125
clozapine, positron emission tomography, **67**:1
computed tomography, affective disorder, **67**:123
computed tomography, schizophrenia, **67**:123
computed tomography, sulcal prominence, **67**:123
dementia, multi-infarct, **67**:71
dementia, positron emission tomography, **67**:71
dementia, wandering behavior, **67**:71
diazepam binding, schizophrenia, **68**:125
diazepam binding, single photon emission computed tomography, **68**:125
dopamine, positron emission tomography, **67**:1
dopamine, receptor binding, **67**:1
geriatric depression, single photon emission computed tomography, **67**:59
magnetic resonance imaging, volumetry, **67**:203
major depression, computed tomography, **67**:123
major depression, sulcal prominence, **67**:123
multi-infarct dementia, positron emission tomography, **67**:71

multi-infarct dementia, wandering behavior, **67**:71
negative symptoms, single photon emission computed tomography, **67**:49, **68**:1
positive symptoms, schizophrenia, **67**:49, **68**:1
positive symptoms, single photon emission computed tomography, **67**:49, **68**:1
positron emission tomography, clozapine, **67**:1
positron emission tomography, multi-infarct dementia, **67**:71
positron emission tomography, wandering behavior, **67**:71
schizophrenia, benzodiazepine receptor distribution, **68**:125
schizophrenia, computed tomography, **67**:123
schizophrenia, diazepam binding, **68**:125
schizophrenia, negative symptoms, **67**:49, **68**:1
schizophrenia, positive symptoms, **67**:49, **68**:1
schizophrenia, single photon emission computed tomography, **67**:49, **68**:1, **68**:125
schizophrenia, sulcal prominence, **67**:123
serotonin, positron emission tomography, **67**:1
serotonin, receptor binding, **67**:1
single photon emission computed tomography, age, **67**:59
single photon emission computed tomography, affective disorder, **67**:59, **68**:1, **68**:143
single photon emission computed tomography, benzodiazepine receptor distribution, **68**:125
single photon emission computed tomography, diazepam binding, **68**:125
single photon emission computed tomography, geriatric depression, **67**:59
single photon emission computed tomography, negative symptoms, **67**:49, **68**:1
single photon emission computed tomography, positive symptoms, **67**:49, **68**:1
single photon emission computed tomography, schizophrenia, **67**:49, **68**:1, **68**:125
stereology, magnetic resonance imaging, **67**:203
sulcal prominence, affective disorder, **67**:123
sulcal prominence, computed tomography, **67**:123
sulcal prominence, schizophrenia, **67**:123
unipolar depression, computed tomography, **67**:123
volumetry, magnetic resonance imaging, **67**:203
volumetry, stereology, **67**:203
wandering behavior, multi-infarct dementia, **67**:71
wandering behavior, positron emission tomography, **67**:71

Globus pallidus

age, iron content, **68**:55
age, magnetic resonance imaging, **68**:55
iron content, age, **68**:55
iron content, magnetic resonance imaging, **68**:55
magnetic resonance imaging, age, **68**:55
magnetic resonance imaging, iron content, **68**:55

Haloperidol

dopamine, positron emission tomography, receptor binding, **67**:163
dopamine, schizophrenia, striatum, **67**:163
positron emission tomography, dopamine, raclopride, receptor binding, **67**:163
positron emission tomography, schizophrenia, striatum, **67**:163
raclopride, positron emission tomography, dopamine receptor binding, **67**:163
raclopride, schizophrenia, striatum, **67**:163
schizophrenia, dopamine, receptor binding, positron emission tomography, **67**:163
schizophrenia, raclopride, striatum, **67**:163
striatum, dopamine, receptor binding, positron emission tomography, **67**:163
striatum, schizophrenia, **67**:163

Limbic system

hippocampal formation, magnetic resonance imaging, **67**:135
hippocampal formation, negative symptoms, schizophrenia, **67**:135
magnetic resonance imaging, hippocampal formation, **67**:135
magnetic resonance imaging, negative symptoms, schizophrenia, **67**:135
magnetic resonance imaging, volumetry, **67**:135
schizophrenia, hippocampal formation, magnetic resonance imaging, **67**:135
schizophrenia, negative symptoms, **67**:135

Lysergic acid diethylamide

electroencephalography, cortical disinhibition, **67**:173
electroencephalographyic multilead mapping, perceptual disorder, **67**:173
evoked potentials, cortical disinhibition, **67**:173
evoked potentials, multilead mapping, **67**:173
evoked potentials, perceptual disorder, **67**:173
perceptual disorder, cortical disinhibition, **67**:173
perceptual disorder, electroencephalography, **67**:173
perceptual disorder, evoked potentials, **67**:173
substance abuse, electroencephalography, **67**:173

Magnetic resonance imaging

age, basal ganglia, **68**:55
age, globus pallidus, **68**:55
age, putamen, **68**:55
age, temporal lobe, **67**:189
age of onset, schizophrenia, **67**:189, **68**:77
Alzheimer's Disease, temporal lobe, **68**:65
anxiety, septohippocampal system, **68**:41
basal ganglia, age, **68**:55
basal ganglia, iron content, **68**:55
childhood schizophrenia, corpus callosum, **68**:77
corpus callosum, childhood schizophrenia, **68**:77
corpus callosum, morphometrics, **67**:81
corpus callosum, schizophrenia, **67**:81, **68**:77
corpus callosum, shape analysis, **67**:81
frontal lobe, stereology, **67**:203
frontal lobe, volumetry, **67**:203

globus pallidus, age, **68**:55
globus pallidus, iron content, **68**:55
hippocampal formation, limbic system, **67**:135
hippocampal formation, schizophrenia, **67**:135
hippocampal formation, temporal lobe, **67**:135
hippocampal formation, third ventricle, **67**:135
hippocampal formation, volumetry, **67**:135
iron content, basal ganglia, **68**:55
limbic system, hippocampal formation, **67**:135
limbic system, schizophrenia, **67**:135
limbic system, volumetry, **67**:135
morphometrics, corpus callosum, **67**:81
morphometrics, neuroanatomic landmarks, **67**:81, **67**:145
morphometrics, schizophrenia, **67**:81
morphometrics, shape analysis, **67**:81
neuroanatomic landmarks, image analysis, **67**:81
neuroanatomic landmarks, morphometrics, **67**:81, **67**:145
neuroanatomic landmarks, reliability, **67**:145
neuroanatomic landmarks, schizophrenia, **67**:81
panic disorder, septohippocampal system, **68**:41
putamen, age, **68**:55
putamen, iron content, **68**:55
schizophrenia, age, **67**:189
schizophrenia, age of onset, **67**:189, **68**:77
schizophrenia, childhood onset, corpus callosum, **68**:77
schizophrenia, corpus callosum, **67**:81, **68**:77
schizophrenia, hippocampal formation, **67**:135
schizophrenia, late onset, **68**:65
schizophrenia, limbic system, **67**:135
schizophrenia, morphometrics, **67**:81
schizophrenia, negative symptoms, **67**:135
schizophrenia, neuroanatomic landmarks, **67**:81
schizophrenia, striatum, **67**:155
schizophrenia, superior temporal gyrus, **67**:155
schizophrenia, temporal lobe, **67**:135, **67**:155, **67**:189, **68**:65
schizophrenia, third ventricle, **67**:135
schizophrenia, volumetry, **67**:135, **67**:155, **68**:65
segmentation, methodology, **67**:215
segmentation, reliability, **67**:215
septohippocampal system, anxiety, **68**:41
septohippocampal system, panic disorder, **68**:41
stereology, methodology, **67**:203, **67**:215
stereology, reliability, **67**:203, **67**:215
striatum, schizophrenia, **67**:155
striatum, volumetry, **67**:155
superior temporal gyrus, schizophrenia, **67**:155
superior temporal gyrus, volumetry, **67**:155
temporal lobe, age, **67**:189
temporal lobe, age of onset of schizophrenia, **67**:189
temporal lobe, late-onset schizophrenia, **68**:65
temporal lobe, schizophrenia, **67**:135, **67**:155, **67**:189, **67**:189, **68**:65
temporal lobe, volumetry, **67**:135, **67**:155, **68**:65
third ventricle, schizophrenia, **67**:135
third ventricle, volumetry, **67**:135
volumetry, frontal lobe, **67**:203
volumetry, hippocampal formation, **67**:135
volumetry, limbic system, **67**:135
volumetry, schizophrenia, **67**:135, **67**:155
volumetry, striatum, **67**:155
volumetry, superior temporal gyrus, **67**:155
volumetry, temporal lobe, **67**:135, **67**:155
volumetry, third ventricle, **67**:135
white matter, childhood schizophrenia, **68**:77

Marijuana

basal ganglia, positron emission tomography, **67**:29
cerebellum, positron emission tomography, **67**:29
orbitofrontal cortex, positron emission tomography, **67**:29
positron emission tomography, basal ganglia, **67**:29
positron emission tomography, cerebellum, **67**:29
positron emission tomography, fluorodeoxyglucose, **67**:29
positron emission tomography, orbitofrontal cortex, **67**:29
tetrahydrocannabinol, positron emission tomography, substance abuse, **67**:29

Morphometrics

corpus callosum, image averaging, **67**:81
corpus callosum, magnetic resonance imaging, **67**:81
corpus callosum, shape analysis, **67**:81
image analysis, neuroanatomic landmarks, **67**:81
image averaging, magnetic resonance imaging, **67**:81
magnetic resonance imaging, corpus callosum, **67**:81
magnetic resonance imaging, image averaging, **67**:81
magnetic resonance imaging, neuroanatomic landmarks, **67**:81, **67**:145
magnetic resonance imaging, schizophrenia, **67**:81
magnetic resonance imaging, shape analysis, **67**:81
neuroanatomic landmarks, magnetic resonance imaging, **67**:81, **67**:145
schizophrenia, corpus callosum, **67**:81
schizophrenia, magnetic resonance imaging, **67**:81
schizophrenia, neuroanatomic landmarks, **67**:81

Neuropathology

caudate nucleus, schizophrenia, **68**:87, **68**:99
caudate nucleus, volume, **68**:87
glia cells, schizophrenia, **68**:99
glia cells, striatum, **68**:99
neuron number, schizophrenia, **68**:99
neuron number, striatum, **68**:99
nucleus accumbens, neuron number, **68**:99
nucleus accumbens, schizophrenia, **68**:87, **68**:99
nucleus accumbens, volume, **68**:87
putamen, neuron number, **68**:99
putamen, schizophrenia, **68**:87, **68**:99
putamen, volume, **68**:87
schizophrenia, caudate nucleus, **68**:87, **68**:99
schizophrenia, glia cells, **68**:99
schizophrenia, neuron number, **68**:99
schizophrenia, nucleus accumbens, **68**:87, **68**:99
schizophrenia, putamen, **68**:87, **68**:99
schizophrenia, striatum, **68**:87, **68**:99
striatum, neuron number, **68**:99

striatum, schizophrenia, **68**:87, **68**:99
striatum, volume, **68**:87

Neuropsychology

abstinence, alcohol abuse, **67**:99
abstinence, Raven's progressive-matrices, **67**:99
abstinence, single photon emission computed tomography, **67**:99
alcohol abuse, abstinence, **67**:99
alcohol abuse, Raven's progressive-matrices, **67**:99
alcohol abuse, single photon emission computed tomography, **67**:99
Alzheimer's Disease, cerebral blood flow, **68**:133
Alzheimer's Disease, longitudinal course, **68**:133
Alzheimer's Disease, single photon emission computed tomography, **68**:133
cerebral blood flow, Alzheimer's Disease, **68**:133
cerebral blood flow, longitudinal course, **68**:133
iodoamphetamine, single photon emission computed tomography, **67**:99
Raven's progressive-matrices, abstinence, **67**:99
Raven's progressive-matrices, alcohol abuse, **67**:99
Raven's progressive-matrices, single photon emission computed tomography, **67**:99
single photon emission computed tomography, abstinence, **67**:99
single photon emission computed tomography, alcohol abuse, **67**:99
single photon emission computed tomography, Alzheimer's Disease, **68**:133
single photon emission computed tomography, cerebral blood flow, **68**:133
single photon emission computed tomography, iodoamphetamine, **67**:99
single photon emission computed tomography, Raven's progressive-matrices, **67**:99
single photon emission computed tomography, smoking, **67**:99
single photon emission computed tomography, Tc-hexamethylpropyleneamine oxime, **68**:133
smoking, single photon emission computed tomography, **67**:99

Orbitofrontal cortex

marijuana intoxication, positron emission tomography, **67**:29
marijuana intoxication, tetrahydrocannabinol, **67**:29
positron emission tomography, fluorodeoxyglucose, **67**:29
positron emission tomography, marijuana intoxication, **67**:29
positron emission tomography, substance abuse, **67**:29
positron emission tomography, tetrahydrocannabinol, **67**:29
substance abuse, positron emission tomography, **67**:29
tetrahydrocannabinol, positron emission tomography, **67**:29

Panic disorder

electroencephalography, magnetic resonance imaging, **68**:41
electroencephalography, multilead mapping, **68**:31
magnetic resonance imaging, electroencephalography, **68**:41
magnetic resonance imaging, septohippocampal system, **68**:41
septohippocampal system, magnetic resonance imaging, **68**:41

Parietal lobe

attention, positron emission tomography, **67**:17
attention, posttraumatic stress disorder, **67**:17
attention, substance abuse, **67**:17
continuous performance test, positron emission tomography, **67**:17
continuous performance test, posttraumatic stress disorder, **67**:17
continuous performance test, substance abuse, **67**:17
positron emission tomography, attention, **67**:17
positron emission tomography, continuous performance test, **67**:17
positron emission tomography, posttraumatic stress disorder, **67**:17
positron emission tomography, substance abuse, **67**:17
posttraumatic stress disorder, attention, **67**:17
posttraumatic stress disorder, continuous performance test, **67**:17
posttraumatic stress disorder, positron emission tomography, **67**:17
substance abuse, attention, **67**:17
substance abuse, continuous performance test, **67**:17
substance abuse, positron emission tomography, **67**:17

Positron emission tomography

age, altanserin, **68**:11
age, cerebellum, **67**:71
age, dementia, **67**:71
age, dopamine, **67**:11
age, frontal cortex, **67**:71
age, methylspiroperidol, **67**:11
age, multi-infarct dementia, **67**:71
age, raclopride, **67**:11
age, receptor binding, **67**:11, **68**:11
age, receptor number, **68**:11
age, serotonin, **68**:11
age, striatum, **67**:11
age, wandering behavior, **67**:71
altanserin, age, **68**:11
altanserin, receptor binding, **68**:11
altanserin, receptor number, **68**:11
altanserin, serotonin, **68**:11
attention, cerebral blood flow, **67**:17
attention, parietal cortex, **67**:17
attention, posttraumatic stress disorder, **67**:17
attention, substance abuse, **67**:17
basal ganglia, marijuana intoxication, **67**:29
cerebellum, age, **67**:71
cerebellum, dementia, **67**:71
cerebellum, marijuana intoxication, **67**:29
cerebellum, multi-infarct dementia, **67**:71
cerebellum, substance abuse, **67**:29
cerebellum, tetrahydrocannabinol, **67**:29
cerebellum, wandering behavior, **67**:71
clozapine, dopamine, **67**:1

clozapine, frontal cortex, **67**:1
clozapine, receptor binding, **67**:1
clozapine, serotonin, **67**:1
clozapine, striatum, **67**:1
continuous performance test, parietal cortex, **67**:17
continuous performance test, posttraumatic stress disorder, **67**:17
continuous performance test, substance abuse, **67**:17
dementia, cerebellum, **67**:71
dementia, frontal cortex, **67**:71
dementia, wandering behavior, **67**:71
dopamine, age, **67**:11
dopamine, clozapine, **67**:1
dopamine, frontal cortex, **67**:1
dopamine, haloperidol, **67**:163
dopamine, methylspiperone, **67**:159
dopamine, methylspiroperidol, **67**:11
dopamine, raclopride, **67**:11, **67**:163
dopamine, receptor binding, **67**:1, **67**:11, **67**:155, **67**:159, **67**:163
dopamine, schizophrenia, **67**:155, **67**:159, **67**:163
dopamine, striatum, **67**:1, **67**:11, **67**:155, **67**:163
fluorodeoxyglucose, age, **67**:71
fluorodeoxyglucose, basal ganglia, **67**:29
fluorodeoxyglucose, cerebellum, **67**:29, **67**:71
fluorodeoxyglucose, dementia, **67**:71
fluorodeoxyglucose, frontal cortex, **67**:71
fluorodeoxyglucose, marijuana intoxication, **67**:29
fluorodeoxyglucose, multi-infarct dementia, **67**:71
fluorodeoxyglucose, orbitofrontal cortex, **67**:29
fluorodeoxyglucose, substance abuse, **67**:29
fluorodeoxyglucose, tetrahydrocannabinol, **67**:29
fluorodeoxyglucose, wandering behavior, **67**:71
frontal cortex, age, **67**:71
frontal cortex, clozapine, **67**:1
frontal cortex, dementia, **67**:71
frontal cortex, dopamine, **67**:1
frontal cortex, multi-infarct dementia, **67**:71
frontal cortex, serotonin, **67**:1
frontal cortex, wandering behavior, **67**:71
haloperidol, dopamine, **67**:163
haloperidol, raclopride, **67**:163
haloperidol, schizophrenia, **67**:163
haloperidol, striatum, **67**:163
marijuana intoxication, basal ganglia, **67**:29
marijuana intoxication, cerebellum, **67**:29
marijuana intoxication, orbitofrontal cortex, **67**:29
methylspiperone, dopamine receptor binding, **67**:159
methylspiperone, schizophrenia, **67**:159
methylspiroperidol, age, **67**:11
methylspiroperidol, dopamine receptor binding, **67**:11
methylspiroperidol, raclopride, **67**:11
methylspiroperidol, striatum, **67**:11
multi-infarct dementia, cerebellum, **67**:71
multi-infarct dementia, frontal cortex, **67**:71
multi-infarct dementia, wandering behavior, **67**:71
orbitofrontal cortex, marijuana intoxication, **67**:29
orbitofrontal cortex, substance abuse, **67**:29
orbitofrontal cortex, tetrahydrocannabinol, **67**:29
parietal cortex, attention, **67**:17
parietal cortex, continuous performance test, **67**:17
parietal cortex, posttraumatic stress disorder, **67**:17
parietal cortex, substance abuse, **67**:17
posttraumatic stress disorder, attention, **67**:17
posttraumatic stress disorder, continuous performance test, **67**:17
posttraumatic stress disorder, parietal cortex, **67**:17
posttraumatic stress disorder, substance abuse, **67**:17
raclopride, age, **67**:11
raclopride, dopamine receptor binding, **67**:11, **67**:163
raclopride, schizophrenia, **67**:163
raclopride, striatum, **67**:11, **67**:163
receptor binding, age, **67**:11, **68**:11
receptor binding, altanserin, **68**:11
receptor binding, clozapine, **67**:1
receptor binding, dopamine, **67**:1, **67**:11, **67**:155, **67**:159, **67**:163
receptor binding, frontal cortex, **67**:1
receptor binding, haloperidol, **67**:163
receptor binding, methylspiperone, **67**:159
receptor binding, methylspiroperidol, **67**:11
receptor binding, raclopride, **67**:11, **67**:163
receptor binding, schizophrenia, **67**:155, **67**:159, **67**:163
receptor binding, serotonin, **67**:1,
receptor binding, striatum, **67**:1, **67**:11, **67**:155, **67**:163
receptor loss with age, altanserin, **68**:11
receptor loss with age, serotonin, **68**:11
reliability, dopamine receptor binding, **67**:163
schizophrenia, dopamine, **67**:155, **67**:159, **67**:163
schizophrenia, haloperidol, **67**:163
schizophrenia, methylspiperone, **67**:159
schizophrenia, raclopride, **67**:163
schizophrenia, receptor binding, **67**:155, **67**:159, **67**:163
schizophrenia, striatum, **67**:155, **67**:163
schizophrenia, temporal lobe, **68**:111
schizophrenia, violence, **68**:111
serotonin, **68**:11
serotonin, age, **68**:11
serotonin, altanserin, **68**:11
serotonin, clozapine, **67**:1
serotonin, frontal cortex, **67**:1
serotonin, receptor binding, **67**:1, **68**:11
serotonin, receptor loss with age, **68**:11
striatum, age, **67**:11
striatum, dopamine, **67**:1, **67**:11, **67**:155, **67**:163
striatum, haloperidol, **67**:163
striatum, methylspiroperidol, **67**:11
striatum, raclopride, **67**:11, **67**:163
striatum, receptor binding, **67**:1, **67**:11, **67**:155, **67**:163
striatum, schizophrenia, **67**:155, **67**:163
substance abuse, basal ganglia, **67**:29
substance abuse, cerebellum, **67**:29
substance abuse, orbitofrontal cortex, **67**:29
substance abuse, attention, **67**:17
substance abuse, continuous performance test, **67**:17
substance abuse, parietal cortex, **67**:17
temporal lobe, schizophrenia, **68**:111
temporal lobe, violence, **68**:111

tetrahydrocannabinol, basal ganglia, **67**:29
tetrahydrocannabinol, cerebellum, **67**:29
tetrahydrocannabinol, orbitofrontal cortex, **67**:29
violence, schizophrenia, **68**:111
violence, temporal lobe, **68**:111
wandering behavior, age, **67**:71
wandering behavior, cerebellum, **67**:71
wandering behavior, dementia, **67**:71
wandering behavior, frontal cortex, **67**:71
wandering behavior, multi-infarct dementia, **67**:71

Posttraumatic stress disorder

attention, parietal cortex, positron emission tomography, **67**:17
continuous performance test, parietal cortex, positron emission tomography, **67**:17
parietal cortex, attention, continuous performance test, **67**:17
parietal cortex, positron emission tomography, **67**:17
positron emission tomography, attention, continuous performance test, **67**:17
positron emission tomography, parietal cortex, **67**:17

Putamen

age, iron content, **68**:55
age, magnetic resonance imaging, **68**:55
iron content, age, **68**:55
iron content, magnetic resonance imaging, **68**:55
magnetic resonance imaging, age, **68**:55
magnetic resonance imaging, iron content, **68**:55

Risperidone

basal ganglia, dopamine, **68**:23
basal ganglia, iodobenzamide, receptor binding, **68**:23
basal ganglia, obsessive-compulsive disorder, schizophrenia, **68**:23
basal ganglia, single photon emission computed tomography, **68**:23
dopamine, basal ganglia, **68**:23
dopamine, iodobenzamide, **68**:23
dopamine receptor binding, obsessive-compulsive disorder, schizophrenia, **68**:23
dopamine, single photon emission computed tomography, **68**:23
iodobenzamide, dopamine receptor binding, obsessive-compulsive disorder, schizophrenia, **68**:23
iodobenzamide, single photon emission computed tomography, **68**:23
obsessive-compulsive disorder, basal ganglia, **68**:23
obsessive-compulsive disorder, iodobenzamide, dopamine receptor binding, **68**:23
obsessive-compulsive disorder, single photon emission computed tomography, **68**:23
schizophrenia, basal ganglia, **68**:23
schizophrenia, iodobenzamide, dopamine receptor binding, **68**:23
schizophrenia, single photon emission computed tomography, **68**:23
single photon emission computed tomography, basal ganglia, **68**:23
single photon emission computed tomography, iodobenzamide, dopamine receptor binding, **68**:23
single photon emission computed tomography, obsessive-compulsive disorder, schizophrenia, **68**:23

Schizophrenia

age, corpus callosum, **68**:77
age, magnetic resonance imaging, **67**:189, **68**:77
age, temporal lobe, **67**:189
age of onset, magnetic resonance imaging, **67**:189, **68**:65, **68**:77
age of onset, temporal lobe, **67**:189, **68**:65
basal ganglia, dopamine receptor binding, **68**:23
basal ganglia, iodobenzamide, **68**:23
basal ganglia, risperidone, **68**:23
basal ganglia, single photon emission computed tomography, **68**:23
benzodiazepine receptor distribution, single photon emission computed tomography, **68**:125
caudate nucleus, neuron number, **68**:99
caudate nucleus, neuropathology, **68**:87, **68**:99
caudate nucleus, volume, **68**:87
childhood schizophrenia, corpus callosum, **68**:77
childhood schizophrenia, magnetic resonance imaging, **68**:77
computed tomography, frontal cortex, **67**:123
computed tomography, sulcal prominence, **67**:123
computed tomography, ventricle-brain ratio, **67**:123
corpus callosum, childhood age of onset, **68**:77
corpus callosum, magnetic resonance imaging, **67**:81, **68**:77
diazepam binding, single photon emission computed tomography, **68**:125
dopamine, basal ganglia, **68**:23
dopamine, haloperidol, **67**:163
dopamine, iodobenzamide, **68**:23
dopamine, methylspiperone, **67**:159
dopamine, raclopride, **67**:163
dopamine, receptor binding, positron emission tomography, **67**:155, **67**:159, **67**:163
dopamine, risperidone, **68**:23
dopamine, single photon emission computed tomography, **68**:23
dopamine, striatum, **67**:155, **67**:163
frontal cortex, computed tomography, **67**:123
frontal cortex, positive and negative symptoms, **67**:49
frontal cortex, single photon emission computed tomography, **67**:49
frontal lobe, benzodiazepine receptor distribution, **68**:125
frontal lobe, diazepam binding, **68**:125
frontal lobe, positive and negative symptoms, **68**:1
frontal lobe, single photon emission computed tomography, **68**:1, **68**:125
gamma-aminobutyric acid, single photon emission computed tomography, **68**:125
glia cells, neuropathology, schizophrenia, **68**:99
haloperidol, dopamine, **67**:163

haloperidol, positron emission tomography, **67**:163
haloperidol, raclopride, **67**:163
haloperidol, striatum, **67**:163
hippocampal formation, magnetic resonance imaging, **67**:135
hippocampal formation, negative symptoms, **67**:135
hippocampal formation, volumetry, **67**:135
iodobenzamide, basal ganglia, **68**:23
iodobenzamide, dopamine, **68**:23
iodobenzamide, receptor binding, **68**:23
iodobenzamide, risperidone, **68**:23
iodobenzamide, single photon emission computed tomography, **68**:23
limbic system, magnetic resonance imaging, **67**:135
limbic system, negative symptoms, **67**:135
limbic system, volumetry, **67**:135
magnetic resonance imaging, age, **67**:189
magnetic resonance imaging, age of onset, **67**:189, **68**:77
magnetic resonance imaging, childhood schizophrenia, **68**:77
magnetic resonance imaging, corpus callosum, **67**:81, **68**:77
magnetic resonance imaging, hippocampal formation, **67**:135
magnetic resonance imaging, limbic system, **67**:135
magnetic resonance imaging, morphometrics, **67**:81
magnetic resonance imaging, negative symptoms, **67**:135
magnetic resonance imaging, neuroanatomic landmarks, **67**:81
magnetic resonance imaging, striatum, **67**:155
magnetic resonance imaging, superior temporal gyrus, **67**:155
magnetic resonance imaging, temporal lobe, **67**:135, **67**:155, **67**:189, **68**:65
magnetic resonance imaging, third ventricle, **67**:135
magnetic resonance imaging, volumetry, **67**:135, **67**:155, **68**:65
magnetic resonance imaging, white matter, **68**:77
methylspiperone, dopamine, **67**:159
methylspiperone, positron emission tomography, **67**:159
methylspiperone, receptor binding, **67**:159
morphometrics, corpus callosum, **67**:81
morphometrics, magnetic resonance imaging, **67**:81
morphometrics, neuroanatomic landmarks, **67**:81
negative symptoms, frontal lobe, **67**:49, **68**:1
negative symptoms, hippocampal formation, **67**:135
negative symptoms, limbic system, **67**:135
negative symptoms, magnetic resonance imaging, **67**:135
negative symptoms, principal component analysis, **67**:49
negative symptoms, single photon emission computed tomography, **67**:49, **68**:1
negative symptoms, temporal lobe, **67**:49, **67**:135, **68**:1
negative symptoms, third ventricle, **67**:135
negative symptoms, volumetry, **67**:135
neuroanatomic landmarks, magnetic resonance imaging, **67**:81
neuroanatomic landmarks, morphometrics, **67**:81
neuron number, neuropathology, **68**:99
neuron number, striatum, **68**:99
neuropathology, caudate nucleus, **68**:87, **68**:99
neuropathology, glia cells, **68**:99
neuropathology, neuron number, **68**:99
neuropathology, nucleus accumbens, **68**:87, **68**:99
neuropathology, putamen, **68**:87, **68**:99
neuropathology, striatum, **68**:87, **68**:99
nucleus accumbens, neuropathology, **68**:87, **68**:99
nucleus accumbens, volume, **68**:87
positive symptoms, frontal lobe, **67**:49, **68**:1
positive symptoms, principal component analysis, **67**:49
positive symptoms, single photon emission computed tomography, **67**:49, **68**:1
positive symptoms, temporal lobe, **67**:49, **68**:1
positron emission tomography, dopamine, **67**:155, **67**:159, **67**:163
positron emission tomography, haloperidol, **67**:163
positron emission tomography, methylspiperone, **67**:159
positron emission tomography, raclopride, **67**:163
positron emission tomography, receptor binding, **67**:155, **67**:159, **67**:163
positron emission tomography, striatum, **67**:155, **67**:163
positron emission tomography, temporal lobe, **68**:111
positron emission tomography, violence, **68**:111
principal component analysis, positive and negative symptoms, **67**:49
putamen, neuropathology, **68**:87, **68**:99
putamen, volume, **68**:87
raclopride, dopamine receptor binding, **67**:163
raclopride, haloperidol, **67**:163
raclopride, positron emission tomography, **67**:163
raclopride, striatum, **67**:163
risperidone, basal ganglia, dopamine receptor binding, **68**:23
risperidone, iodobenzamide, **68**:23
risperidone, single photon emission computed tomography, **68**:23
single photon emission computed tomography, basal ganglia, **68**:23
single photon emission computed tomography, benzodiazepine receptor distribution, **68**:125
single photon emission computed tomography, diazepam binding, **68**:125
single photon emission computed tomography, dopamine, **68**:23
single photon emission computed tomography, frontal lobe, **67**:49, **68**:1, **68**:125
single photon emission computed tomography, iodobenzamide, **68**:23
single photon emission computed tomography, iomazenil uptake, **68**:125
single photon emission computed tomography, positive and negative symptoms, **67**:49, **68**:1
single photon emission computed tomography, receptor binding, **68**:23
single photon emission computed tomography, risperidone, **68**:23
striatum, dopamine receptor binding, **67**:155, **67**:163
striatum, glia cells, **68**:99
striatum, haloperidol, **67**:163
striatum, magnetic resonance imaging, **67**:155
striatum, neuron number, **68**:99
striatum, neuropathology, **68**:87, **68**:99
striatum, positron emission tomography, **67**:155, **67**:163
striatum, raclopride, **67**:163
striatum, volume, **68**:87
striatum, volumetry, **67**:155
sulcal prominence, computed tomography, **67**:123

superior temporal gyrus, magnetic resonance imaging, **67**:155
superior temporal gyrus, volumetry, **67**:155
temporal lobe, age, **67**:189
temporal lobe, age of onset, **67**:189
temporal lobe, magnetic resonance imaging, **67**:135, **67**:155, **67**:189, **68**:65
temporal lobe, negative symptoms, **67**:49, **67**:135, **68**:1
temporal lobe, positive symptoms, **67**:49, **68**:1
temporal lobe, positron emission tomography, **67**:155, **68**:111
temporal lobe, single photon emission computed tomography, **67**:49, **68**:1
temporal lobe, violence, **68**:111
temporal lobe, volumetry, **67**:135, **67**:155, **68**:65
third ventricle, magnetic resonance imaging, **67**:135
third ventricle, negative symptoms, **67**:135
third ventricle, volumetry, **67**:135
ventricle-brain ratio, computed tomography, **67**:123
violence, positron emission tomography, **68**:111
violence, temporal lobe, **68**:111
white matter, childhood schizophrenia, **68**:77
white matter, magnetic resonance imaging, **68**:77

Serotonin

age, altanserin, receptor binding, **68**:11
age, positron emission tomography, **68**:11
age, receptor loss with age, **68**:11
altanserin, positron emission tomography, **68**:11
altanserin, receptor binding, **68**:11
altanserin, receptor loss with age, **68**:11
clozapine, dopamine receptor binding, **67**:1
clozapine, frontal cortex, striatum, **67**:1
clozapine, positron emission tomography, **67**:1
dopamine, clozapine, **67**:1
dopamine, frontal cortex, positron emission tomography, **67**:1
dopamine, receptor binding, striatum, **67**:1
frontal cortex, clozapine, positron emission tomography, **67**:1
frontal cortex, receptor binding, **67**:1
positron emission tomography, age, **68**:11
positron emission tomography, altanserin, **68**:11
positron emission tomography, clozapine, **67**:1
positron emission tomography, dopamine, **67**:1
positron emission tomography, frontal cortex, **67**:1
positron emission tomography, receptor binding, **67**:1, **68**:11
positron emission tomography, receptor loss with age, **68**:11
positron emission tomography, striatum, **67**:1
striatum, clozapine, **67**:1
striatum, dopamine receptor binding, **67**:1
striatum, positron emission tomography, **67**:1

Single photon emission computed tomography

abstinence, alcohol abuse, **67**:99
abstinence, iodoamphetamine, **67**:99
abstinence, neuropsychology, **67**:99
abstinence, Raven's progressive-matrices, **67**:99
abstinence, substance abuse, **67**:99
affective disorder, age, **67**:59
affective disorder, frontal lobe, **67**:59, **68**:1, **68**:143
affective disorder, temporal lobe, **67**:59, **68**:1
age, affective disorder, **67**:59
age, frontal cortex, **67**:59
age, temporal lobe, **67**:59
alcohol abuse, abstinence, **67**:99
alcohol abuse, neuropsychology, **67**:99
alcohol abuse, Raven's progressive-matrices, **67**:99
Alzheimer's Disease, cerebral blood flow, **68**:133
Alzheimer's Disease, longitudinal course, **68**:133
Alzheimer's Disease, neuropsychological tests, **68**:133
basal ganglia, dopamine, **68**:23
basal ganglia, iodobenzamide, **68**:23
basal ganglia, obsessive-compulsive disorder, **68**:23
basal ganglia, receptor binding, **68**:23
basal ganglia, risperidone, **68**:23
basal ganglia, schizophrenia, **68**:23
benzodiazepine receptor distribution, schizophrenia, **68**:125
diazepam binding, benzodiazepine receptor distribution, **68**:125
diazepam binding, schizophrenia, **68**:125
dopamine, basal ganglia, **68**:23
dopamine, iodobenzamide, **68**:23
dopamine, obsessive-compulsive disorder, **68**:23
dopamine, receptor binding, **68**:23
dopamine, risperidone, **68**:23
dopamine, schizophrenia, **68**:23
frontal lobe, affective disorder, **67**:59, **68**:1, **68**:143
frontal lobe, benzodiazepine receptor distribution, schizophrenia, **68**:125
frontal lobe, diazepam binding, schizophrenia, **68**:125
frontal lobe, geriatric depression, **67**:59
frontal lobe, positive and negative symptoms, **67**:49, **68**:1
frontal lobe, schizophrenia, **67**:49, **68**:1, **68**:125
gamma-aminobutyric acid, benzodiazepine receptor distribution, schizophrenia, **68**:125
gamma-aminobutyric acid, diazepine binding, schizophrenia, **68**:125
gamma-aminobutyric acid, schizophrenia, **68**:125
geriatric depression, frontal cortex, **67**:59
geriatric depression, temporal lobe, **67**:59
graphical analysis, cerebral blood flow, **68**:143
heroin, opiate withdrawal, **67**:39
iodoamphetamine, substance abuse, **67**:99
iodobenzamide, basal ganglia, **68**:23
iodobenzamide, dopamine, **68**:23
iodobenzamide, obsessive-compulsive disorder, **68**:23
iodobenzamide, receptor binding, **68**:23
iodobenzamide, risperidone, **68**:23
iodobenzamide, schizophrenia, **68**:23
iomazenil uptake, schizophrenia, **68**:125
negative symptoms, frontal lobe, **67**:49, **68**:1
negative symptoms, positive symptoms, **67**:49, **68**:1
negative symptoms, principal component analysis, **67**:49
negative symptoms, schizophrenia, **67**:49, **68**:1
negative symptoms, temporal lobe, **67**:49, **68**:1
neuropsychological tests, Alzheimer's Disease, **68**:133
neuropsychology, alcohol abuse, **67**:99
neuropsychology, Raven's progressive-matrices, **67**:99
neuropsychology, substance abuse, **67**:99

obsessive-compulsive disorder, basal ganglia, **68**:23
obsessive-compulsive disorder, dopamine, **68**:23
obsessive-compulsive disorder, iodobenzamide, **68**:23
obsessive-compulsive disorder, receptor binding, **68**:23
obsessive-compulsive disorder, risperidone, **68**:23
opiate withdrawal, heroin, **67**:39
positive symptoms, frontal lobe, **67**:49, **68**:1
positive symptoms, negative symptoms, **67**:49, **68**:1
positive symptoms, principal component analysis, **67**:49
positive symptoms, schizophrenia, **67**:49, **68**:1
positive symptoms, temporal lobe, **67**:49, **68**:1
Raven's progressive-matrices, alcohol abuse, **67**:99
Raven's progressive-matrices, substance abuse, **67**:99
receptor binding, basal ganglia, **68**:23
receptor binding, dopamine, **68**:23
receptor binding, iodobenzamide, **68**:23
receptor binding, obsessive-compulsive disorder, **68**:23
receptor binding, risperidone, **68**:23
receptor binding, schizophrenia, **68**:23
risperidone, basal ganglia, **68**:23
risperidone, dopamine, **68**:23
risperidone, iodobenzamide, **68**:23
risperidone, obsessive-compulsive disorder, **68**:23
risperidone, receptor binding, **68**:23
risperidone, schizophrenia, **68**:23
schizophrenia, basal ganglia, **68**:23
schizophrenia, benzodiazepine receptor distribution, **68**:125
schizophrenia, diazepam binding, **68**:125
schizophrenia, dopamine, **68**:23
schizophrenia, frontal lobe, **67**:49, **68**:1, **68**:125
schizophrenia, gamma-aminobutyric acid, **68**:125
schizophrenia, iodobenzamide, **68**:23
schizophrenia, iomazenil uptake
schizophrenia, positive and negative symptoms, **67**:49, **68**:1
schizophrenia, risperidone, **68**:23
schizophrenia, temporal lobe, **67**:49, **68**:1
smoking, alcohol abuse, **67**:99
smoking, substance abuse, **67**:99
substance abuse, opiate withdrawal, **67**:39
substance abuse, neuropsychology, **67**:99
substance abuse, Raven's progressive-matrices, **67**:99
substance abuse, smoking, **67**:99
Tc-hexamethylpropyleneamine oxime, affective disorder, **67**:59, **68**:1, **68**:143
Tc-hexamethylpropyleneamine oxime, age, **67**:59
Tc-hexamethylpropyleneamine oxime, Alzheimer's Disease, **68**:133
Tc-hexamethylpropyleneamine oxime, frontal lobe, **67**:49, **67**:59, **68**:1, **68**:143
Tc-hexamethylpropyleneamine oxime, geriatric depression, **67**:59
Tc-hexamethylpropyleneamine oxime, heroin withdrawal, **67**:39
Tc-hexamethylpropyleneamine oxime, schizophrenia, **67**:49, **68**:1
Tc-hexamethylpropyleneamine oxime, substance abuse, **67**:39
Tc-hexamethylpropyleneamine oxime, temporal lobe, **67**:49, **67**:59, **68**:1
temporal lobe, affective disorder, **67**:59, **68**:1
temporal lobe, age, **67**:59
temporal lobe, geriatric depression, **67**:59
temporal lobe, positive and negative symptoms, **67**:49, **68**:1
temporal lobe, schizophrenia, **67**:49, **68**:1

Striatum

age, dopamine, **67**:11
age, methylspiroperidol, **67**:11
age, positron emission tomography, **67**:11
age, raclopride, **67**:11
age, receptor binding, **67**:11
caudate nucleus, neuropathology, **68**:87, **68**:99
caudate nucleus, schizophrenia, **68**:87, **68**:99
caudate nucleus, volume, **68**:87
clozapine, dopamine receptor binding, **67**:1
clozapine, positron emission tomography, **67**:1
clozapine, serotonin, **67**:1
dopamine, age, **67**:11
dopamine, clozapine, **67**:1
dopamine, haloperidol, **67**:163
dopamine, magnetic resonance imaging, **67**:155
dopamine, methylspiroperidol, **67**:11
dopamine, positron emission tomography, **67**:1, **67**:11, **67**:155, **67**:163
dopamine, raclopride, **67**:11, **67**:163
dopamine, receptor binding, **67**:1, **67**:11, **67**:155, **67**:163
dopamine, schizophrenia, **67**:155, **67**:163
glia cells, neuropathology, **68**:99
glia cells, schizophrenia, **68**:99
haloperidol, dopamine receptor binding, **67**:163
haloperidol, positron emission tomography, **67**:163
haloperidol, raclopride, **67**:163
haloperidol, schizophrenia, **67**:163
methylspiroperidol, age, **67**:11
methylspiroperidol, dopamine, **67**:11
methylspiroperidol, positron emission tomography, **67**:11
methylspiroperidol, receptor binding, **67**:11
neuron number, caudate nucleus, **68**:99
neuron number, neuropathology, **68**:99
neuron number, nucleus accumbens, **68**:99
neuron number, putamen, **68**:99
neuron number, schizophrenia, **68**:99
neuropathology, caudate nucleus, **68**:87, **68**:99
neuropathology, glia cells, **68**:99
neuropathology, neuron number, **68**:99
neuropathology, nucleus accumbens, **68**:87, **68**:99
neuropathology, putamen, **68**:87, **68**:99
neuropathology, schizophrenia, **68**:87, **68**:99
nucleus accumbens, neuron number, **68**:99
nucleus accumbens, neuropathology, **68**:87, **68**:99
nucleus accumbens, schizophrenia, **68**:87, **68**:99
nucleus accumbens, volume, **68**:87
positron emission tomography, age, **67**:11
positron emission tomography, clozapine, **67**:1
positron emission tomography, dopamine receptor binding, **67**:1, **67**:11, **67**:155, **67**:163
positron emission tomography, haloperidol, **67**:163
positron emission tomography, methylspiroperidol, **67**:11
positron emission tomography, raclopride, **67**:11, **67**:163

positron emission tomography, schizophrenia, **67**:155, **67**:163
putamen, neuron number, **68**:99
putamen, neuropathology, **68**:87, **68**:99
putamen, schizophrenia, **68**:87, **68**:99
putamen, volume, **68**:87
raclopride, age, **67**:11
raclopride, dopamine, **67**:11, **67**:163
raclopride, haloperidol, **67**:163
raclopride, positron emission tomography, **67**:11 **67**:163
raclopride, schizophrenia, **67**:163
schizophrenia, caudate nucleus, **68**:87, **68**:99
schizophrenia, dopamine, **67**:155, dopamine, **67**:163
schizophrenia, glia cells, **68**:99
schizophrenia, haloperidol, **67**:163
schizophrenia, neuron number, **68**:99
schizophrenia, neuropathology, **68**:87, **68**:99
schizophrenia, nucleus accumbens, **68**:87, **68**:99
schizophrenia, positron emission tomography, **67**:155, **67**:163
schizophrenia, putamen, **68**:87, **68**:99
schizophrenia, raclopride, **67**:163
volume, caudate nucleus, **68**:87
volume, nucleus accumbens, **68**:87
volume, putamen, **68**:87

Substance abuse/dependence

alcohol abuse, abstinence, **67**:99
alcohol abuse, neuropsychology, **67**:99
alcohol abuse, Raven's progressive-matrices, **67**:99
alcohol abuse, single photon emission computed tomography, **67**:99
alcohol abuse, smoking, **67**:99
attention, continuous performance test, **67**:17
attention, parietal cortex, **67**:17
attention, positron emission tomography, **67**:17
attention, posttraumatic stress disorder, **67**:17
basal ganglia, marijuana intoxication, **67**:29
basal ganglia, positron emission tomography, **67**:29
basal ganglia, tetrahydrocannabinol, **67**:29
cerebellum, marijuana intoxication, **67**:29
cerebellum, positron emission tomography, **67**:29
cerebellum, tetrahydrocannabinol, **67**:29
continuous performance test, parietal cortex, **67**:17
continuous performance test, positron emission tomography, **67**:17
continuous performance test, posttraumatic stress disorder, **67**:17
cortical disinhibition, lysergic acid diethylamide, **67**:173
electroencephalography, cortical disinhibition, **67**:173
electroencephalography, lysergic acid diethylamide, **67**:173
evoked potentials, lysergic acid diethylamide, **67**:173
hallucinogen, perceptual disorder, **67**:173
heroin, single photon emission computed tomography, **67**:39
iodoamphetamine, single photon emission computed tomography, **67**:99
lysergic acid diethylamide, cortical disinhibition, **67**:173
lysergic acid diethylamide, electroencephalography, **67**:173
lysergic acid diethylamide, evoked potentials, **67**:173
lysergic acid diethylamide, perceptual disorder, **67**:173
marijuana intoxication, basal ganglia, cerebellum, orbitofrontal cortex, **67**:29
marijuana intoxication, positron emission tomography, **67**:29
neuropsychology, alcohol abuse, **67**:99
neuropsychology, single photon emission computed tomography, **67**:99
opiate withdrawal, single photon emission computed tomography, **67**:39
orbitofrontal cortex, marijuana intoxication, **67**:29
orbitofrontal cortex, positron emission tomography, **67**:29
orbitofrontal cortex, tetrahydrocannabinol, **67**:29
parietal cortex, attention, **67**:17
parietal cortex, continuous performance test, **67**:17
parietal cortex, positron emission tomography, **67**:17
parietal cortex, posttraumatic stress disorder, **67**:17
perceptual disorder, lysergic acid diethylamide, **67**:173
positron emission tomography, attention, **67**:17
positron emission tomography, basal ganglia, cerebellum, **67**:29
positron emission tomography, continuous performance test, **67**:17
positron emission tomography, marijuana intoxication, **67**:29
positron emission tomography, orbitofrontal and parietal cortex, **67**:29
positron emission tomography, posttraumatic stress disorder, **67**:17
positron emission tomography, tetrahydrocannabinol, **67**:29
posttraumatic stress disorder, attention, **67**:17
posttraumatic stress disorder, continuous performance test, **67**:17
posttraumatic stress disorder, parietal cortex, **67**:17
posttraumatic stress disorder, positron emission tomography, **67**:17
Raven's progressive-matrices, alcohol abuse, **67**:99
Raven's progressive-matrices, single photon emission computed tomography, **67**:99
single photon emission computed tomography, alcohol abuse, abstinence, **67**:99
single photon emission computed tomography, heroin, **67**:39
single photon emission computed tomography, iodoamphetamine, **67**:99
single photon emission computed tomography, neuropsychology, **67**:99
single photon emission computed tomography, opiate withdrawal, **67**:39
single photon emission computed tomography, Raven's progressive-matrices, **67**:99
single photon emission computed tomography, smoking, **67**:99
single photon emission computed tomography, Tc-hexamethylpropyleneamine oxime, **67**:39
smoking, single photon emission computed tomography, **67**:99
tetrahydrocannabinol, basal ganglia, cerebellum, orbitofrontal cortex, **67**:29
tetrahydrocannabinol, positron emission tomography, **67**:29

Temporal lobe

affective disorder, age, **67**:59
affective disorder, single photon emission computed tomography, **67**:59, **68**:1
age, affective disorder, **67**:59

age, magnetic resonance imaging, **67**:189
age, schizophrenia, **67**:189
age, single photon emission computed tomography, **67**:59
age of onset, schizophrenia, **67**:189, **68**:65
Alzheimer's disease, magnetic resonance imaging, **68**:65
geriatric depression, single photon emission computed tomography, **67**:59
hippocampal formation, limbic system, **67**:135
hippocampal formation, magnetic resonance imaging, **67**:135
hippocampal formation, negative symptoms, **67**:135
hippocampal formation, schizophrenia, **67**:135
hippocampal formation, volumetry, **67**:135
limbic system, magnetic resonance imaging, **67**:135
limbic system, negative symptoms, **67**:135
limbic system, schizophrenia, **67**:135
limbic system, volumetry, **67**:135
magnetic resonance imaging, age, **67**:189
magnetic resonance imaging, hippocampal formation, **67**:135
magnetic resonance imaging, limbic system, **67**:135
magnetic resonance imaging, negative symptoms, **67**:135
magnetic resonance imaging, schizophrenia, **67**:135, **67**:155, **67**:189, **68**:65
magnetic resonance imaging, superior temporal gyrus, **67**:155
magnetic resonance imaging, volumetry, **67**:135, **67**:155, **68**:65
negative symptoms, affective disorder, **68**:1
negative symptoms, hippocampal formation, **67**:135
negative symptoms, limbic system, **67**:135
negative symptoms, magnetic resonance imaging, **67**:135
negative symptoms, positive symptoms, **67**:49, **68**:1
negative symptoms, schizophrenia, **67**:49, **67**:135, **68**:1
negative symptoms, single photon emission computed tomography, **67**:49, **68**:1
positive symptoms, negative symptoms, **67**:49, **68**:1
positive symptoms, schizophrenia, **67**:49, **68**:1
positive symptoms, single photon emission computed tomography, **67**:49, **68**:1
positron emission tomography, violence, **68**:111
schizophrenia, age, **67**:189
schizophrenia, age of onset, **67**:189
schizophrenia, hippocampal formation, **67**:135
schizophrenia, limbic system, **67**:135
schizophrenia, magnetic resonance imaging, **67**:135, **67**:155, **67**:189, **68**:65
schizophrenia, negative symptoms, **67**:49, **67**:135, **68**:1
schizophrenia, positive symptoms, **67**:49, **68**:1
schizophrenia, positron emission tomography, **67**:155, **68**:111
schizophrenia, single photon emission computed tomography, **67**:49, **68**:1
schizophrenia, superior temporal gyrus, **67**:155
schizophrenia, temporal lobe length, **67**:189
schizophrenia, violence, **68**:111
schizophrenia, volumetry, **67**:135, **67**:155, **68**:65
single photon emission computed tomography, affective disorder, **67**:59, **68**:1
single photon emission computed tomography, age, **67**:59
single photon emission computed tomography, geriatric depression, **67**:59
single photon emission computed tomography, negative symptoms, **67**:49, **68**:1
single photon emission computed tomography, positive symptoms, **67**:49, **68**:1
single photon emission computed tomography, schizophrenia, **67**:49, **68**:1
superior temporal gyrus, magnetic resonance imaging, **67**:155
superior temporal gyrus, schizophrenia, **67**:155
superior temporal gyrus, volumetry, **67**:155
violence, positron emission tomography, **68**:111
violence, schizophrenia, **68**:111
volumetry, hippocampal formation, **67**:135
volumetry, limbic system, **67**:135
volumetry, magnetic resonance imaging, **67**:135, **67**:155
volumetry, negative symptoms, **67**:135
volumetry, schizophrenia, **67**:135, **67**:155
volumetry, superior temporal gyrus, **67**:155

Tetrahydrocannabinol. See Marijuana

Ventricle-brain ratio. See Computed tomography

Violence
positron emission tomography, schizophrenia, **68**:111
positron emission tomography, temporal lobe, **68**:111
schizophrenia, positron emission tomography, **68**:111
schizophrenia, temporal lobe, **68**:111
temporal lobe, positron emission tomography, **68**:111
temporal lobe, schizophrenia, **68**:111